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HIV-Tat-interacting protein of 60 KDa (TIP60) is a lysine 
acetyltransferase implicated in transcription, DNA damage response and 
apoptosis. It is known to be downregulated in multiple cancers. TIP60 is 
shown to act as a haploinsufficient tumour suppressor in MYC-induced 
lymphomagenesis. Additionally, downregulation of TIP60 is shown to be a 
potential marker for cancer malignancy and poor Overall Survival (OS). 
In cervical cancers, Human Papillomavirus (HPV) E6 oncogene targets 
cellular p53, BAK and some of the PDZ domain containing proteins for 
proteasome mediated degradation through E6AP ligase. Other than this, E6 
oncoprotein from both high-risk and low-risk HPVs were shown to target 
TIP60. However, the destabilization of TIP60 mediated by E6 was E6AP 
independent suggesting a novel mechanism yet to be identified. Additionally, 
whether destabilization of TIP60 contributes to HPV E6 mediated tumour 
transformation remains unclear. A proteomic analyses revealed that 
EDD1/UBR5, an E3 ubiquitin ligase overexpressed in cancers, is a binding 
partner of TIP60. Cycloheximide treatment and ubiquitination assay reveal 
that EDD1 negatively regulates TIP60’s protein stability through 
ubiquitination dependent proteasome degradation. More importantly, HPV E6 
utilizes EDD1 to mediate TIP60 destabilization. Colony formation assays 
show that gain-of-function either by overexpressing TIP60 or by depleting 
EDD1 in HPV positive cervical cancer cells significantly inhibits colony 
formation in vitro. This is strongly supported by the in vivo studies where re-
activation of TIP60 in cervical cancer cells dramatically reduces tumour 
formation. In summary, a novel ligase through which E6 destabilizes TIP60 
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was identified. More interestingly, this study implying a distinct tumour 
suppressor role for TIP60 in cervical cancers shows that reactivation of TIP60 
through inhibiting EDD1 could be of therapeutic value.  
Other than tumour growth, metastasis is an important feature of cancer. 
Among various signalling pathways, TIP60 is implicated in regulating 
epithelial-mesenchymal transition (EMT), an essential process of cancer 
metastasis. In my attempt to identify the role of TIP60 in inhibiting cancer 
metastasis, I have used in vitro and in vivo models to show that TIP60 
expression abrogates cell migration and metastatic potential of breast cancer 
cells. Mechanistically, this was through TIP60’s ability to destabilize DNMT1 
and inhibit SNAIL2’s function (SNAIL2 mediated EMT/cell migration). 
Depletion of TIP60 stabilizes DNMT1 and increase SNAIL2 levels, resulting 
in EMT. Recruitment of DNMT1 to SNAIL2 targets in the absence of TIP60 
increases DNA methylation on their promoter region and further represses 
expression of epithelial markers. In pathophysiological scenario, TIP60 is 
significantly down-regulated in breast cancer patients with poor Overall 
Survival (OS) and Disease-Free Survival (DFS) prognoses. These data suggest 
that levels of TIP60 can be a prognostic marker of breast cancer progression 
and stabilization of TIP60 could be a promising strategy to treat cancers. 
Taken together, my study reveals the mechanism of TIP60’s tumour 
suppressor function including inhibition of both tumour growth and 
metastasis. I have summarised my work into five categories (introduction, 
objective, materials and methods, results and discussion), which are divided 
into nine chapters.   
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Chapter 1: Introduction 
In 1996, by using Yeast Two Hybrid assay, G. Chinnadurai et al identified 
a protein specifically interacting with HIV Tat transactivator through the N-
terminal 31 amino acids which contains the essential cysteine rich portion of 
Tat activation domain (Kamine et al., 1996). They named this protein TIP60 – 
Tat interactive protein 60 kDa. In their study, they also found that 
overexpression of TIP60 results in an increase of Tat transactivation of HIV-1 
promoter without changing the basal activity of HIV-1 promoter or the 
heterologous RSV promoter, suggesting that TIP60 is a cofactor of HIV Tat 
protein in activating HIV expression.  
Since then multiple groups including ours have identified role of TIP60 
and have demonstrated its importance in regulating cellular pathways (Chen et 
al., 2015; Du et al., 2010b; Jha et al., 2010; Tang et al., 2013) (Figure 1).  TIP60 
has been implicated in multiple cellular pathways such as DNA damage 
response, apoptosis, chromatin remodelling and transcriptional regulation (Jha 
and Dutta, 2009; Sapountzi et al., 2006; Squatrito et al., 2006). This is through 
its ability to acetylate both histone and non-histone proteins, and by doing so it 
acts as a regulator of these proteins, for example p53 and Ataxia 
Telangiectasia Mutated (ATM) kinase (Sun et al., 2005; Sun et al., 2007; 
Sykes et al., 2006; Tang et al., 2006). These studies suggest that TIP60 
modulate function of a wide range of cellular proteins that are essential in 
multiple cellular pathways.  
As an important regulator in cell, dysregulation of TIP60 correlates with 
multiple diseases including cancers. In 2007, Gorrini et al. identified TIP60 as 
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a haplo-insufficient tumour suppressor using E(mu)-MYC transgenic mice that 
are heterozygous for TIP60 gene (Gorrini et al., 2007). Further research also 
found that down-regulation of TIP60 highly correlates with cancer progression 




Figure 1 TIP60 is involved in multiple cellular pathways.  




1.1 TIP60 is a lysine acetyltransferase 
1.1.1 Structural characteristics of TIP60 
TIP60 is encoded by HTATIP gene located at 11q13.1 and consists of 14 
exons (Sapountzi et al., 2006). There are at four different splice variants of 
TIP60 due to alternative splicing (Figure 2). Isoform 2 is most studies form of 
TIP60. Isoform 1 results from an additional translation of intron 1 which 
might have regulatory function (Legube and Trouche, 2003). Isoform 3 results 
from an exclusive translation of exon 5 that encodes a proline rich region and 
appears to function similar to isoform 1 (Ran and Pereira-Smith, 2000). 
Isoform 4 results from an additional translation of intron 1 and an exclusive 
translation of exon 5. 
TIP60 was first identified as a histone lysine acetyltransferase in 1997 by 
Yamamoto and Horikoshi (Yamamoto and Horikoshi, 1997). In their study, 
TIP60 was identified as a nuclear protein with a conserved region named 
MYST domain (Figure 3) which is also found in other acetyltransferase such 
as MOZ (Borrow et al., 1996), MOF (Hilfiker et al., 1997), YBF2/SAS3 
(Reifsnyder et al., 1996) and SAS2 (Ehrenhofer-Murray et al., 1997; 
Reifsnyder et al., 1996), indicating a acetyltransferase function of TIP60. The 
group of acetyltransferases that contain MYST domain are categorized under 
MYST family of acetyltransferase. The common feature of this family is 
transfers acetyl group from Acetyl-CoA to lysine residues of target protein. 
The structure of human TIP60 and yeast Esa1 are similar (Figure 3). The 
catalytic domain of TIP60 includes a region that mediates Acetyl-CoA binding 
and a C2H2-type zinc finger, which might be involved in substrate 
recognition. Within the MYST family, TIP60 is closely related to MOF as 
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both contain a chromodomain N-terminal of MYST domain and they are 
known to acetylate common substrates such as histone H4 and p53 (Sykes et 
al., 2006; Taipale et al., 2005). 
 
 







Figure 3 Diagram highlighting functional domains of human TIP60 and yeast Esa1. 









1.1.2 Histone targets of TIP60 
In 1998, Kimura and Horikoshi identified six lysines in core histones that 
are acetylated by TIP60; lys-5 of histone H2A, lys-14 of histone H3 and lys-5, 
lys-8, lys-12, lys-16 of histone H4. Further, it is reported that TIP60 is usually 
a part of a histone remodeller complex – NuA4 – where it functions as a 
histone acetyltransferase. NuA4 complex, also known as TIP60 complex in 
human, is a multiprotein complex consist of at least 16 subunits (Figure 4) 
(Doyon and Cote, 2004). TIP60 is the catalytic subunit of human NuA4 
complex and plays a central role in the function of the complex. This complex 
is capable of at least three interrelated enzymatic activities: histone H2A/H4 
acetylation, ATP-dependent histone H2AZ/H2B dimer exchange and DNA 
helicase (Auger et al., 2008). Studies have implicated that it involved in 
multiple cellular pathways that correlates with TIP60 regulated pathways.  
TIP60 is recruited to the chromatin and mediates histone acetylation as a 
complex. For example, TIP60 is recruited to the chromatin by c-MYC with 
four other components of the NuA4 complex: TRRAP, p400, TIP48 and 
TIP49 (Frank et al., 2003). This is essential for c-MYC induced histone H4 
acetylation, as overexpression of catalytic inactive of TIP60 decrease the level 
of c-MYC induced histone acetylation (Frank et al., 2003).  
1.1.3 Non-histone targets of TIP60 
TIP60 not only acetylates histones but also non-histone proteins. TIP60 
usually acetylates non-histone proteins independently instead of forming 
TIP60 complex. Till now, several non-histone proteins, including post-
translational modifier and transcription factors, are identified as TIP60’s 
targets. TIP60 mediated acetylation on these non-histone targets usually 
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regulate their activity which might lead to tumour suppression, for example, 
ATM (Sun et al., 2005; Sun et al., 2007), p53 (Sykes et al., 2006; Tang et al., 
2006) and p21 (Lee et al., 2013). However, further research also identified that 
TIP60 acetylates c-MYC (Patel et al., 2004) and cancer metastasis inducer 
TWIST1 (Shi et al., 2014), and this is important for their oncogenic function, 
indicating a bivalent role of TIP60 in carcinogenesis.  
 
Figure 4 Schematic representation of human NuA4 complex. 




1.2 TIP60 in regulating DNA damage response 
DNA damage arises from the error of replication and/or exposure of 
exogenous reagent. There are different kinds of DNA damage and DNA 
double stand break (DSB) is one kind, which is difficult for cell to repair. 
TIP60 is essential for DSB repairing. DSB is repaired in two ways: 
homologous recombination (HR) and non-homologous end joining (NHEJ). 
NHEJ is generally considered to be error-prone, whereas HR is generally 
considered to be error-free (Sun et al., 2010). TIP60 has been implicated in 
response to homologous recombination repair pathway. This is through two 
roles of TIP60 in DSB: chromatin remodelling by human NuA4 complex at 
DSB sites and activation of ATM signalling pathway. By activating the DNA 
damage response (DDR), TIP60 protects cells from genome instability caused 
by DSB and supresses the transforming events that might lead to cancer. 
1.2.1 TIP60 activation during DNA damage response 
TIP60 is activated during DSB by interacting with H3K9Me3 through its 
chromodomain (Sun et al., 2009). H3K9Me3 is known to predominantly 
locate in heterochromatin (Barski et al., 2007; Regha et al., 2007). For DSB 
localized around heterochromatin, the original H3K9Me3 could play a role in 
recruiting TIP60. However, majority of cellular H3K9Me3 is bound by 
heterochromatin protein 1 (HP1) (Jacobs and Khorasanizadeh, 2002; Nielsen 
et al., 2002), which questions how H3K9Me3 could be available to TIP60? 
Recent studies found the involvement of casein kinase 2 (CK2) (Ayoub et al., 
2008; Sun et al., 2009) in regulating binding of HP1 to H3K9Me3. 
Phosphorylation of HP1 by CK2 results in release of HP1 bounded to 
H3K9Me3, which creates unoccupied domains of H3K9Me3 for interacting 
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with TIP60 chromodomain (Ayoub et al., 2008; Sun et al., 2009). However, 
released HP1 remains chromatin bound via its chromoshadow domain instead 
of re-localizing to nucleoplasm (Luijsterburg et al., 2009). Further release of 
HP1 from chromatin requires phosphorylation on KAP-1 by active ATM. This 
would further release HP1/KAP-1 complex from chromatin and generate a 
relaxation region to facilitate DNA repairing (Ziv et al., 2006). 
However, this does not explain how TIP60 is activated on open chromatin 
region that lacks H3K9Me3. Recent studies found that a complex containing 
HP1, KAP-1 and a H3K9 methyltransferase SUV39H1 are rapidly enriched on 
the chromatin at DSB sites (Ayrapetov et al., 2014). SUV39H1 catalyses 
H3K9Me3 and facilitates additional HP1/KAP-1/SUV39H1 enrichment 
around DSB sites through interaction between HP1 and nascent H3K9Me3. 
This would result in spreading of H3K9Me3 and recruiting TIP60 to DSB sites, 
providing a mechanism of TIP60 activation around euchromatin region that 
lack H3K9Me3. 
1.2.2 Histone acetylation by TIP60 at DNA damage sites 
Acetylation, among all the other modifications, has a role to change the 
surface charge distribution of the targeted proteins and further change the 
accessibility of the genome or other proteins. Acetylation of histones by TIP60 
(NuA4) complex is also very important for DNA damage response pathway. 
When there are DNA double strand breaks, TIP60 mediated acetylation on 
histone H4 lysine 16 (H4K16Ac) acts as a switch of homologous 
recombination (HR) repair pathway and non-homologous end joining (NHEJ) 
repair pathway (Tang et al., 2013). Mechanistically, H4K16Ac promotes 
homologous recombination by promoting BRCA1 recruitment to DSB sites 
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and inhibits non-homologous end joining by inhibiting H4K20Me2 mediated 
53BP1 recruitment (Tang et al., 2013). In addition to this, Jacquet et al 
recently demonstrated that TIP60 is involved in promoting HR pathway by 
competing with RNF168 (Jacquet et al., 2016). 53BP1 recruitment to DSB 
sites not only involves H4K20Me2 but also H2AK15Ub. TIP60 acetylation on 
H2AK15 inhibits RNF168 ubiquitination on the same sites, thereby inhibiting 
53BP1 recruitment at DNA damage sites. 
Taken together, TIP60 promotes HR and ablate NHEJ by inhibiting both 
H4K20Me2 and H2AK15Ub mediated recruitment of 53BP1. 
1.2.3 TIP60 and ATM activation 
ATM activation initiates the signalling pathways that would recruit DNA 
damage repair molecules and activate cell cycle checkpoints. ATM 
phosphorylation on H2AX provides a platform for the recruitment of DNA 
repair complex including 53BP1, BRCA2 and NBS1 (Stucki et al., 2005). 
ATM phosphorylation on p53 and CHK2 plays a crucial role in cell cycle 
arrest. Thus activation of ATM is a crucial step in DNA damage response. 
Recent studies reveal TIP60’s catalytic activity is crucial for ATM 
activation. TIP60 interacts with the FATC domain of ATM, and acetylates 
K3016 of ATM (Sun et al., 2007). Mutation of lysine 3016 of ATM results in 
defective ATM dependent activation of DDR, suggesting an important role of 
TIP60 acetylation in ATM activation. Inactivation of MRN complex (also 
reported be involved in ATM activation (Sun et al., 2009)), ablates acetylation 
and activation of ATM by TIP60. Interestingly, loss of functional MRN 
complex delays both recruitment of TIP60 to DSB sites and activation of 
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TIP60, suggesting that MRN complex might be involved in recruitment of 
TIP60-ATM to DSB sites, which would lead to the activation of TIP60 by 
H3K9Me3 and acetylation of ATM by TIP60.  
1.3 TIP60 as a regulator of transcription factors 
1.3.1 TIP60 acetylates transcription factors which function as 
tumour suppressor 
TIP60 is reported to mediate acetylation on several transcription factors 
and this would lead to tumour suppression. The most well-known transcription 
factor acetylated by TIP60 is p53. Acetylation of p53 on lysine 120 by TIP60 
modulates the decision between cell cycle arrest and apoptosis, which is 
crucial for p53 dependent apoptosis but not p53 induced cell cycle arrest 
(Sykes et al., 2006; Tang et al., 2006). The K120R mutation results in mis-
regulation of p53 pro-apoptotic targets such as BAX and PUMA, however the 
non-apoptotic targets such as p21 and hMDM2 remain unaffected.  
Another transcription factor known to be acetylated by TIP60 is p21. 
Acetylation of p21 on lysine 161 and 163 by TIP60 is required for 
stabilization of p21 and this is necessary for p21 induced cell cycle arrest 
during DNA damage response (Lee et al., 2013). Acetylation mimetic 
mutations K161Q and K163Q decrease the polyubiquitination of p21 in 
H1299 cells and further enhance p21 mediated cell cycle arrest. Lee et al. also 
found these mutations to delay growth of p21 null MEFs.  
1.3.2 TIP60 acetylates oncogenic transcription factor 
 It is also reported that TIP60 could mediate acetylation of oncogenic 
transcription factors that is essential for their oncogenic activity. Among them, 
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the most well-known is c-MYC. TIP60 mediated acetylation on oncoprotein c-
MYC (Patel et al., 2004) increase its stability. However, the acetylation site on 
c-MYC by TIP60 is yet to be identified. Additionally, not only TIP60 but also 
GCN5 acetylates c-MYC, and GCN5 seems occupy the predominant role in 
acetylating c-MYC. Therefore, role of TIP60 in c-MYC acetylation and 
functional regulation need further investigation.   
Another oncogenic transcription factor acetylated by TIP60 reported 
recently is TWIST1 (Shi et al., 2014). TIP60 mediates TWIST1 di-acetylation 
on K73 and K76, which is required for TWIST1 and BRD4 interaction. 
Furthermore, the interaction between TWIST1 and BRD4 is essential for 
WNT5A expression and important for breast cancer progression. However, 
this study only identified TIP60-TWIST1-BRD4 axis in WNT5A expression 
cancer cells, whether TIP60-TWIST1-BRD4 axis is essential to WNT5A non-
expression cancer cells need to be further investigated. Additionally, TIP60 
has been implicated as a tumour suppressor in many cellular pathways, 
however this study found that TIP60 could facilitate the progression of 





1.4 TIP60 in transcriptional regulation  
1.4.1 TIP60 as a co-activator of transcription 
It is believable that TIP60 could also interact with several transcription 
factors and further assist the regulation of the downstream of these 
transcription factors (Figure 5A). For example, TIP60 complex is recruited to 
MYC target gene through interacting with c-MYC. This would result in an 
increased acetylation of histone H4 and further activation of target genes 
(Frank et al., 2003). Overexpression of catalytic inactive TIP60 delays the 
acetylation on histone H4 induced by c-MYC, and also reduced recruitment of 
c-MYC to chromatin. 
TIP60 is also known to be a co-activator of NF-ᴋB (nuclear factor kappa 
light chain gene enhancer in B cells) in the regulation of its target genes, for 
example, KAI1, a metastasis suppresser gene. TIP60 is recruited to KAI1 
promoter by NF-ᴋB p50. This would activate the transcription of KAI1 gene 
and inhibit cancer metastasis (Kim et al., 2005). However, β-catenin could 
replace TIP60 on KAI1 promoter when it is overexpressed or TIP60 is 
depleted. This would further repress KAI1 expression that results in promoting 
cancer metastasis. Therefore, the balance between TIP60 and β-catenin 
determine the expression level of KAI1 and further determine the metastatic 
status of cancer.  
Other than these, TIP60 is important in E2F1 target gene transcription as 
well. It is reported that E2F1 recruits TIP60 complex to target promoter in late 
G1 phase and results in histone H4 hyper-acetylation on target promoter which 
would activate target gene (Taubert et al., 2004). Additionally, TIP60 complex 
interacts with myeloid transcription factor C/EBPα (CCAAT/enhancer binding 
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proteins), resulting in an enhancement of acetylation on histone H3 and H4 
and activates downstream targets including C/EBPα itself (Bararia et al., 
2008). 
1.4.2 TIP60 as co-repressor of transcription 
In most cases, TIP60 is reported to co-activate expression of genes. 
However, TIP60 can also act as a co-repressor of certain gene expression. 
TIP60 acts as a co-repressor through either recruits repressor complex (Figure 
5B) or interacts with transcription factor with repressive function (Figure 5C). 
For example, TIP60 is reported to interact with both HDAC7 (histone 
deacetylase 7) and STAT3 (Xiao et al., 2003),  This allows TIP60 to recruit 
HDAC7 to STAT3 target sites (Figure 5B) and represses STAT3 target gene 
expression (Xiao et al., 2003). Additionally, it is reported that TIP60 represses 
transcription by associating with transcription repressor ZEB1 (zinc finger E 
box binding protein) in certain cell types (Hlubek et al., 2001).  
 
 
Figure 5 Models of TIP60 
involvement in 
transcription.  
(A) TIP60 is recruited by 
transcription factor, 
resulting in hyperacetylaiton 
on H4 and further activation 
of transcription. (B) TIP60 
recruits repress complex and 
inhibit transcription activity. 
(C) TIP60 associates with 
transcription repressor to 






1.5 TIP60 is regulated by post-translational modification 
TIP60 is tightly regulated in cell via various processes. Regulation of 
TIP60 by protein-protein interaction and post-translational modification is 
well documented. However, regulation of TIP60 at transcription level is not 
well studied. Interestingly, TIP60 is known to be positively regulated by 
circadian transcription factor, CLOCK and this is through binding of CLOCK 
to the E-box motif on TIP60 promoter (Miyamoto et al., 2008). 
Regulation of TIP60 by protein binding has been discussed in detail 
section 1.1.2, 1.2.2 and 1.4. Hence, in this section, regulation of TIP60 by 
post-translational modification will be discussed in detail. 
1.5.1 Acetylation on TIP60 
TIP60 can be acetylated by p300/CBP acetyltransferase on lysine 268 and 
lysine 282 of TIP60 that is located within the zinc finger domain of TIP60, 
however, the effects of these acetylation on TIP60 are yet to be explored (Col 
et al., 2005).  
TIP60 is known to be auto-acetylated in response to DNA damage. The 
auto-acetylation of TIP60 occurs on lysine 327 of TIP60 that is located within 
the active site of the MYST domain (Wang and Chen, 2010; Xiao et al., 2014; 
Yang et al., 2012a). Interestingly, acetylation upregulates TIP60’s catalytic 
activity, as mutations on K327 (K327R and K327Q) abolishes both TIP60 
auto-acetylation on wild-type TIP60 and its targets such as histone H4 (Yang 
et al., 2012a). Mechanistically, this auto-acetylation of TIP60 results in 
dissociation of TIP60 oligomer and enhances its association with substrates 
(Wang and Chen, 2010). Among deacetylases, SIRT1 has been identified to 
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deacetylate K327 of TIP60 and negatively regulates its activity (Wang and 
Chen, 2010). Moreover, p300 has been shown to interact with TIP60 and 
facilitates TIP60 auto-acetylation on K327 and shown to be involved in the 
activation of FOXP3 (Xiao et al., 2014). 
1.5.2 Phosphorylation on TIP60 
TIP60 was identified to be phosphorylated at Serine 86 (Ser86) and Serine 
90 (Ser90) when human TIP60 was overexpressed in insect cells. 
Interestingly, TIP60’s acetyltransferase activity is modulated by these 
phosphorylation (Lemercier et al., 2003). Further, Ser90 was identified to be 
phosphorylated by Cyclin B/Cdc2 (cell division cycle 2) in vitro and in vivo. 
Consistent with this, Ser90 phosphorylated TIP60 accumulates in G2/M phase 
of the cell cycle and this is abolished after treat the cell with cyclin kinase 
inhibitor, Roscovitine (Seliciclib or CYC202) (Lemercier et al., 2003). This 
suggests that TIP60 is activated in G2/M phase and important for the 
regulation of G2/M cell cycle arrest. 
Ser86 was identified to be phosphorylated by GSK3β (glycogen synthase 
kinase 3) (Charvet et al., 2011; Lin et al., 2012) and this phosphorylation of 
TIP60 is involved in p53 dependent cell apoptosis (Charvet et al., 2011). As 
discussed in section 1.3.1, TIP60 mediated acetylation on p53 K120 
determines p53 to induce cell apoptosis rather than cell cycle arrest. Charvet et 
al demonstrated that TIP60 phosphorylation resistant mutant S86A, was 
unable to acetylate p53 K120 and activate PUMA expression (Charvet et al., 
2011). In addition to this, it was also reported that Ser86 phosphorylation of 
TIP60 is involved in regulation of autophagy (Lin et al., 2012). GSK3-TIP60-
ULK1 forms a signalling pathway. GSK3 mediated Ser86 phosphorylation on 
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TIP60 stimulates TIP60 dependent acetylation on ULK1 kinase and results in 
activation of ULK1 dependent autophagy under serum deprived condition.  
Recently, a new site, tyrosine 44 (Tyr44) of TIP60 was identified to be 
phosphorylated by a tyrosine kinase named c-Abl (Kaidi and Jackson, 2013). 
This phosphorylation of TIP60 promotes its interaction with H3K9Me3 which 
is required for TIP60 mediated acetylation on ATM and activation of ATM 
dependent signalling in response to DNA damage. 
1.5.3 Ubiquitination on TIP60 
TIP60 is an unstable protein with short half-life, which ranges from 30 
minutes to 2 hour. In cell, low level of TIP60 is maintained via Proteasome. 
Degradation by Proteasome is triggered by mono- or poly-ubiquitination on 
target proteins catalysed by ubiquitin ligase. However, little is known about 
the regulation of TIP60 thorugh ubiquitin-proteasome system (UPS) and 
ubiquitin ligase involved in ubiquitination on TIP60 is under explored. TIP60 
is known to be targeted for proteasome degradation by MDM2 (mouse double 
minute 2) (Legube et al., 2002). MDM2 was demonstrated to be involved in 
targeting TIP60 to proteasome degradation. MDM2 mediates TIP60 
proteasome degradation through physically interacting with TIP60 and 
through its E3 ligases activity it poly-ubiquitinates TIP60. This helps maintain 
low level of TIP60 in normal physiological scenario. However, when cells are 
exposed to DNA damage, for example, exposure to UV irradiation this inhibits 
MDM2 mediated TIP60 proteasome degradation resulting in accumulation of 
TIP60 in response to DNA damage. However, the mechanism of the inhibition 
of MDM2 mediated TIP60 degradation is still unclear. 
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TIP60 was also known to be targeted by p300/CBP-associated E4-type 
ubiquitin ligase (Col et al., 2005). This is utilized by HIV Tat to destabilized 
TIP60 resulting in impairment of TIP60 dependent apoptotic cell response to 
DNA damage. Interestingly, p300/CBP acetyltransferase activity is not 
involved in this process. 
Since TIP60 has a high turnover, involvement of ligase(s) other than 
MDM2 and p300/CBP cannot be overruled.  
1.6 TIP60 represses viral genome transcription and is destabilized 
by viral oncoproteins through ubiquitin proteasome system 
TIP60 is destabilized by viral oncoproteins via ubiquitin-proteasome 
system (UPS), for example HIV Tat protein utilize p300/CBP-associated E4-
type ubiquitin ligase to destabilize TIP60 (Col et al., 2005). In addition to HIV 
TAT, human papillomaviruses (HPVs) also targets TIP60 to UPS. 
HPV are non-enveloped DNA viruses that infect mucosal or cutaneous 
squamous epithelium and cause hyper-proliferation (Howley and Livingston, 
2009; zur Hausen, 2002). HPV infection causes cancer mainly due to the 
destabilization of p53 and pRB by viral E6 and E7 protein respectively 
(Munger and Howley, 2002; zur Hausen, 2002). HPV E6 interacts by its N-
terminal residues with p53 and with a cellular ubiquitin ligase E6AP (E6-
associated protein), forming a complex that results in ubiquitin-mediated 
degradation of p53 by the proteasome (Cooper et al., 2003; Huibregtse et al., 
1991, 1993; Scheffner et al., 1993). 
Recently our group discovered that TIP60 was also destabilized by HPV 
E6 in cervical cancer (Jha et al., 2010). This destabilization was proteasome 
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dependent since MG132 treatment restored TIP60 level. Interestingly, deletion 
and mutational analysis of E6 reveals that this is through the N-terminal region 
of E6 and does not require interaction with E6AP suggesting a novel ligase 
might be utilized by E6 to destabilize TIP60. 
As far as biological significance is concerned, it was demonstrated that 
TIP60 could repress viral gene transcription and this was through TIP60-
dependent acetylation of H4 on HPV promoter, and recruitment of BRD4-
repressor complex (Jha et al., 2010). These data suggests that E6 destabilizes 
TIP60 to release the expression of early viral proteins, and ablation of p53 
dependent cellular pathways. These data also highlight an important role of 
TIP60 in regulating virus transcription and the reason why viral proteins such 
as HPV E6 would target TIP60 for degradation. Whether regulation is 
common to other oncoviruses or restricted to HIV and HPV needs further 
investigation. 
1.7 Down-regulation of TIP60 might be a potential marker for the 
malignancy of cancer 
TIP60 is downregulated in multiple cancers. As mentioned above, TIP60 
is downregulated in various virus-induced cancers including HPV induced 
cervical cancer. Apart from that, the TIP60 gene expression is downregulated 
in colon carcinomas and lung cancers (ME et al., 2006). Moreover, loss of 
nuclear TIP60 staining is found in mammary carcinomas (Gorrini et al., 2007). 
These studies indicate that reduced TIP60 expression correlates with tumour 
development. This is consistent with the studies identifying association 
between TIP60 expression, cancer metastasis and survival of patients. Along 
these lines, Chen et al. used tissue microarray containing a large number of 
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melanoma biopsies and evaluated the expression of TIP60 in 
pathophysiological scenario and clinical outcome (Chen et al., 2012). Their 
data demonstrated that reduced TIP60 expression is significantly associated 
with melanoma metastasis and predicts a poorer survival in melanoma 
patients. They also showed that forced TIP60 expression inhibits melanoma 
cell migration. 
Downregulation of TIP60 was also observed in colorectal cancer. TIP60 
downregulation showed significant correlation with larger tumour size, poorly 
differentiated type, peritoneal dissemination, distant metastasis, and higher 
stage of TNM classification (Sakuraba et al., 2009). These suggested that 
TIP60 was more frequently downregulated in advanced colorectal carcinoma 
and downregulation of TIP60 could be a potential marker for the malignancy 
of colorectal cancer. 
1.8 Epithelial mesenchymal transition and cancer metastasis 
Epithelial-mesenchymal transition (EMT) is a highly conserved cellular 
program that allows polarized, immotile epithelial cells to convert to motile 
mesenchymal cells (Yang and Weinberg, 2008). EMT process can be 
categorised into three major changes in cellular phenotype (Boyer and Thiery, 
1993; Hay, 1995): (1) morphological changes from a cobblestone-like 
monolayer of epithelial cells with an apical-basal polarity to dispersed, 
spindle-shaped mesenchymal cells with migratory protrusions; (2) changes of 
differentiation markers from cell-cell junction proteins and cytokeratin 
intermediate ﬁlaments to vimentin ﬁlaments and ﬁbronectin and (3) the 
functional changes associated with the conversion of stationary cells to motile 
cells that can invade through extra cellular matrix (ECM). Although all three 
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changes are not observed during EMT; acquisition of the ability to migrate and 
invade ECM as single cells is considered a functional hallmark of the EMT 
program (Yang and Weinberg, 2008). 
EMT program has been implicated in the dissemination of single 
carcinoma cells from primary epithelial tumours (Thiery, 2002). Systemic 
spread of tumour cells has already been detected from early lesions in HER-2 
transgenic mice and in human ductal carcinoma, which suggest that metastasis 
is not necessarily a late event in tumour progression (Husemann et al., 2008). 
Additionally, morphological evidence has shown that EMT occurs at invasive 
fronts of human tumours (Prall, 2007). Similarly, in colon carcinoma, EMT 
occurs at the invasive front and produces single migratory cells that shows 
reduced E-CADHERIN expression (Thiery et al., 2009). 
Many EMT-inducing transcription factors, including SNAIL1, SNAIL2, 
dEF1, SIP1, TWIST1, FOXC2, and GOOSECOID, have been associated with 
tumour invasion and metastasis (Yang and Weinberg, 2008). The involvement 
of several EMT-inducing transcription factors has been reported in human 
carcinomas. For example, overexpression of TWIST1 was associated with 
distant metastasis and poor survival in N-MYC-ampliﬁed neuroblastomas 
(Valsesia-Wittmann et al., 2004) and in melanomas (Hoek et al., 2004). 
The main functions of these transcription factors are to bind to the 
promoter of cell adhesion molecules to inhibit their expression or binding to 
the promoter of cell migration related proteins to activate their expression. 
During the EMT process, changes in cell morphology associate with 
downregulation of cell adhesion proteins such as E-CADHERIN and EpCAM, 
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and upregulation of cell migration related proteins such as FIBRONECTIN or 
VIMENTIN.  
1.9 TIP60 antagonizes DNMT1 
There are three classes of DNA methyltransferase (DNMTs): DNMT1, 
DNMT2 and DNMT3 (DNMT3A and DNMT3B) (Bestor, 2000). De novo 
DNA methylation is catalysed by DNMT3A and DNMT3B, whereas 
maintenance of DNA methylation during cell proliferation is done by DNMT1 
(Jones and Baylin, 2007). Among all the DNMTs, DNMT1 is the most 
abundantly expressed (Espada et al., 2011). DNMTs are progressively 
upregulated in cancers including colorectal adenoma-carcinoma (Schmidt et 
al., 2007), suggesting an oncogenic function of DNMTs.  
TIP60 is known to form a complex with DNMT1 through UHRF1, 
resulting in TIP60 mediated acetylation on DNMT1 and promoting DNMT1 
ubiquitination-dependent degradation (Du et al., 2010b). This regulation of 
DNMT1 maintains the proper DNMT1 level at different stages of cell cycle i.e 
promote DNMT1 degradation at the end of S phase or the beginning of G2 
phase (Du et al., 2010b). Previous studies also reported that TIP60 mediated 
DNMT1 degradation can be facilitated by RGS6 (Regulator of G-protein 
signalling 6) to suppress Ras-induced cellular transformation (Huang et al., 
2014), suggesting a tumour suppressor function of TIP60 by targeting 




Chapter 2: Objectives and Significance 
2.1. The mechanism and the biological implications of E6 mediated 
TIP60 degradation 
As discussed earlier, HPV E6 mediated destabilization of TIP60 was 
independent of E6AP. When I embarked onto this project, E6AP was the only 
E6 associated ligase identified. Thus, suggesting an interesting challenge of 
identifying the molecular mechanism that is utilized by HPV E6 to destabilize 
TIP60.  
But why would these viruses destabilize TIP60, in particular high-risk 
HPVs. TIP60 has been implicated in apoptosis and cell cycle arrest through 
acetylation of p53. However, these viruses target p53 for degradation, 
suggesting a novel function of TIP60 in virus-induced cancers. Thus, I decided 
to investigate the biological implications of restoring TIP60 in virus-induced 
cancers. 
2.2. The mechanism of TIP60 mediated inhibition of cancer metastasis 
As discussed earlier, downregulation of TIP60 was correlated with cancer 
metastasis suggesting TIP60’s role in inhibiting cancer metastasis. Thus I 
focused on investigating role of TIP60 in inhibiting cancer metastasis using 
both in vitro and in vivo models. Following which, I identify the molecular 




Chapter 3: Materials and Methods 
Cell lines: HeLa, MDA-MB-468 and HEK293T cells were cultured in 
Dulbecco's modified Eagle's medium high glucose (Sigma-Aldrich, Cat. NO. 
D5796) supplemented with 10% fetal bovine serum (Sigma-Aldrich, Cat. NO. 
F7524). Ca-SKI cells were grown in RPMI medium (HyClone, Cat. NO. 
SH30027.01) supplemented with 10% fetal bovine serum (Sigma-Aldrich, 
Cat. NO. F7524). MCF10A cells (ATCC CRL-10317TM) were cultured in 
Dulbecco’s modified eagle’s media (DMEM)/F12 (1:1) media (Gibco, Cat. 
No. 11330-032) supplemented with 5% horse serum (Gibco, Cat.No. 16050-
122), 20 ng/ml epithelial growth factor (Peprotech, Cat. No.AF-100-15), 0.5 
mg/ml hydrocortisone (Sigma-Aldrich, Cat. No. H-0888), 100 ng/ml cholera 
toxin (Sigma-Aldrich, Cat. No. C-8052) and 10 μg/ml insulin (Sigma-Aldrich, 
Cat. No. I-1882). MDA-MB-231-luc-D3H2LN (PerkinElmer, Cat. No. 
119369) cells were cultured in DMEM with high glucose (Sigma-Aldrich, Cat. 
No. D-5796), supplemented with 10% foetal bovine serum (Sigma-Aldrich, 
Cat. No. F-7524), 1 mM sodium pyruvate (Gibco, Cat.No. 11360-070) and 1% 
of 100× MEM non-essential amino acid solution (Sigma, Cat. No. M-7145). 
HCC1937 cells were cultured in DMEM with high glucose, supplemented 
with 10% fetal bovine serum and 1 mM sodium pyruvate. Cell cultures were 
incubated at 37ºC with 5% CO2. 
siRNA transfection: siRNAs target different genes were transfected  using 
Lipofectamine RNAiMax reagent from Invitrogen/Life Technologies (Cat. 
No. 56532). The siRNA mixture used contained 15 l Lipofectamine 
RNAiMax, 2 ml optimum media (Gibco, Cat. No. 31985-070) and 20 nM 
siRNA. The transfection mixture was incubated for 20 min at room 
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temperature and then 1×106 cells were seeded in a 10-cm plate together with 
the siRNA mixture. After 6 h, the transfection mixture was replaced by growth 
media. Cells were harvested 72 h after siRNA transfection. 
Plasmids transfection: HeLa cells were transfected using calcium phosphate 
precipitation method. Briefly, 7×105 cells were seeded into 10-cm dish 16 
hours before transfection. On the day of transfection, 10 g total DNA were 
mixed with 190 l TE buffer (10 mM Tris-HCL pH 8.0, 1 mM EDTA), 22 l 
2 mM CaCl2 and 200 l 2X HBS buffer (274 mM NaCl, 10 mM KCl, 1.4 mM 
Na2HPO4, 42 mM HEPES pH 7.05). After incubating in room temperature for 
20 minutes, the DNA mixtures were added into cells drop by drop. Cells were 
harvested 24 hours after transfection. HEK293T cells were transfected using 
Lipofectamine 2000 reagent from Invitrogen/Life Technologies 
(Invitrogen/Life Technologies, Cat. No. 52887) following the manufactory 
protocol. 
siRNA sequences: siControl: Forward: 5’-
CGUACGCGGAAUACUUCGAdTdT-3’; Reverse: 5’-
UCGAAGUAUUCCGCGUACGdTdT-3’. siTIP60: Forward: 5’-
UGAUCGAGUUCAGCUAUGAdTdT-3’; Reserve: 5’-
UCAUAGCUGAACUCGAUCAdTdT-3’. siEDD1: Forward: 5’-
CAACUUAGAUCUCCUGAAAdTdT-3’; Reverse: 5’-
UUUCAGGAGAUCUAAGUUGdTdT-3’. siSNAI2 (Cat. No. sc-38393), 
siDNMT1 (Cat.No.sc-35204) and siDNMT3B (Cat. No. sc-37759) were 
purchased from Santa Cruz Biotechnology. 
26 
 
Plasmids: pCDNA-β-Gal, pCDNA-16E6, shRNA constructs against control 
and EDD1 were kindly provided by Prof. Lawrence Banks (ICGEB, Trieste). 
MSCV-Flag-TIP60WT, MSCV-Flag-TIP60*WT, MSCV-Flag-TIP60*KD 
were generated in lab. *, siRNA resistant; KD, catalytic inactive form. pcDNA 
SNAIL2-MYC was purchased from Addgene. FUW-FLAG-DNMT1-E2A-
mCherry-T2A was kindly provided by Prof. Daniel G Tenen (CSI, Singapore). 
Mutagenesis: To generate siRNA-resistant wild-type or catalytically inactive 
TIP60, the siRNA binding sites were mutated by using QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent, Cat. No. 200522). The PCR primers 
used for mutagenesis: TIP60*: forward: 
reverse: 5’-
CCACTTTGGAGAGTTCgTAtgaaAAtTCaATtAGCAGCTTGCCGTAGCC-
3’. TIP60KD: forward: 5’-
CTGCCTCCCTACgAGCGCCGGGagTACGGCAAGCTG-3’; reverse: 5’-
CAGCTTGCCGTActCCCGGCGCTcGTAGGGAGGCAG-3’. 
Western analysis: Proteins were separated on SDS-PAGE gels, transferred 
onto nitrocellulose membranes (BioRad, Cat. No. 9004-70-0), and detected 
using a primary antibody against β-GAL (Promega, Cat. NO. Z37880, 
1:10000), EDD1 (SantaCruz Biotechnology, Cat. NO. sc-9562, 1:500), 
ACTININ (SantaCruz Biotechnology, Cat. NO. 166524, 1:1000). β-ACTIN 
(SantaCruz Biotechnology, Cat.No. sc-81178, 1:1000), FIBRONECTIN 
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(SantaCruz Biotechnology, Cat. No. sc-8422, 1:500), EpCAM (Cell Signaling, 
Cat. No. 2626S, 1:1000), SNAIL2 (Cell Signaling, Cat. No. 9585S, 1:1000), 
FLAG (SantaCruz Biotechnology, Cat.No. sc-807, 1:1000), E-CADHERIN 
(BD Biosciences, Cat.No. 610182), DNMT1 (Abcam, Cat. No. 92314) and 
TIP60 rabbit polyclone antibody was generated in the lab. 
Protein half-life examination:  The half-life of TIP60 and DNMT1 are 
examined by cycloheximide (Sigma Aldrich, Cat. No. C7698) treatment. 
Briefly, 3.5 ×105 cells were seeded into 6-cm dishes 16 hours before 
treatment. On the day of treatment, 100 g/ml cycloheximide were added into 
the media and cells were harvested after 0, 1 or 2 hours treatment for TIP60 
and 0, 6, 12 hours treatment for DNMT1. Protein half-life was then examined 
by western blot.  
Purification of mRNA: Total RNA was isolated using TRIZOL reagent 
(Invitrogen/Life Technologies, Cat No. 15596-026) following the 
manufacturer’s protocol. RNA was dissolved in nuclease-free water for 
reverse transcription-PCR. 
Reverse transcription and quantitative PCR: Complementary DNA 
(cDNA) was synthesised using iScript cDNA Synthesis Kit (Bio-Rad, Cat. No. 
170-8891) according to manufacturer’s protocols. Quantitative PCR (qPCR) 
was performed with primer sets corresponding to primer list table (Table 1) 
and using iTaq Universal SYBR Green Supermix (Bio-Rad, Cat. No. 172-
5125) on an Applied Biosystems 7500 Fast Real Time PCR system. Results 
were analysed and are represented as fold change. 
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Table 1 Sequences of primers used for RT-qPCR 




TIP60 AATGTGGCCTGCATCCTAAC TGTTTTCCCTTCCACTTTGG 
CDH1 TTACTGCCCCCAGAGGATGA TGCAACGTCGTTACGAGTCA 
EpCAM GCTGGCCGTAAACTGCTTTG ACATTTGGCAGCCAGCTTTG 
VIM CTGCCAACCGGAACAATGAC CATTTCACGCATCTGGCGTT 
SNAI1 TCTTTCCTCGTCAGGAAGCC GATCTCCGGAGGTGGGATGG 
SNAI2 CTCCTCATCTTTGGGGCGAG CTTCAATGGCATGGGGGTCT 
TWIST1 TCGGACAAGCTGAGCAAGATT GCAGCTTGCCATCTTGGAGT 
CDH2 CCGGTTTCATTTGAGGGCAC TCCCTCAGGAACTGTCCCAT 
FN1 AACCCTTCCACACCCCAATC ACTGGGTTGCTGACCAGAAG 
ZEB1 AGGATGACCTGCCAACAGAC CTTCAGGCCCCAGGATTTCTT 
ZEB2-1 CCCTGGCACAACAACGAGAT AATTGCGGTCTGGATCGTGG 




GAPDH CAGCCTCAAGATCATCAGCA TGTGGTCATGAGTCCTTCCA 
DNMT1 TACCTGGACGACCCTGACCTC CGTTGCATCAAAGATGGACA 




Stable cell lines: Virus was generated by transfecting 5×106 293T cells with 
the plasmids [MSCV construct: i.e., MSCV vector control, TIP60 wild type 
(TIP60WT), siRNA-resistant TIP60 wild type (TIP60*WT), and siRNA-
resistant catalytically inactive TIP60 (TIP60*KD); LPCX construct: i.e., 
LPCX vector control, TIP60 wild type (TIP60WT)] using Lipofectamine 2000 
(Invitrogen/Life Technologies, Cat. No. 52887), as per manufacturer’s 
protocol. Viruses were harvested after 72 h of transfection and were used to 
infect 1×106 MCF10A or HCC1937 or MDA-MB-468 or 2×106 MDA-MB-
231-luc-D3H2LN cells or HeLa cells together with polybrene (Sigma-Aldrich, 
Cat. No. 107689) reagent (4 µg/ml). After 6 h, media containing the virus was 
replaced by growth media. After 24 h, puromycin was added into the growth 
media for selection. Media with antibiotics was changed every 48 h until the 
mock-transfected cells died. The cells were continuously selected for 2 weeks 
and for the creation of stable cell lines. EDD1 stably depleted [shRNA 
constructs: i.e. shTR2 (luciferase control) and shEDD1] HeLa cells and 293T 
cells were kindly provided by Prof. Lawrence Banks (ICGEB, Trieste). The 
list for stable cell lines is indicated in Table 2. 






















WT, wild type; KD, catalytic inactive; *, siRNA resistant 
 
Colony formation assay (CFA): 2×103 cells per well were seed in 6 well 
plates with media containing 5% FBS. After 2 weeks, the colonies were 
stained with Cristal Violet (Simga Aldrich, Cat. No. C3886) and quantified 
using Image J software (http://imagej.nih.gov/ij/).  
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Soft agar assays: 12 well plates were coated with bottom agar [2X DMEM 
supplemented with 20% FBS and 1% agar (BioRad, Cat. No. 161-3111) 1:1 
mixture]. Then 1×103 cells were mix with upper agar (2X DMEM 
supplemented with 20% FBS and 0.8% agar 1:1 mixture) and seeded onto the 
bottom agar. Plates were incubated at 37 ºC with 5% CO2 for 2 weeks. The 
colonies were stained with Giemsa stain and quantified using Image J 
software.  
In vivo mice experiment: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 
were obtained courtesy of Chan Shing Leng (National University of 
Singapore). HeLa-LPCX or HeLa-TIP60 cells were suspended in 100 µl of 
serum-free DMEM medium at a concentration of 1 × 105 cells/ml, or 1 × 106 
cells/ml supplemented with BD Matrigel matrix (BD Biosciences, Cat. No. 
354234), and were injected subcutaneously into the right or left flank of NSG 
mice. Tumours were excised and total tumour weight recorded. All animal 
studies were done according to approved protocols by the NUS Institutional 
Animal Care and Use Committee (IACUC), Singapore. 
In vitro invasion assay: In vitro invasion assay was performed as described 
previously (Korah et al., 2000) using the BD MatrigelTM Invasion chamber 
and 24-well plate 8.0 Micron insert (BD BiocoatTM, Cat. No. 354480). Briefly, 
50,000 MM-Luc-MSCV, or MM-Luc-FT60WT cells were seeded onto the top 
layer of the chamber and mixed with serum-free media. The bottom layer was 
filled with 750 µl growth media comprising 2% foetal bovine serum. After 8 
h, cells that had invaded into the bottom layer were stained and quantitated 
using ImageJsoftware (http://imagej.nih.gov/ij/).  
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Wound-healing assay: Wound-healing assays were performed as described 
previously (Chen et al., 2012; Oxmann et al., 2008). Briefly, siRNA-
transfected (siControl, siTIP60, siDNMT1,siTIP60/siDNMT1, siSNAI2 and 
siTIP60/siSNAI2) MCF10A cells or the stable metastatic breast cancer cell line 
was seeded into the wells of 24-well plates at 100% confluence. Cells were 
then maintained in complete media for another 12 h for adhesion. Cells were 
then subjected to serum-starved conditions for next 24 h. A wound was 
created using a fine pipette tip and the detached cells were removed by gently 
washing the wells with phosphate-buffered saline. The closure of wound was 
monitored every 24 h. For MCF10A, HCC1937 and MDA-MB-468 cells, the 
area of the wound was measured at 0 h and the percentage of movement was 
calculated by using the following formula: (area of wound at 0 hours – area of 
wound at n hours) / area of wound at 0 hour × 100, where n is a specific time. 
For MDA-MB-231-luc-D3H2LN, the number of cells migrated during gap 
healing were counted. Each experimental group was repeated three times. 
Immunofluorescence: MCF10A cells were transfected with siControl and 
siTIP60 as described above and were grown on a cover slide, fixed with 3.7% 
paraformaldehyde (Sigma-Aldrich, Cat. No. P-6148), and incubated with E-
CADHERIN (BD Biosciences, Cat. No. 610182, 1:500), β-CATENIN (BD 
Biosciences, Cat. No. 610153, 1:500) or FLAG (Santa Cruz Biotechnology, 
Cat.No. sc-807, 1:500) primary antibodies. Secondary antibodies used were 
Alexa Fluor 488 donkey anti-rabbit IgG (H+L) (Invitrogen/Life Technologies, 
Cat. No. A21206, 1:500) and Alexa Fluor 594 donkey anti-mouse IgG (H+L) 
(Invitrogen/Life Technologies, Cat. No. A21203, 1:500).  
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Chromatin immunoprecipitation quantitative PCR (ChIP-qPCR): ChIP 
was performed as described earlier (Jha et al., 2010; Karnani et al., 2007). 
Briefly, 5×106 cells were transfected with siControl or siTIP60 in a 15-cm 
plate. After 72 h of siRNA treatment, cells were cross-linked with 1% 
formaldehyde (SantaCruz Biotechnology, Cat. No. sc-203049A) for 10 min at 
room temperature, and then washed twice with ice-cold phosphate-buffered 
saline. Cells were harvested by scraping and centrifuged at 1750 g for 15 min 
to collect the cell pellet. Cells were then resuspended in SDS lysis buffer (1% 
SDS, 0.01 M EDTA and 0.05 M Tris-HCl, pH 8.0) and sonicated (ON: 15 sec 
and OFF: 45 sec at 30% amplitude for 15 cycles) to obtain DNA fragments 
ranging from 100 to 500 bp. Chromatin was isolated by centrifuging at 15300 
g for 15 min at 4ºC and the supernatant was collected for 
immunoprecipitation. 
Immunoprecipitation was performed with anti-SNAIL2 antibody (Cell 
Signaling, Cat. No. 9585) or anti-DNMT1 antibody (Abcam, Cat. No. 
ab87656) overnight at 4C, followed by incubation with protein A/G PLUS 
agarose beads (SantaCruz Biotechnology, Cat. No. sc-2003) for 3 h. Beads 
were then washed with (i) low-salt immune complex buffer (0.1% SDS, 1% 
TritonX-100, 0.002 M EDTA, 0.02 M Tris-HCl, pH 8.0, and 0.15 M NaCl), 
(ii) high-salt immune complex buffer (0.1% SDS, 1% Triton-X-100, 0.002 M 
EDTA, 0.02 M Tris-HCl, pH 8.0, and 0.5 M NaCl), (iii) LiCl buffer (0.25 M 
lithium chloride, 1% NP40, 0.001 M EDTA, 0.01 M Tris-HCl, pH 8.0, and 1% 
deoxycholate) and (iv) TE buffer (0.001 M EDTA and 0.01 M Tris-HCl, pH 
8.0). Beads were eluted in 100 µl elution buffer (1% SDS and 0.0084% 
NaHCO3) three times with agitation for 15 min each. Chromatin was reversed 
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cross-linked by adding 0.2 M NaCl and was heated at 65ºC for 4 h. The 
proteins bound to DNA were digested by adding 20 µg proteinase K 
(AppliChem, Cat. No. 39450-01-6) and incubated at 45ºC for 1 h. DNA was 
purified using a PCR purification kit (QIAGEN, Cat. No. 28106) and used as 
template for qPCR. The results were analysed and are represented as percent 
input. Table 3 shows the sequence information for the primers used for qPCR 
(Stanisavljevic et al., 2011). 
Table 3.  Sequences of primers used for ChIP-qPCR. Red are the primer sets used in 
Figure 31, Figure 32 and Figure 39. 
  Forward (5'-3') Reverse (5'-3') 
FN11 TATTTTATGGGTTTTCTTCCT AGCGGCTGGGAGGAAAGGGAG 
FN12 GGAGCCCGGGCCAATCGGCG TGTGCAGCACAGCCGGCGCGG 
FN13 TCCTTCCCCCAGAATCAATGAA GGGAAGCCGAGTGTTTCTTCC 
FN14 GTTGAGACGGTGGGGGAGAGA CCGTCCCCTTCCCCA 
EpCAM1 TTTAGTAGAGACAGGTTTTCA TTTTATGTTTTAATTGTGAAT 
EpCAM2 CGGGTGTGGTGGTGGGCGCCT CCACCACACCCGGCTGATCCA 
EpCAM3 AAGCCACAATAACCAGTTAGT GGCAACAAGAGCGAAACTCCG 
EpCAM4 TTTTATTTTTTGAGATGGAGT TGGTGAAACCCATCTCAACTA 
EpCAM5 TATGAAGTATTTATAATTATT TAGAGCCAAATACTGAGAACC 
EpCAM6 CTAATTTTGTATCTTTTAGTA TTTTCGTTTTCATAAGCATTT 
EpCAM7 GTTCTGGAAGGTTCTCTGCCT CCATGGCGGCGTTAGGGATCT 










DNA methylation analysis using bisulphite pyrosequencing: DNA 
methylation analyses were performed as described previously (Mikeska et al., 
2011). Briefly, DNA was bisulphite converted using EpiTect Fast DNA 
bisulfite kit (Qiagen) according to the manufacturer’s protocol. Prior to 
pyrosequencing, PCR reactions were carried out using PyroMark PCR kit 
(Qiagen) in a 50 µl reaction volume (PCR primers used: promoter region: 
forward: GAAGGTTTTTTGTTTGTGTTTGTAT; reverse: 
[Btn]ACCCTCTCCACAAATATAAACC. 1st intron region: forward: 
GGGTATAATAGGGAGGGGATTAAG; reverse: [Btn] 
CCAAAACCATTTCCCTACCAA; Btn, biotin). An initial polymerase 
activation step of 15 min at 95°C was followed by 40 cycles of 30 s at 94°C, 
30 s at 56°C and 30 s at 72°C, and a final step of 5 min at 72°C. The 
biotinylated PCR products were extracted with streptavidin sepharose beads 
(GE Healthcare) according to the manufacturer's instructions and released into 
a PSQ 96 Low Plate (Biotage) containing 40 µl pyrosequencing primer 
(promoter region: GAGACGAAGTATTTGGGG; 1st intron region: 
GGGAGGGGATTAAGA) which has been diluted with annealing buffer to a 
final concentration of 0.4 µM. The plate was incubated at 80°C for 2 min, 
cooled to room temperature and run on a PyroMark ID machine (Biotage) 
using PyroMark Gold reagents (Qiagen) as specified by the manufacture. 
Results were analyzed with PyroMark software for DNA methylation 
quantification. 
Co-immunoprecipitation (co-IP): 5 µg of pcDNA-SNAIL2-MYC and 5 µg 
of FUW-FLAG-DNMT1-E2A-mCherry-T2A were co-expressed in 293T 
cells. FLAG-DNMT1 was immunoprecipitated using FLAG-M2 agrose beads 
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(Sigma Aldrich, Cat. No. A2220) and associated SNAIL2-MYC was probed 
using SNAIL2 antibody indicated above. Untransfected 293T cells serves as 
transfection control and 293T cells overexpressed SNAIL2-MYC alone serves 
as IP control. 
Bioluminescence assay in mice: Tail-vein injection was performed as 
described previously (Liang et al., 2005; Yang et al., 2012b). Briefly, 6-week-
old NOD/SCID mice (Invivos, Singapore) were divided into three groups with 
four mice per group. Each mouse received a tail-vein injection of 5×105 MM-
Luc-MSCV or MM-Luc-FT60WT or MM-Luc-FT60KD cells, and images 
were taken every 7 days after injection using IVIS 200 Pre-clinical in vivo 
Imaging System. All protocols for animal studies were reviewed and approved 
by the Institutional Animal Care and Use Committee at the National 
University of Singapore. Analyses of the images were performed as described 
previously (Craft et al., 2005; Wu et al., 2001) using Living Image software 
(IVIS imaging system). 
Data preprocessing of Affymetrix microarray gene expression: Data 
processing of microarray gene expression of breast cancer samples is 
described elsewhere (Kumar et al., 2013). Briefly, 26 breast cancer cohorts on 
Affymetrix U133A or U133Plus2 were downloaded from Gene Expression 
Omnibus (GEO) and Array Express. Robust Multichip Average (RMA) 
normalisation was performed on each cohort and, the normalised data was 
standardised using ComBat (Johnson et al., 2007) to remove batch effects. The 
standardised data yielded a dataset of 3,992 breast cancer tumours, and 22 
normal breast tissue samples.  
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Identification of breast cancer subtypes: Breast cancer subtype signature 
was obtained from the study by Prat et al. (2010) (Prat et al., 2010). 
Subsequently, single sample Gene Set Enrichment Analysis (ssGSEA) 
(Verhaak et al., 2010) was performed to estimate enrichment scores for the six 
breast cancer subtype signatures (Basal, Claudin-Low, Luminal-A, Luminal-
B, ERBB2+, and Normal-like) expressed in each sample. Each sample was 
then assigned a subtype depending on the ssGSEA enrichment score. 
Statistical analysis: Statistical significance evaluations were computed by 
Mann–Whitney test, Spearman Correlation Coefficient, log-rank test of 
Graphpad Prism® ver 5.04 and two sample two tailed student t-test. Error bars 




TIP60 functions as a tumour suppressor in HPV-induced cervical cancer 
and is degraded by HPV E6 through ubiquitin proteasome system 
4.1 Overexpressing TIP60 inhibits tumour growth  
TIP60 is a tumour suppressor and is a transcriptional repressor of E6 
expression. Therefore, I reasoned that gain-of-function of TIP60 might 
antagonize E6 mediated cellular growth and thereby inhibit tumour cell 
growth in HPV-induced cervical cancer cells. To address this, I used retroviral 
system to generate HeLa cells (Figure 6A) stably overexpressing FLAG-
TIP60. I then characterized the growth ability of HeLa-TIP60 cells in vitro by 
colony formation assay. HeLa-LPCX vector control or HeLa-TIP60 
expressing cells were seeded at very low density (2×103/per well in 6 well 
plate) for colony formation assays and maintained in antibiotic selection. After 
two weeks the colonies were fixed, stained and quantified. Representative 
images in Figure 6B and the quantifications in Figure 6C show that 
overexpression of TIP60 inhibited the ability of HeLa cells to form colonies 
by over 70%. Further, I questioned whether this phenomenon is due to the 
inhibition of E6 function. To address this, I overexpressed either pcDNA 
vector alone or pcDNA HPV18 E6 in HeLa-LPCX and HeLa-TIP60 cells 
(Figure 6D). Interestingly, I found that in vector control cells, overexpressing 
TIP60 decreases E6 endogenous level, which suggests that TIP60 might 
decrease HeLa cells colony formation ability through downregulating 
expression of E6. Then I performed colony formation assay, in Figure 6B and 
Figure 6C, I observed that by overexpression of E6 in HeLa-TIP60 cells 
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significantly rescued the colony formation when compared with vector control 
and there was no change in colony formation of HeLa-LPCX cells 
overexpressing E6 compared with vector control. These data suggested that 






Figure 6. Overexpressing TIP60 inhibits colony formation of HeLa cells in vitro and 
HPV 18 E6 rescues the growth defect in HeLa-TIP60 cells.  
(A) Western blot analysis confirming retroviral-induced TIP60 expression in HeLa-
TIP60 cells. (B) Representative images from the CFA performed in HeLa stable cells 
indicated in D. (C) Bar graph represent the results obtained from quantifications of at 
least three independent experiments. Quantifications were performed using Image J 
software; error bars represent the standard deviation. Significance is represented as 
***p<0.001. (D) HeLa-LPCX or HeLa-TIP60 cells were transiently transfected with 














Based on the in vitro results, I wanted to investigate this strong 
phenotype of TIP60 on cellular growth in vivo. NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NSG) mice were subcutaneously injected with 1×106 HeLa-
LPCX cells on the left and 1×106 HeLa-TIP60 cells on the right. Tumour sizes 
were measured every week. After seven weeks, the mice were sacrificed and 
the tumours were excised. The representative images from Figure 7A, B and 
quantifications from Figure 7C shows that the tumours induced by HeLa-
LPCX cells were significantly reduced by 80% with TIP60 overexpression. I 
was then highly interested in verifying the TIP60 expression in these tumours. 
The total protein from the tumour tissue was extracted and western blotted 
with anti-FLAG antibody to detect overexpressed TIP60. As shown in Figure 
7D anti-FLAG band corresponding to TIP60 was detected only from tumours 
induced by HeLa-TIP60 cells and not in the control. Mice from all the repeats 



















Figure 7. Overexpressing TIP60 inhibits tumour growth in vivo.  
(A) Representative images of the mice subcutaneously injected with HeLa LPCX and 
HeLa LPCX-TIP60 cells on the left and the right side, respectively. (B) Images 
showing the difference in sizes of tumour obtained from HeLa LPCX and HeLa-
TIP60 cells. (C) Graph showing tumour growth monitored in six mice at indicated 
times. The graph is represented in volume (mm3) calculated using the formula: 
Volume (V)=Width (W)(2) × Length (L)/2. Error bar represented the standard 
deviation from six mice. Statistical significance was performed using student t-test 
and is represented as *, p<0.05; ***, p<0.001. (D) Protein isolated from tumours was 

















Figure 8. Mice (n=6) used in the in vivo experiment shown in Figure 7.  
Overexpressing TIP60 inhibit tumour growth in vivo. (A) Representative images of 
the mice subcutaneously injected with HeLa LPCX and HeLa LPCX-TIP60 cells on 
the left and the right side, respectively. (B) Images showing the difference in sizes of 







4.2 HPV E6 utilizes E3 ubiquitin ligase EDD1/UBR5 to regulate 
TIP60 protein turn over 
From mass spectrometry analyses of TIP60 interacting proteins, Dr. 
Vanitha Krishna Subbaiah identified E3 ubiquitin ligase EDD1/UBR5 as an 
interacting partner of TIP60 (data not shown). Therefore, I hypothesized that 
EDD1 might regulate the protein stability of TIP60. To investigate this, two 
stable cell lines were generated: HeLa shcontrol which served as control and 
HeLa shEDD1 which stably depleted EDD1 (Figure 9). Interestingly, 
depletion of EDD1 increased TIP60 protein level (Figure 9A) but not TIP60 
mRNA level (Figure 9B), suggesting that EDD1 might regulate TIP60 level 
through regulating its protein stability. Then HeLa shcontrol or shEDD1 cells 
were treated with cyclohexamide (CHX) for indicated time point to block 
protein synthesis. The residual levels of endogenous TIP60 were then 
determined using anti-TIP60 antibody (Figure 10A). The quantification was 
shown in Figure 10B. Within 2 hours of CHX treatment, TIP60 protein 
stability increased by 60% upon depleting endogenous EDD1.  
Based on these results, I decided to ascertain the effects of HPV E6 on 
TIP60 levels in the absence of endogenous EDD1. For this, we generated 
293T cells stably expressing shEDD1, and depletion of EDD1 was confirmed 
by western blot (Figure 11A). In these stable cells, FLAG-TIP60 was 
transfected either in combination with pcDNA vector or pcDNA-HPV18 E6 
and the total cellular lysates were analyzed by western blot (Figure 11B). 
Cyclohexamide treatments for indicated time points were performed in these 
transfected cells. Western blot was shown in Figure 10C and quantification in 
Figure 11D, E. From this experiment, I observed that depleting EDD1 
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stabilizes TIP60 also in 293T cell (Figure 11C, D). Additionally, 
overexpressing HPV18 E6 destabilized TIP60 (Figure 11C). Furthermore, the 
decreased protein stability of TIP60 caused by overexpressing E6 was rescued 
by depleting EDD1 (Figure 11C, E). These results suggest that EDD1 co-
operates with E6 in destabilizing TIP60. 
  
Figure 9. EDD1 regulates TIP60 at protein level but not at mRNA level.  
(A) HeLa cells stably overexpressing either shcontrol or shEDD1 shRNA. Western 
blot using indicated antibodies shows a depletion of EDD1 and increase of TIP60 
protein level. (B) Verification of the expression of EDD1 and TIP60 in HeLa 
shcontrol and HeLa shEDD1 cells at mRNA level using qPCR. EDD1 expression 
decreases significantly whereas expression of TIP60 does not change. Error bars 
represent standard deviation from at least three independent experiments. Statistical 
























Figure 10. EDD1 regulates the stability of endogenous TIP60 in HPV-positive cells.  
(A) HeLa-shcontrol and HeLa-shEDD1 cells were treated with 100 μg/ml of 
cycloheximide for indicated times, to inhibit RNA translation. The cellular lysates 
were probed with indicated antibodies. (B) Graph represents results from at least 
three independent cycloheximide treatment experiments performed in HeLa-shcontrol 
and HeLa-shEDD1 cells. The band intensities were quantified using Image J software. 
TIP60 levels were normalized to 100% at time zero. Error bar indicates the standard 
deviation from at least three independent experiments. Statistical significance was 





































































Figure 11. HPV 18 E6 utilized EDD1 to destabilize TIP60.  
(A) Validation of 293T shEDD1 stable cell lines. (B) Overexpression of either vector 
or HPV18 E6 in 293T shControl and shEDD1 cells. Total cell lysates were probed 
with HPV18 E6 antibody to validate the expression. (C) Transfected cells from B 
were transfected along with FLAG-TIP60. After 24 h, cells treated with 100 μg/ml of 
cycloheximide for indicates times and the cellular lysates were probed with FLAG 
antibody to examine the stability of FLAG-TIP60. (D and E) Graph represented 
results from at least three independent cycloheximide treatment experiments. The 
band intensities were quantified using Image J software. FLAG-TIP60 levels were 
normalized to 100% at time zero. Error bar represented the standard deviation. 
Significance is represented as *, p<0.05; **, p<0.01.  
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4.3 Depleting EDD1 stabilizes TIP60 and inhibit tumour growth  
As EDD1 destabilizes TIP60, I wanted to investigate whether stable 
depletion of endogenous EDD1 could result in a similar phenotype as 
observed with HeLa LPCX-TIP60 stable cells. To study this, I performed the 
in vitro and in vivo experiments as perform earlier with HeLa LPCX and HeLa 
LPCX-TIP60 cells.  
In in vitro assay, I tested the ability of HeLa shControl and shEDD1 
cells to form colonies using colony formation assay. The representative 
images in Figures 12A and quantification in Figure 12B show that loss of 
EDD1 (HeLa shEDD1) significantly inhibits the colony formation ability of 
HeLa cells similar to HeLa-TIP60 cells and this was TIP60 dependent, as 
depletion of TIP60 by shRNA rescued the inhibition on colony formation.  
In the in vivo assay, I tested the tumour growth ability of HeLa 
shControl and shEDD1 cells in mice. To do so, 1×105 cells of both HeLa 
shcontrol (on the left side) and HeLa shEDD1 (on the right side) cells were 
injected subcutaneously into the mice. The tumour size was measured at 7-day 
intervals over a period of 5 weeks. The representative images (Figure 13A 
and B) and quantifications (Figure 13C) show that the tumours induced by 
HeLa shcontrol cells were significantly reduced when stably ablating 
endogenous EDD1 expression, suggesting the biological importance of 
TIP60’s regulation by EDD1. The knockdown of EDD1 and stabilization of 
TIP60 in the tumours were verified by western blot analysis (Figure 13D). 




















Figure 12. Inhibition of colony formation in vitro by depleting EDD1 is dependent 
on TIP60.  
(A) Representative images from CFA on HeLa shControl and shEDD1 cells 
transfected with either shControl or shTIP60 construct. (B) Quantifications of at least 
three independent experiments. Quantifications were performed using Image J 




























Figure 13. Depletion of EDD1 stabilizes TIP60 and inhibits tumour growth in vivo.  
(A) Representative images of the mice subcutaneously injected with HeLa shControl 
and HeLa shEDD1 cells on the left and the right side, respectively. (B) Images 
showing the difference in sizes of tumour obtained from HeLa shControl and HeLa 
shEDD1 cells. (C) Graph showing tumour growth monitored in six mice at indicated 
times. The graph is represented in volume (mm3) calculated using the formula: 
Volume (V)=Width (W)(2) × Length (L)/2. Error bars represent the standard 
deviation from six mice. Statistical significance was performed using student t-test 
and represented as **, p<0.01; ***, p<0.001. (D) Protein isolated from tumours 
injected with HeLa shControl and HeLa shEDD1 cells was analyzed by western blot 




















Figure 14. Mice (n=6) used in the in vivo experiment shown in Figure 13.  
Depletion of EDD1 inhibits tumour growth in vivo. (A) Representative images of the 
mice subcutaneously injected with HeLa shControl and HeLa shEDD1 cells on the 
left and the right side, respectively. (B) Images showing the difference in sizes of 











4.4 TIP60 acts as an inhibitor of cell migration in cervical cancer 
I have demonstrated that restoring TIP60 levels either by 
overexpressing or by depleting EDD1 results in decreased growth. In addition 
to suppression of growth, I was interested in to investigating whether TIP60 is 
capable of inhibiting cancer metastasis as ability of cells to migrate and invade 
distant organ is huge problem in treatment of cancer. In order to characterize 
this, a preliminary wound-healing assay was performed using HeLa-LPCX 
and HeLa-TIP60 cells. A 40% decrease in cell migration was observed; 




Figure 15. TIP60 inhibits cervical cancer cell migration in vitro.  
Wound-healing assays were performed using HeLa-LPCX and HeLa-TIP60 cells. 
Representative images are shown in (A) and the quantitation in (B). ***, p< 0.001. 
 
In order to further investigate the molecular mechanism of TIP60 
mediated inhibition of cell migration, I decided to use breast cancer models 





























TIP60 inhibits cancer metastasis of breast cancer 
As mentioned in Chapter 1, TIP60 expression level negatively 
correlated with cancer malignancy. A more comprehensive study screening 
expression of TIP60 in several breast cancer cell lines revealed that TIP60 
level decreased in highly metastatic breast cancer cells compared to mild 
metastatic cells (Figure 16) (Pandey et al., 2015). This suggested that TIP60 
might inhibit cancer metastasis of breast cancer. 
 
Figure 16.  TIP60 protein levels in different breast cancer cell lines (Pandey et al., 
2015). 
5.1 Overexpressing TIP60 inhibits cell migration and invasion 
To identify the role of TIP60 as an inhibitor of EMT, I overexpressed 
TIP60 in a highly metastatic triple negative breast cancer cell line (MDA-MB-
231), and depleted TIP60 in non-tumourigenic breast epithelial cells 
(MCF10A). Wound-healing and Boyden chamber assays were used to score 
for migration and invasion potential in each of these two scenarios. For all the 
experiments related to the metastatic breast cancer cell line, I used a derivative 
of MDA-MB-231 cells that stably express the luciferase gene (MDA-MB-231-
Luc-D3H2LN); this enabled us to not only monitor cell migration, early 
tumour growth and metastases in vivo, but also to quantify tumour burden in 






cell line to either stably overexpressing wild-type TIP60 (MM-Luc-FT60WT) 
or its catalytically inactive form (MM-Luc-FT60KD) (Table 2). Cells stably 
expressing the vector (MM-Luc-MSCV) were used as the negative control. 
Overexpression of wild-type TIP60 inhibited cell migration in vitro by 50% 
(Figure 17A, B) and cell invasion by 20 % (Figure 17C, D). Interestingly, 
this inhibition was dependent on TIP60’s catalytic activity, as overexpression 
of its catalytically inactive form failed to inhibit cell migration (Figure 17A, 
B).  
Validation of the expression of TIP60WT and TIP60KD was 
performed by quantitative PCR and western blot (Figure 18A, B). Validation 
of the catalytic activity of TIP60WT and TIP60KD was performed by western 
based in vitro HAT assay using core histone as substrate (Figure 18C). Wild-
type TIP60 and catalytic inactive form of TIP60 were purified from MM-Luc-
FT60WT or MM-Luc-FT60KD cells. Wild-type TIP60 increased the level of 
pan acetyl H4 but catalytically inactive TIP60 could, indicating that TIP60KD 



















Figure 17. TIP60 inhibits cell migration and invasion in vitro.  
(A-B) TIP60 inhibits cell migration. Wound-healing assays were performed using 
MDA-MB-231-Luc-D3H2LN cells expressing vector (MM-Luc-MSCV), wild-type 
TIP60 (MM-Luc-FT60WT), or the catalytically inactive form of TIP60 (MM-Luc-
FT60KD) (see chapter 3). Representative images are shown in (A) and the 
quantitation in (B). ***, p< 0.001. (C-D) TIP60 inhibits cell invasion. Boyden 
chamber assays with matrigel were performed, as detailed in chapter 3. 


























Figure 18. Validating the stable cell lines that overexpress either wild-type TIP60 or 
catalytically inactive form of TIP60. 
(A) mRNA level of TIP60. (B) Protein level of TIP60. Error bars represent standard 
deviation. (C) Validation of the catalytic activity of wild-type TIP60 and catalytic 
inactive form of TIP60. Wild-type TIP60 and catalytic inactive form of TIP60 were 
purified from MM-Luc-FT60WT or MM-Luc-FT60KD cells. In vitro HAT assay 












To confirm if the same phenotype could be observed in other 
metastatic breast cancer cell lines, wild-type TIP60 and catalytic inactive form 
of TIP60 were overexpressed in another two cell lines: HCC1937 (HCC1937-
MSCV, HCC1937-TIP60WT, HCC1937-TIP60KD) and MDA-MB-468 
(MM468-MSCV, MM468-TIP60WT, MM468-TIP60KD) (Table 2). Similar 
to the observation in MDA-MB-231 cells, overexpression of wild-type TIP60 
inhibited the migration of both HCC1937 and MDA-MB-468 cells, however 











Figure 19. Overexpression of TIP60 inhibits cell migration in HCC1937 and MDA-
MB-468 cells.  
Wound-healing assays were performed using HCC1937 or MDA-MB-468 cells 
expressing vector (MSCV), wild-type TIP60 (TIP60WT), or the catalytically inactive 
form of TIP60 (TIP60KD) (see chapter 3 for details). (A, B) Validation of the 
expression of TIP60WT and TIP60KD. (C, D) TIP60 inhibits cell migration in 
HCC1937 cells. Cell migration images are shown in (C) and the quantitation in (D). 
*** P< 0.001. (E, F). TIP60 inhibits cell migration in MDA-MB-468 cells. Cell 















To extend these studies into an animal model system, I studied the 
metastasis of MDA-MB-231 cells in 6-week-old NOD/SCID mice, comparing 
the metastatic potential of TIP60WT and TIP60KD with control cells. In this 
in vivo study, MDA-MB-231 cells expressing the luciferase reporter gene (i.e., 
MM-Luc-MSCV, MM-Luc-FT60WT and MM-Luc-FT60KD) were injected 
into mice through the tail vein, and luminescence-based non-invasive imaging 
was used to monitor the metastasis of cells (Figure 20A). The quantifications 
from four repeats show that TIP60 overexpression led to a dramatic reduction 
in the metastatic potential of these cells scored by reduced lung metastasis as 
compared with the control cells and this is dependent on TIP60’s catalytic 
activity (Figure 20B). The expression of TIP60WT and TIP60KD in both cell 
lines and tumour tissues were verified by western blot (Figure 20C). These 
data suggest an inhibitory role of TIP60 in breast cancer metastasis both in 
















Figure 20. TIP60 inhibits metastasis in an in vivo animal model.  
(A) Representative images. 5×105 MDA-MB-231-Luc-D3H2LN cells expressing 
vector (MM-Luc-MSCV), wild-type TIP60 (MM-Luc-FT60WT), or the catalytically 
inactive form of TIP60 (MM-Luc-FT60KD) were injected through the tail vein and 
tumour growth and metastasis were monitored through bioluminescence imaging (see 
chapter 3 for details). (B) Quantitation of the tumour size metastasis to lung. The 
intensities were quantified using live imaging (see chapter 4 for details). (C) 
Validating the expression of TIP60 in both cell lines and tumours. Proteins isolated 











5.2 Depleting TIP60 promotes cell migration and invasion  
Conversely, to test if depletion of TIP60 could increase cell migration, 
I reduced TIP60 levels in MCF10A cells using siRNA and performed wound-
healing assays. I observed that when depleting TIP60, cells loose cell-cell 
adhesion, become more elongated and mesenchymal (Figure 21). Additionally, 
TIP60 depletion enhanced cell motility by >40%, resulting in a much faster 
closure of the wound as compared to siControl-treated cells (Figure 22A, B). 
Furthermore, similar results were also observed in MCF10A overexpressing 
wild-type TIP60 (Figure 22C, D). These data suggest that in epithelial cells, 
















Figure 22. Depleting TIP60 promotes cell migration in vitro.  
(A-B) Depletion of TIP60 increases cell migration. MCF10A cells were treated with 
indicated siRNAs. Representative images are shown in A and quantitation in B. ***, 
p< 0.001. (C-D) Stable TIP60-expressing MCF10A cells show a similar phenotype as 
the parental cells. Representative images of M10FT60WT cells treated with siControl 














5.3 Depleting TIP60 alters the expression and localization of EMT 
markers 
TIP60 mediated EMT phenotype was studied by screening the 
expression of EMT markers in TIP60-depleted cells. Interestingly, I found the 
transcript levels of two of the major mesenchymal markers SNAIL2 (SNAI2) 
and FIBRONECTIN (FN1) to be elevated by ~2 and ~10 fold, respectively. I 
also observed a 50% reduction in the expression of epithelial marker Epithelial 
Cell Adhesion Molecule (EpCAM) (Figure 23A); these findings were re-
capitulated at the protein level (Figure 23B) and in another breast epithelial 
cell line, MCF7 (Figure 23C). SNAIL2 is one of the master regulators of 
EMT, as its expression in epithelial cells triggers the first and necessary phase 
of the EMT process; i.e., desmosomal disruption and cell spreading (Taube et 
al., 2010; Villarejo et al., 2014). This essentially occurs because of SNAIL2’s 
functions as a transcriptional repressor of epithelial genes, such as EpCAM, 
and as an activator of the mesenchymal gene FN1. EpCAM is involved in cell-
cell recognition and adhesion, whereas FIBRONECTIN is a key component of 
the extracellular matrix promoting cell migration (Park and Schwarzbauer, 
2014; Stanisavljevic et al., 2011; Sun et al., 2014). I also found that the cells 
depleted of TIP60 undergo plasma membrane-to-cytoplasmic re-localization 
of E-CADHERIN (Figure 24A) and β-CATENIN (Figure 24B) compared to 









Figure 23. Overexpression of TIP60 alters the expression of EMT markers.  
(A) Expression analysis of the genes involved in EMT after depletion of TIP60. 
Results were analysed as fold change against siControl-treated cells. (B) Western blot 
analysis of the proteins showing changes in expression after depletion of TIP60. (C) 
Depletion of TIP60 in MCF7 cells shows similar expression patterns of EMT markers 














Figure 24. Depletion of TIP60 results in cell membrane-to-cytoplasmic re-
localization of E-CADHERIN and β-CATENIN. 
Depletion of TIP60 results in cell membrane-to-cytoplasmic re-localization of E-
cadherin (A) and β-catenin (B). Flag-TIP60 was detected using Anti-Flag antibody. 








5.4 Alteration of the expression of EMT markers is TIP60 specific 
and dependent on TIP60 catalytic activity 
To rule out any off-target effects of the siRNA, three cell lines using 
MCF10A cells as the parental cell line were generated: MSCV vector control 
(M10MSCV), wild-type TIP60 (M10FT60WT) and a siRNA-resistant wild-
type TIP60 (M10FT60*WT) (Table 2). The siRNA-resistant constructs were 
generated by synonymous mutations; i.e., the siRNA targeting site was 
mutated such that the nucleotide sequence was modified, but the protein 
sequence remained unchanged. To test if these cell lines behaved similar to the 
parental cell line, we depleted both the endogenous and exogenous TIP60 and 
performed wound-healing assays, mRNA quantitation, and protein expression 
assays. Figure 25 confirms that the knockdown of both exogenous and 
endogenous TIP60 produced phenotypes similar to that of the parental 




Figure 25. Stable TIP60-expressing MCF10A cells show a similar phenotype as the 
parental cells.  
(A) Expression analysis for the EMT markers in M10FT60WT treated with siControl 
or siTIP60. (B) Western blot analysis of the proteins showing changes in expression, 







Figure 26 validates expression of TIP60 (wild-type, catalytic dead and 
siRNA resistant form) in the stable cell lines mentioned above. As shown in 
Figure 26A, treatment with siTIP60, only the endogenous, but not the siRNA 
resistant form of TIP60 was depleted, demonstrating a successful rescue of 
TIP60 level under these conditions. 
Overexpression of TIP60 resulted in a 50% reduction in FN1 
expression and a 2-fold increase in EpCAM expression (Figure 27A, B). 
Importantly, the expression of siRNA-resistant TIP60 rescued the levels of 
FN1 and EpCAM at both the RNA and protein levels, indicating this 
phenotype was TIP60-specific (Figure 27). However, SNAI2 expression could 
only be rescued partially in such a scenario (Figure 27C). Since FN1 has been 
reported to upregulate SNAI2 to promote metastasis, it is possible that the 
reduction in TIP60 provides the initial trigger to up-regulate SNAI2, but that 
FN1 maintains SNAI2’s levels during metastasis (Knowles et al., 2013). 
To gain a deeper insight into the molecular mechanism of TIP60’s 
function, whether the lysine acetyltransferase activity of TIP60 is required for 
SNAIL2-mediated regulation of EMT. Thus a cell line expressing TIP60 that 
was catalytically inactive and siRNA-resistant (M10FT60*KD) was generated. 
Intriguingly, this form of TIP60 failed to rescue the expression level of FN1 
and EpCAM (Figure 27), indicating that the catalytic activity of TIP60 is 










Figure 26. Expression of TIP60 in MCF10A stable cell lines. 
Expression analysis of level of total TIP60 (A) and endogenous TIP60 (B) in different 
























Figure 27. TIP60 mediated inhibition of Epithelial-mesenchymal transition is 
specific to TIP60 and depends on its catalytic activity.  
(A-C) Expression analysis of genes identified to change when TIP60 is depleted 
using siTIP60 in parental (MCF10A), vector control (M10MSCV), stable cells 
expressing wild-type TIP60 (M10FT60WT), siRNA-resistant wild-type TIP60 
(M10FT60*WT) and catalytically inactive and siRNA-resistant TIP60 
(M10FT60*KD). (D) Western blots for the proteins with differential expression upon 
TIP60 depletion.  
 
To further strengthen this observation is TIP60 specific and catalytic 
activity dependent, cell lysates from MDA-MB-231 cells with overexpression 
of either wild-type TIP60 or catalytic inactive form of TIP60 (MM-Luc-
MSCV, MM-Luc-FT60WT, MM-Luc-FT60KD) were examined using western 
blot. EpCAM level increased by overexpressing wild-type TIP60 compared to 
control but not catalytic inactive form of TIP60 (Figure 28). This was in 
contrast to MCF10A, where the expression of EpCAM was inversely 
modulated upon depleting TIP60 (Figure 23B). FIBRONECTIN and SNAIL2 
expression did not alter in MDA-MB-231 cells by overexpressing wild-type 
TIP60 or catalytic inactive form of TIP60 (data not shown). This could be due 
to the feedback regulation between FIBRONECTIN and SNAIL2 in highly 





SNAIL2 could upregulate each other and ensure maintenance of both of them 
at high level in more metastatic cells. However, restoration of EpCAM level is 
sufficient to inhibit cell migration and invasion (Tai et al., 2007), which 
explains the inhibitory function of TIP60 in MDA-MB-231 cell metastasis. 
This suggests that the regulation of EpCAM plays a predominant role in TIP60 
mediated inhibition of breast cancer metastasis. 
 
Figure 28. The expression of EpCAM in MDA-MB-231 cells overexpressing either 




TIP60 regulates expression of EpCAM and FIBRONECTIN through 
regulating the expression and function of SNAIL2 
6.1 Regulation of cell migration by TIP60 is SNAIL2 dependent 
SNAIL2 belongs to the family of zinc finger transcription factors, 
which regulates the expression of EMT-related genes by interacting with the 
E-boxes in their promoter regions (Huang et al., 2012; Thiery et al., 2009; 
Villarejo et al., 2014; Yang and Weinberg, 2008). To investigate the role of 
SNAIL2 in TIP60 mediated alteration of the expression of EMT markers, both 
TIP60 and SNAIL2 were depleted and I observed that, in comparison with the 
single depletion of TIP60, the co-depletion was able to rescue both FN1 and 
EpCAM at the mRNA and protein levels (Figure 29). This suggests that TIP60 
regulation on the expression of FN1 and EpCAM was SNAIL2 dependent.  
To further investigate the biological implication, wound-healing assay 
using MCF10A cells with depleted TIP60 alone or TIP60 and SNAIL2 
together was performed. A 40% increase in cell migration was observed when 
TIP60 alone was depleted and this was further reduced nearly 30% when both 
TIP60 and SNAIL2 were depleted (Figure 30), suggesting that regulation of 













Figure 29. TIP60 regulates Epithelial-mesenchymal transition through regulating 
SNAIL2.  
(A) Change in expression of the genes in TIP60-depleted condition is SNAIL2 
dependent. mRNA levels of genes identified to be differentially expressed when 
TIP60 is depleted either alone or in combination with SNAIL2 in MCF10A cells. (B) 











Figure 30 Regulation of the cell migration by TIP60 is SNAIL2 dependent.  
Wound-healing assay was performed as described in chapter 3. The increased cell 
migration after depletion of TIP60 was restored by co-depleting TIP60 and SNAIL2. 











6.2 TIP60 inhibits SNAIL2 enrichment on its target promoters 
SNAIL2 has previously been implicated in the promoter-dependent 
transcriptional regulation of EMT genes. Thus, whether the TIP60-mediated 
transcriptional regulation of EpCAM and FN1 also occurred through the 
promoter regions of these genes need to be ascertained. To this end, ChIP-
qPCR (chromatin immunoprecipitation quantitative PCR) was performed 
using an anti-SNAIL2 antibody in presence or absence of TIP60. Primers were 
designed to amplify different regions of the promoters of FN1 and EpCAM 
(Figure 31A, B). Among the primers tested, two were chosen for each 
promoter, one from the distal site, which lacked E-box motif (SNAIL2 binding 
site), and the other from the proximal site, which showed enrichment for 
SNAIL2 association (Figure 31C, D and Table 3). When the occupancy of 
SNAIL2 on these promoters was tested in wild-type (MCF10A) cells, I found 
a significant increase in SNAIL2 occupancy on the FN1 and EpCAM 
promoters in the absence of TIP60 (Figure 32A). In order to test if these 
changes were TIP60 specific and if the catalytic activity of TIP60 was 
required to inhibit the binding of SNAIL2 to the promoters, SNAIL2’s 
occupancy in the three stable cell lines was checked, M10FT60WT, 
M10FT60*WT, and M10FT60*KD (Figure 32B-D). Remarkably, I found that 
the enrichment of SNAIL2 on FN1 and EpCAM promoter (Figure 32B) can be 
restored back to control level by overexpressing wild-type TIP60 (Figure 32C) 
but this was not observed when catalytically inactive form of TIP60 was 
overexpressed (Figure 32D), suggesting that the SNAIL2 promoter occupancy 
was regulated by TIP60 and was dependent on TIP60’s catalytic activity. 

















Figure 31. Screening the ChIP-qPCR primers for FN1 and EpCAM promoters. 
(A, B) Schematics of the promoter and 5’ regions of the FN1 and EpCAM. The qPCR 
primer sets for chromatin immunoprecipitation (ChIP) are shown in the schematics 
and detailed in Table 3. Promoters and 5’UTR regions: FN1, GenBank: AF550582.1; 
EpCAM, GenBank: AY148099.1. (C, D) ChIP-qPCR analysis of MCF10A cells 
transfected with TIP60 siRNA. The SNAIL2-bound DNA was immunoprecipitated 
using the anti-SNAIL2 antibody. Two primer sets from each promoter—one on the 
distal site and the other on the proximal—were chosen for further analysis: FN13 and 
FN14 for FN1 promoter, and EpCAM3 and EpCAM7 for EpCAM promoter. Primer 
sets that were chosen are marked red in the figures. Results of qPCR are plotted as 
fold change against IgG control. (E) TIP60 knockdown efficiency of the ChIP 
















Figure 32. TIP60 regulates SNAIL2 enrichment on target promoters.  
(A) Chromatin immunoprecipitation quantitative PCR (ChIP-qPCR) assays were 
performed to check the enrichment of SNAIL2 on target promoters in the presence or 
absence of TIP60. Results were analysed and are represented as percentage input. 
RNA isolates from the cells of the same experiment were used to check the 
expression levels by RT-qPCR (Figure 32). (B-D). SNAIL2 binding to its target 
promoter is regulated by TIP60 and depends on its catalytic activity. ChIP-qPCR 
analysis for SNAIL2 binding was performed in the presence (siControl) or absence 
(siTIP60) of TIP60 in MCF10A cells stably expressing wild-type TIP60 
(M10FT60WT), siRNA-resistant, wild-type TIP60 (M10FT60*WT) or the 
catalytically inactive and siRNA-resistant TIP60 (M10FT60*KD). The FN1 and 

















Figure 33. TIP60 knockdown efficiency of the ChIP samples in Figure 32.  
MCF10A (A), M10FT60WT (B), M10FT60*WT (C) and M10FT60*KD (D) were 
treated with siControl and siTIP60 for 72 hours. Small aliquot were harvested for 
checking the knockdown efficiency. The rest of the cells were used for ChIP 















Cross talk between two epigenetic regulators, TIP60 and DNMT1 
determines the metastasis potential of breast cancer 
7.1 TIP60 regulates the expression of EMT markers through 
regulating the stability of DNMT1 
DNMT1 is known to induce EMT by repressing expression of cell 
adhesion molecules (Fukagawa et al., 2015). Since DNMT1 is destabilized by 
TIP60 (Du et al., 2010b), whether SNAIL2 mediated repression of epithelial 
genes were DNMT1 dependent was tested. DNMT1 was depleted using 
siRNA either alone or in combination with TIP60. Depletion of TIP60 
stabilized DNMT1 at protein level (Figure 34A-C), suggesting that TIP60 
regulates the protein stability of DNMT1. When compared to TIP60 depletion, 
the co-depletion of TIP60 and DNMT1 rescued FN1 and EpCAM both at the 
mRNA and protein levels (Figure 34D, E). Interestingly, SNAIL2 was also 
rescued both at mRNA and protein levels when TIP60 and DNMT1 were co-
depleted (Figure 34D, E). Taken together, these data suggest that TIP60 
regulates the expression of SNAIL2 as well as FN1 and EpCAM through its 







Figure 34. Epithelial-mesenchymal transition in absence of TIP60 is DNMT1 
dependent.  
(A-C) TIP60 regulates DNMT1 protein stability. MCF10A cells transfected with 
siControl or siTIP60 were treated with 100 µg/ml cycloheximide for up to 12 hours. 
Cell lysates from indicating time points were examined by western blot (B) and 
quantified (C), **, P<0.01; ***, P<0.001. The knockdown efficiency of TIP60 was 
shown in (A). (D) Protein levels of genes identified to be differentially expressed 
when TIP60 is depleted either alone or in combination with DNMT1 in MCF10A 













7.2 TIP60 and DNMT1 levels regulates the cell migration potential 
To have a biological readout of DNMT1 mediated activation of the 
EMT program, DNMT1’s effect on cell migration in TIP60 depleted condition 
was tested. For this, wound-healing assay was performed. I observed a 50% 
increase of cell migration when TIP60 alone was depleted and this was 
rescued to 20% when both TIP60 and DNMT1 were co-depleted (Figure 35A, 
B). These data suggests that decreased levels of TIP60 stabilizes DNMT1, 




Figure 35. TIP60 regulates cell migration in vitro by ablating DNMT1.  
(A) The representative pictures of wound healing assay. (B) Quantifications of wound 
healing assay from at least three independent experiments. ***, p<0.001. (C) TIP60 
and DNMT1 knockdown efficiency of the samples used in A and B. Error bars 









7.3 TIP60 regulates the DNA methylation statues on EpCAM 
promoter 
In order to identify the molecular determinant of DNMT1-SNAIL2 
driven EMT program, I sought to estimate DNA methylation on SNAIL2 
regulated promoters. For this, MCF10A cells were treated with different 
siRNA combinations (siControl, siTIP60, siDNMT1, siTIP60+siDNMT1). 
Genomic DNA was isolated and the methylation specific sequencing was 
performed. A significant increase in DNA methylation on EpCAM promoter (-
51 to -32) in TIP60 depleted cells was observed, and interestingly, this was 
rescued when TIP60 was co-depleted with DNMT1 (Figure 36A, B), 
suggesting that the increased methylation observed was dependent on 
DNMT1. However, depleting DNMT1 alone did not change the DNA 
methylation in this region, this may be because the basal level of DNA 
methylation in this region is due to other DNA methyltransferases such as 
DNMT3A or DNMT3B (Figure 37). The DNA methylation in this region (-51 
to -32) was fully dependent on DNMT1 only in the absence of TIP60, as co-
depleting TIP60 and DNMT1 reduced this increased DNA methylation level 
to nearly zero (Figure 36A, B). I also noted that depleting TIP60 did not 
change DNA methylation on EpCAM 1st intron region +542 to +601 (Figure 
36C), suggesting that the intron region was not responsive to decreased levels 
of TIP60. However, depletion of DNMT1 alone showed a subtle decrease in 
DNA methylation on 1st intron region +542 to +601 (Figure 36C). In 
summary, these results suggest that DNMT1 methylate both regions on 
EpCAM promoter, but TIP60 only affects DNMT1 mediated DNA 
methylation on promoter region -51 to -32 which was next to SNAIL2 binding 
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site (E-Box binding site) and overlaps with the SNAIL2 enrichment region on 




Figure 36. Recruitment of DNMT1 to EpCAM promoter results in its 
hypermethylation in the context of depleting TIP60. 
(A, B, C) TIP60 only regulates DNMT1 mediated DNA methylation on EpCAM 
promoter region -51 to -32 (A, B) but not on region +542 to +601 (C). TIP60 and 
DNMT1 were depleted in MCF10A cells either alone or in combination. DNA from 
cells was isolated and bisulphite pyrosequencing was performed as detailed in 
Methods. (D) TIP60 and DNMT1 knockdown efficiency for the samples used for 


















Figure 37. The basal level of DNA methylation on EpCAM promoter region (-51 to -
32) presents in siControl cells is due to DNMT3B de novo methylation.  
(A, B) Genomic DNA isolated from MCF10A cells transfected with siControl or 
siDNMT3B was used to perform bisulphite pyrosequencing. (C, D) The knockdown 

















7.4 SNAIL2 recruits DNMT1 to EpCAM promoter in the absence of 
TIP60 
Next, I sought to investigate the molecular mechanism of DNMT1 
mediated repression of EpCAM expression. For this, I checked methylation 
status of EpCAM promoter on depleting SNAIL2 and TIP60. I observed that 
the increased DNA methylation on EpCAM promoter region -51 to -32 on 
depleting TIP60 was further decreased significantly on depleting both TIP60 
and SNAIL2 (Figure 38A, B), suggesting that TIP60 regulates DNMT1-
dependent DNA methylation on EpCAM promoter through SNAIL2. 
However, it did not show any changes on EpCAM 1st intron region +542 to 
+601 (Figure 38C). To further investigate the mechanism of SNAIL2 
mediated regulation of DNA methylation on EpCAM promoter, I first depleted 
SNAIL2 and observed no change in DNMT1 level (both protein and mRNA) 
(Figure 39A and data not shown). Then a ChIP-qPCR experiment using 
antibody against DNMT1 was performed, interestingly I observed an increase 
in the enrichment of DNMT1 on EpCAM promoter region (-51 to -32) upon 
depleting TIP60 (Figure 39B). This increase of DNMT1 enrichment further 
reduced to control level upon co-depleting SNAIL2 and TIP60 (Figure 39B). 
However, the enrichment of DNMT1 on EpCAM 1st intron region (+542 to 
+601) did not change upon depleting SNAIL2. These suggest that SNAIL2 
only regulates the recruitment of DNMT1 to EpCAM promoter region (-51 to -
32), which contains SNAIL2 binding site. To further investigate the 
association between DNMT1 and SNAIL2, FLAG-DNMT1 and SNAIL2-
MYC were co-expressed in 293T cell. FLAG-DNMT1 was 
immunoprecipitated and associated SNAIL2-MYC was observed by western 
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blot (Figure 39C). Taken together, these results suggest that DNMT1 catalyse 
the DNA methylation on both EpCAM promoter region -51 to -32 and region 
+542 to +601. SNAIL2recruits DNMT1 to EpCAM promoter region -51 to - 3 





Figure 38. SNAIL2 dependent regulation of EpCAM promoter hypermethylation in 
the context of depleting TIP60.  
SNAIL2 specifically regulates methylation on EpCAM promoter region -51 to -32 (A, 
B) but not on promoter region +542 to +601 (C) in the absence of TIP60. (D) TIP60 
and SNAIL2 knockdown efficiency for the samples used for bisulphite 

























Figure 39. SNAIL2 recruits DNMT1 to target promoter.  
(A) Depletion of SNAIL2 does not change the level of DNMT1. (B) DNMT1 was 
recruited to EpCAM promoter region (-51 to -32) by SNAIL2 in the absence of 
TIP60. ChIP-qPCR using the antibody against DNMT1 was performed. Two pairs of 
primers were designed to amplify the EpCAM promoter region (-51 to -32) and 
EpCAM 1st intron region (+542 to +601) respectively. The EpCAM promoter region 
amplified here overlaps with the region amplified by previous EpCAM proximal 
primers used in Figure 31, but more specific to CpG sites tested in this region. (C) 
DNMT1 associates with SNAIL2. FLAG-DNMT1 and SNAIL2-MYC were co-
expressed in 293T. Co-immunoprecipitation was performed as detailed in chapter 3. 
FLAG-DNMT1 was immunoprecipitated and associated SNAIL2-MYC was probed 
using western blot. (D) Model of the mechanism of the regulation of EpCAM 













Changes in chromatin landscape play an important role in the process of 
carcinogenesis. DNA methylation and post-translation modification on histone 
tails are among the most investigated epigenetic alterations, and have been 
implicated in tumourigenesis. TIP60, as a histone acetyltransferase, is a 
chromatin remodeler involved in multiple cellular physiological process and 
its decreased expression has been reported in several cancers (Chen et al., 
2012; Gorrini et al., 2007; Gupta et al., 2013; Jha et al., 2010; Sakuraba et al., 
2009). Viral oncoproteins were also reported to destabilize TIP60 in viral-
induced cancers (Gupta et al., 2013; Jha et al., 2010), and restoring TIP60 
level has been shown to inhibit tumour growth (Subbaiah et al., 2015) 
suggesting a tumour suppressive function. In HPV-induced cervical cancers, 
HPV E6 destabilizes TIP60 in an E6AP independent manner (Jha et al., 2010). 
However, the mechanism of E6 mediated TIP60 degradation was not 
identified. In this study, I demonstrated that EDD1 is utilized by E6 to 
destabilize TIP60 and depleting EDD1 results in the stabilisation of TIP60 and 
further inhibits tumour growth, pheno-copying the overexpression of TIP60 
(Figure 40). Reactivation of TIP60 through the inhibition of EDD1 is a 
potential therapy to treat cervical cancer (Figure 41). 
As a tumour suppressor, TIP60 activates downstream pathways to induce 
tumour suppression. Besides the upstream regulation mechanism of TIP60 by 
HPV E6, the downstream tumour suppression pathways were not explored. 
The main role of TIP60 identified to date is the maintenance of genomic 
stability, in addition to regulating apoptosis and transcription. However, recent 
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studies indicate that TIP60 might involve in more other downstream pathways, 
for example, TIP60 downregulation correlates with metastasis in several 
cancers (Chen et al., 2012; Kim et al., 2005; Sakuraba et al., 2009). This 
leaves an interesting gap about the mechanism of TIP60 mediated inhibition 
on cancer metastasis. In this study, I identified that TIP60 inhibits EMT 
through ablating DNMT1-SNAIL2 axis as evidenced by both in vitro and in 
vivo models (Figure 42). Mechanistically, depletion of TIP60 promotes EMT 
by stabilizing DNMT1, which results in increased expression of SNAIL2. The 
upregulated SNAIL2 would then recruit DNMT1 to EpCAM promoter region 
(-51 to -32), resulting in hypermethylation of EpCAM promoter and repression 
of EpCAM expression. This study has identified the mechanism of TIP60 
mediated inhibition of EMT program and has discovered an important link 
between two epigenetic modulators – TIP60 and DNMT1. The data presented 
here imply four potential therapeutic strategies to treat SNAIL2 driven 
metastatic breast cancers: (i) Reactivation of TIP60; (ii) Restoration of TIP60 
dependent acetylation on DNMT1; (iii) Inhibition of DNMT1 activity by 
inhibitors; (iv) Synergy between DNMT1 inhibitor and histone deacetylase 
(HDAC) inhibitor.  
Taken together, I have identified TIP60 function as a tumour suppressor 
in two ways: inhibits both tumour growth and cancer metastasis. Additionally, 
I have also discovered the mechanism of E6 mediated destabilization of TIP60 
in cervical cancer and identified the mechanism of TIP60 mediated inhibition 
on breast cancer metastasis. Most importantly, this study implies potential 
therapeutic ways to treat cancer: (i) reactivating TIP60 through inhibiting 
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EDD1 and (ii) synergy between demethylating agent (DNMT1 inhibitor) and 





Figure 40 Model for HPV E6 mediated TIP60 degradation.  
























Figure 41. Model for the mechanism of HPV E6 mediated TIP60 degradation. 
HPV E6 utilizes EDD1 to destabilize TIP60 through ubiquitin-dependent proteasome 
degradation. Restoration of TIP60 by inhibiting the interaction between EDD1 and 

















Figure 42. Model for TIP60-mediated inhibition of Epithelial- mesenchymal 
transition.  
TIP60 destabilizes DNMT1 and inhibits SNAIL2 driven EMT program. Decreased 





8.1 As a tumour suppressor, TIP60 inhibits tumour growth both in 
vitro and in vivo 
TIP60 functions as a tumour suppressor in multiple ways. For example, 
TIP60 acetylation on p53 lysine 120 acts as a switch between p53 induced cell 
cycle arrest and apoptosis, pushing the cell towards apoptosis (Sykes et al., 
2006; Tang et al., 2006). Additionally, during DNA Damage Response, TIP60 
is known to be recruited to DNA damage site through histone H3 lysine 9 
trimethylation, facilitating TIP60 acetylation on Ataxia Telangiectasia 
Mutated (ATM) which would activate ATM signalling and induce cell cycle 
arrest (Sun et al., 2005). Furthermore, TIP60 dependent acetylation on p21 
(Cip1/WAF1) lysine 161 and 163 is required for the stabilization of p21 and 
facilitates p21 mediated cell cycle arrest during DNA damage response (Lee et 
al., 2013). Additionally, Gorrini et al. from Amati’s group found that the 
immunohistochemical staining of TIP60 was decreased in mammary 
carcinomas and they further identified that TIP60 as a haplo-insufficient 
tumour suppressor in MYC-induced lymphomagenesis (Gorrini et al., 2007). 
However, most of these TIP60 mediated tumour suppressor pathways are 
dependent on p53.  
In this study, I identified TIP60 as a tumour suppressor in HPV-induced 
cervical cancer. Overexpressing TIP60 inhibits colony formation of HeLa cells 
in vitro (Figure 6) and tumour growth in vivo (Figure 7, 8). HPV oncoprotein 
E6 is known to destabilize p53 through an E3 ubiquitin ligase, E6AP 
(Huibregtse et al., 1991; Scheffner et al., 1993), in HeLa cells. The fact that 
TIP60 could inhibit tumour growth in functionally p53 null cells, indicates that 
TIP60 might regulate a novel tumour suppressor pathway which is 
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independent of p53. A transcriptome analysis using RNA sequencing and a 
proteomic analysis using mass spectrometry could be done to identify the p53 
independent tumour suppression pathway mediated by TIP60. 
8.2 Reactivation of TIP60 by inhibiting EDD1 might be a potential 
cancer therapy 
EDD1 (E3 identified by Differential Display), also known as UBR5 
(Ubiquitin protein ligase E3 component n-recognin 5) is often mutated and/or 
overexpressed in cancer (Figure 43). As previously reported, in breast cancer, 
EDD1 overexpression correlates with gene copy number increase (Clancy et 
al., 2003). While in ovarian cancer, the overexpression of EDD1 associates 
with high risk of disease recurrence and death (O'Brien et al., 2008). 
Furthermore, ovarian cancer with high EDD1 expression resistant to cisplatin 
and the sensitivity to cisplatin can be restored when EDD1 was depleted, 
suggesting a new therapeutic target for chemo-resistant ovarian cancer 
(O'Brien et al., 2008). 
This study revealed the mechanism of TIP60 degradation in cervical 
cancer. In cervical cancer, TIP60 is destabilized by EDD1 (Figure 9, 10) and 
HPV E6 utilizes this mechanism to degrade TIP60 (Figure 11). Additionally, I 
identified that inhibition of EDD1 restores TIP60 level and inhibits colony 
formation in vitro (Figure 12) and tumour growth in vivo (Figure 13, 14). 
These results indicate that TIP60 is a substrate of EDD1 ubiquitin ligase. 
Therefore, for future study, it would be very interesting to map the interaction 
domain between TIP60 and EDD1 through performing co-
immunoprecipitation experiment by overexpressing different deletion 
constructs of TIP60. By mapping the interaction domain, small molecule 
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compound can be designed to ablate the interaction and restore TIP60 level in 
cervical cancers. This might possess huge therapeutic value. Furthermore, 
since EDD1 is a well-known oncogene overexpressed in multiple cancers, 
TIP60 might be destabilized in the same way by EDD1 in other cancers other 
than cervical cancers. Therefore, EDD1-TIP60 inhibitor might be a potential 
universal cancer treatment drug. 
 
Figure 43. EDD1 is overexpressed and/or mutated in multiple cancers.  




8.3 Viral oncoproteins other than HPV E6 might also destabilize 
TIP60 through the ubiquitin pathway 
Fifteen percent of human cancers worldwide maybe attributed to viruses 
(zur Hausen, 1991). Especially in cervical cancer and liver cancer, viruses are 
one of the major risk factors for cancer development. Both RNA and DNA 
viruses are shown to be capable of inducing cancer development. Human 
papilloma virus (HPV), Epstein-Barr virus (EBV), Hepatitis B virus (HBV), 
Human herpes virus 8 [(HHV-8) also known as Kaposi sarcoma-associated 
herpes virus (KSHV)] and Merkel cell polyomavirus (MCV) are the DNA 
viruses known to cause human cancers. Human T-lymphotrophic virus-1 
(HTLV-1) and Hepatitis C virus (HCV) are the oncogenic RNA virus. 
Adenovirus is not known to contribute to human cancer, but it can transform 
human cells and can also contribute to tumour development in new-born rats 
(Gupta et al., 2013).  
Till now, TIP60 has been reported to be destabilized by HPV and 
adenovirus. Adenovirus destabilizes TIP60 through its oncoproteins EIB55K 
and E4orf6, however the ligase involved in this mechanism has not been 
identified yet (Gupta et al., 2013). HPV oncoprotein E6 destabilizes TIP60 
through an E6AP independent manner (Jha et al., 2010), and this study has 
identified EDD1 to be the ligase involved in targeting TIP60 to degradation.  
These findings might suggest that other oncoviruses might also be capable 
of destabilizing TIP60. It is very interesting to investigate TIP60 stability in 
other oncovirus infected cells. Further, it would be interesting to see if the 
stability is dependent on the ubiquitin proteasome system. EDD1 might be the 
ligase utilized by other oncoviruses. If not, a ligase screen could be done to 
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identify all the ligases that regulate the stability of TIP60. Most importantly, if 
TIP60 is destabilized by all the oncoviruses, restoring TIP60 level by targeting 
the ubiquitin ligase involved might be a universal therapeutic way to treat all 
the virus induced cancers.   
8.4 EpCAM participates in inhibition of tumour invasion and is 
regulated by promoter hypermethylation 
EpCAM is one of the epithelial genes involved in inhibiting the EMT 
process. It is known that EpCAM level would increase in the initial stage of 
cancer development but decreases dramatically during malignant 
transformation and progression (Joo et al., 2005). Loss of EpCAM expression 
is associated with aggressive cancers and poor prognoses (Kim et al., 2003; 
Songun et al., 2005). Moreover, EpCAM expression level is lower in 
circulating and metastatic tumour cells than in their corresponding primary 
tumours (Rao et al., 2005; Takes et al., 2001). These imply that dynamic 
change of EpCAM expression level is a regulated event during the process of 
tumour invasion and metastasis (Jojovic et al., 1998).  
Expression of EpCAM is regulated through epigenetic regulation 
including promoter methylation and histone modification. It was shown that 
methylation on H3K9 associates with the repression of EpCAM expression 
(Margueron et al., 2005). However, DNA hypermethylation of EpCAM 
promoter is the key determinant for repression of EpCAM expression (Tai et 
al., 2007). The methylation status of EpCAM promoter anti-correlates with 
EpCAM expression (Tai et al., 2007). Additionally, DNA methyltransferase 
inhibitor (5-aza-2’-deoxycytidine) treatment reactivated the EpCAM 
expression and inhibited cancer cell invasiveness (Alberti et al., 1994; Spizzo 
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et al., 2007), suggesting a role of DNA hypermethylation in regulating 
EpCAM expression. Interestingly, HDACi (Trichostatin A) treatment has a 
less significant effect on EpCAM expression compared to DNA 
methyltransferase inhibitor (5-aza-2’-deoxycytidine) treatment, suggesting a 
dominant role of DNA methylation in regulating EpCAM expression (Tai et 
al., 2007). 
Although DNA methylation seems to have a dominant role, it is likely that 
histone modifications and DNA methylation would work together since DNA 
methyltransferase inhibitor (5-aza-2’-deoxycytidine) and HDACi (Trichostatin 
A) treatment together, synergistically resulted in a higher activation of 
EpCAM expression compared to each individual treatment. (Tai et al., 2007). 
This suggests a correlation between histone modifiers and DNA 
methyltransferase in regulating target gene expression.  
This study has identified a mechanism of regulation of DNA 
hypermethylation on EpCAM promoter, which involves TIP60, DNMT1 and 
SNAIL2 (Figure 17-39). In clinical samples, expression of EpCAM might 
inhibit the metastatic property of tumours and therefore correlates with better 
prognoses of patients (Basak et al., 2000) and loss of EpCAM expression 
might be a potential marker for the malignancy of cancer (Takes et al., 1997). 
Since the EpCAM expression is repressed by promoter DNA hypermethylation 
this finding might suggest a new strategy to reactivate EpCAM expression in 




8.5 TIP60 antagonizes DNMT1 in regulating EpCAM expression 
Aberrant DNA methylation is one of the key epigenetic mechanisms that 
contributes to the process of carcinogenesis (Robertson, 2001). DNA 
methylation catalysed by DNMTs primarily occurs on the CpG island of the 
promoter regions and results in gene repression (McCabe et al., 2009). 
DNMT1 is reported to methylate promoters of epithelial genes such as 
EpCAM and CDH1, and results in the repression of cell adhesion molecules 
and promotes EMT process (Alberti et al., 1994; Fukagawa et al., 2015; Melki 
et al., 1999; Spizzo et al., 2007; Tai et al., 2007). 
This study has reported a novel function of TIP60 to regulate DNMT1 
degradation and inhibit EMT process in a DNMT1 dependent manner (Figure 
34, 35). Additionally, TIP60 inhibits DNMT1 recruitment on EpCAM 
promoter by inhibiting SNAIL2 function (Figure 39), which results in 
hypomethylation of EpCAM promoter and further promotion of expression 
(Figure 36, 38). Taken together, TIP60 regulates DNMT1 through both 
protein stability and chromatin enrichment. More importantly, this regulation 
of DNMT1 required TIP60’s catalytic activity.  
Moving forward, one lead from this study would be to investigate whether 
the same mechanism of TIP60-DNMT1 axis is also found in other cellular 
processes. If so, the drug inhibitor targeting this mechanism might has a more 
general therapeutic value. 
8.6 SNAIL2 recruits DNMT1 to target promoter for repression 
SNAIL family proteins are known to repress expression of cell adhesion 
molecule and promote expression of mesenchymal related molecule. Previous 
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studies have indicated that SNAIL1 recruits epigenetic repressor complex such 
as HDAC1/2, PRC2, LSD1 and G9a (Lin et al., 2014) to CDH1 promoter for 
maintaining the repression. Whereas, recruitment of p65 subunit of NK-κB 
and PARP1 by SNAIL1 to FN1 promoter activates its expression 
(Stanisavljevic et al., 2011).  
However, little is known for mechanism of SNAIL2 mediated regulation. 
Previous studies investigating both SNAIL1 and SNAIL2 together, assumed 
that SNAIL2 behaves similar to SNAIL1, thus SNAIL2 was not studied in 
detail. As it has been recently reported that a non-equivalent role of SNAIL1 
and SNAIL2 in repression of E-CADHERIN expression (Villarejo et al., 
2014) (Ye et al., 2015), it would be interesting to identify the molecular 
mechanism of SNAIL2 mediated regulation.  
Here, we showed that both EpCAM and FN1 are direct targets of SNAIL2 
(Figure 31-33). More interestingly, we showed that SNAIL2 recruits DNMT1 
to EpCAM promoter region -51 to -32 for repression in the absence of TIP60 
(Figure 39). SNAIL2 utilizes this mechanism to trigger DNA 
hypermethylation on EpCAM promoter and regulates EpCAM expression 
(Figure 38). As little is known about SNAIL2 mediated regulation, this study 
reveals a novel mechanism of SNAIL2 mediated gene expression. Whether 
SNAIL2 generally utilizes this mechanism in repressing other target genes 
needs further investigation. 
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8.7 DNMT1 is recruited by certain transcription factor to specific 
site 
As a maintenance DNA methyltransferase, DNMT1 copies the pre-
existing DNA methylation onto the new DNA strand during DNA replication 
(Sharif et al., 2007). Interaction with replication component, PCNA and 
URHF1, is crucial for DNMT1 function during replication (Qin et al., 2015; 
Schermelleh et al., 2007). Previous studies based on chromatin 
immunoprecipitation revealed that DNMT1-PCNA-URHF1 complex 
methylates DNA without site specific (Hervouet et al., 2010).  
However, little is known about DNMT1 mediated site-specific DNA 
methylation. Previous reported that DNMT1 might interact with transcription 
factors such as SP1 and trigger site-specific methylation (Hervouet et al., 
2010). More studies need to be done to reveal this mechanism as DNMT1 
might also function as a site-specific DNA methyltransferase which would be 
crucial for gene expression. 
This study revealed a novel transcription factor, SNAIL2, which interacts 
with DNMT1 (Figure 39C) and recruits DNMT1 to specific site of EpCAM 
promoter (Figure 39B). This finding suggests that DNMT1/transcription 
factors interaction might be a more common mechanism of DNMT1-regulated 
gene expression.        
8.8 TIP60 inhibits SNAIL2-DNMT1 recruitment to target promoter 
and activates gene expression 
Histone acetylation is normally correlated with gene activation. The 
acetylation usually happens on the lysine residue of histone tails resulting in 
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neutralization of positive charge and reduction of histone associating affinity 
for DNA (Hong et al., 1993). As a consequence, this will alter the nucleosome 
confirmation and increase the accessibility of transcription regulator to 
chromatin (Lee et al., 1993; Norton et al., 1989; Vettese-Dadey et al., 1996). 
On the other hand, DNA methylation which occurs on CpG island of gene 
promoter results in gene repression (McCabe et al., 2009). 
DNA methylation has been found to be correlated with histone 
deacetylation (El-Osta and Wolffe, 2000). Acetylated histones are enriched in 
unmethylated DNA region but absent from methylated DNA region (Irvine et 
al., 2002). Additionally, reports showed that histone deacetylase complex is 
recruited by methylated DNA through methyl-CpG binding protein MeCP2 
(Jones et al., 1998; Kaludov and Wolffe, 2000; Nan et al., 1998). Furthermore, 
a study showed that histone H3 and H4 acetylation negatively correlated with 
DNA methylation in the regulation of death-associated protein kinase (Satoh 
et al., 2002). These suggest that histone acetylation and DNA methylation 
might work inversely to regulate gene expression. However, the mechanism 
remains unknown. This study might indicate a novel mechanism of histone 
acetylation inhibits DNA methylation. 
TIP60 is known to activate gene expression through facilitating histone 
acetylation (Frank et al., 2003; Kim et al., 2005). Additionally, this study 
showed that TIP60 induces EpCAM promoter hypomethylation through 
inhibiting SNAIL2-DNMT1 recruitment (Figure 36-39). Most importantly, 
the inhibition of SNAIL2 recruitment required TIP60 acetyltransferase activity 
(Figure 31-33). Taken together, TIP60 might inhibit SNAIL2-DNMT1 
recruitment through mediating histone acetylation. Future, chromatin 
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immunoprecipitation of TIP60 mediated histone acetylation need to be done to 
confirm this hypothesis.  
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8.9 Synergy of DNMT1 inhibitor and histone deacetylase inhibitor 
might be a therapeutic way to treat cancers 
Histone deacetylase (HDAC) and DNA methylation are two of the major 
epigenetic repression systems in cell. Additionally, both these regulatory 
mechanism are involved in cancer initiation, progression and maintenance.  
For histone deacetylase, aberrant expression has been shown in multiple 
cancers (Ozdag et al., 2006), such as breast cancer (Krusche et al., 2005), lung 
cancer (Minamiya et al., 2011), liver cancer (Rikimaru et al., 2007), prostate 
cancer (Weichert et al., 2008b), gastric cancer (Weichert et al., 2008a) and 
colorectal cancer (Weichert et al., 2008c). Additionally, HDAC has been 
shown to involve in the silencing of tumour suppressor in cancers, such as p21 
(Glozak and Seto, 2007) and BRCA1 (breast cancer 1) (Eot-Houllier et al., 
2009). Therefore, histone deacetylase inhibitors have been used in cancer 
therapy, for example vorinostat and romidepsin for T cell lymphoma (Duvic et 
al., 2007; Piekarz et al., 2009).  
For DNA methylation, its role in carcinogenesis has been discussed in 
previous section. Hypermethylation of tumour suppressor gene is often 
observed in cancers. Thus, azacitidine, a DNMT inhibitor is used to prevent 
hypermethylation and treatment of therapy (Constantinides et al., 1977). 
As discussed in above section, the link between histone deacetylase and 
DNA methylation has been identified. Additionally, histone acetylation and 
DNA methylation has been shown to work inversely in regulating gene 
expression. Therefore, targeting DNMTs and HDACs by inhibitors might be 
an efficient regime for cancer treatment (Cameron et al., 1999; Fraczek et al., 
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2012). Studies have already showed that 5-aza-2’deoxycytidine (DNMT 
inhibitor) and TSA (HDAC inhibitor) combination treatment re-expressed 
repressed gene much higher than TSA or 5-aza-2’deoxycytidine alone 
(Chiurazzi et al., 1999).  Additionally, TSA and 5-aza-2’deoxycytidine 
combination treatment has showed to robust prolong effect on cancers 
(Cameron et al., 1999). 
This study revealed a novel mechanism of TIP60 mediated ablation of 
SNAIL2-DNMT1 axis in an acetylation dependent manner and supports the 
notion that combination of HDAC inhibitor and DNMT1 inhibitor might have 
therapeutic value in treatment of SNAIL2 driven breast cancer. 
8.10 Regulation of SNAIL2 
SNAIL2 is one of the members of SNAIL family proteins. Among all the 
members, SNAIL1 is studied extensively, whereas less is known about 
SNAIL2. In most of the cases, SNAIL1/2 were considered to be involved in 
similar mechanistic pathways, however, in some cases they were demonstrated 
to have diverse functions (Ye et al., 2015). As far as SNAIL1 is concerned, it 
is regulated at different levels. For instance, at transcriptional level, SNAI1 is 
regulated by signalling pathways such as TGF-β (Peinado et al., 2003), Notch 
(Sahlgren et al., 2008; Timmerman et al., 2004), WNT (Bachelder et al., 2005; 
Zhou et al., 2004; Zhou and Hung, 2005) and HIF1-α (Imai et al., 2003). At 
post-transcriptional level, SNAIL1 is known to be regulated by several 
microRNAs such as miR-9 (Liu et al., 2012a), miR-34 (Kim et al., 2011), Let-
7d (Chang et al., 2011) and miR-30a (Kumarswamy et al., 2012). At protein 
level, SNAIL1’s stability is known to be regulated by E3 ubiquitin ligases 
such as FBXL14 (Lander et al., 2011) and β-TRCP(Zhou et al., 2004) and 
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kinases such as GSK3β (Yook et al., 2006), LATS2 (Zhang et al., 2012), 
PKD1 (Du et al., 2010a) and PAK1 (Yang et al., 2005). Whereas SNAI2 has 
been previously reported to be transcriptionally regulated by several 
transcription factors, such as ELF5 (Chakrabarti et al., 2012), FOXA1, KLF4 
(Liu et al., 2012b), SOX3 (Acloque et al., 2011) and SIM2s (Laffin et al., 
2008). At post-transcriptional level, SNAIL2 is regulated by several 
microRNAs such as miR-1/200 (Liu et al., 2013) and miR-203 (Zhang et al., 
2011), and is known to be phosphorylated by kinases such as GSK3β (Wu et 
al., 2012) and FBXL14 (Vernon and LaBonne, 2006). Interestingly, these 
phosphorylation stabilizes SNAIL2 which is similar to the effect on SNAIL1.  
In this study, we have identified expression of SNAIL2 to be regulated by 
DNMT1 (Figure 34, 39). However, I did not observe any change in DNA 
methylation on SNAI2 promoter (data not shown), suggesting an indirect role 
of DNMT1 in regulating SNAI2 transcription. Further studies investigating the 
molecular mechanism of DNMT1 dependent SNAIL2 regulation will be an 
exciting avenue to explore.  
8.11 Cancer metastasis assays 
Curing the primary tumour has high success rates, metastasis is always 
difficult to treat and is the main cause of cancer related death (McClatchey, 
1999). During the metastasis, tumour cells must migrate and invade to the 
circulating system, travel to distant organ, invade and migrate out of the 
circulating system and finally adhesion and form a new tumour at distant 
place. Thus invasion, migration and adhesion are main cellular behaviours 
related to metastasis (McClatchey, 1999). 
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To further investigate metastasis process as well as to develop drug 
targeting this process, it is necessary to have experimentally model metastasis 
both in vitro and in vivo.   
In vitro modelling systems focus on the cellular properties of metastasis: 
invasion and migration. Several models have been developed to assess the 
ability of cell migration and invasion. Wound-healing assay is commonly used 
to evaluate cell migration (Chen et al., 2012; Oxmann et al., 2008). Same as 
what has been used in this study, the ability of cells to migrate and the speed at 
which it closes the wound. In vitro invasion assay is usually performed using 
an invasion chamber with Matrigel coated (Korah et al., 2000) and is 
commercial available. These chamber with Matrigel mimic the situation of 
tumour cells passing through the barrier and invading into the circulating 
system. The invasion ability is evaluated by the number of cells invading to 
the opposite site of the chamber. Moreover, chemotactic invasion could also 
be measured by adding additional chemo-attractions into the bottom layer.  
Confocal microscopy is also commonly used in in vitro models (Kim and 
Wirtz, 2011). This technique allows researchers to visualize cell migration and 
invasion more easily. With this technique, researchers are able to target one 
single cell or a group of cells, and monitor the process of cell migration and 
adhesion on a cultured plate or cell invading through a chamber. Fluorescence 
or bioluminescent molecules are often used to label the cells in order to 
efficient visualization of the migration and invasion process (Bos et al., 2010).  
In vitro models are convenient and time saving, and can be used to define 
the function of potential metastasis regulators or targeting drugs with a short 
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turnaround time. However, metastasis is a complicated cascade with multiple 
steps and requires microenvironment. These models can only provide avenues 
to analyse limited events of metastasis cascade and its challenging to mimic 
microenvironment in vitro (Bos et al., 2010). Therefore, in vivo models could 
be more accurate systems to study metastasis.  
There are several experimental models used to model metastasis in vivo. 
Immunodeficiency mice are used as animal model in these in vivo assays. The 
classic assay is to inject cancer cells into the tail vein of the immunodeficiency 
mice and test their ability to form tumour in lung. Additionally, intra-cardiac 
injection could also be performed and the ability of cancer cells to form 
tumour in distal organs, mostly lung, is evaluated same way as tail vein 
injection. Finally, intravenous injection via mesenteric vein is also used to 
evaluate liver metastasis (Li et al., 2010). Bioluminescent labelling of injected 
cells allows them to be tracked by microscopy without sacrificing the mice. 
The advantages of these assays are the successful measurement of late stage of 
metastasis. However, they fail to measure the earlier angiogenesis and 
invasion stages of the metastasis progress. Therefore, these assays might be an 
incomplete measurement of complete metastasis (Bos et al., 2010; 
McClatchey, 1999; Mendoza et al., 2010). 
Another in vivo assay is to inject the cancer cells directly into the 
peritoneum and their ability to adhere to the surrounding mesothelium 
(McClatchey, 1999). The advantage of this assay is the successful 
measurement of the adhesion and survival of cancer cells under physiological 
relevant scenarios (McClatchey, 1999). However, this assay fails to evaluate 
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the entire migration and invasion process of metastasis and in my opinion is 
less rigorous than tail vein injection.  
Investigating the regulating gene of metastasis as well as developing drug 
targeting metastasis requires better metastasis models. A truly physiological 
model should involves subcutaneous injection, formation of primary tumour, 
angiogenesis, spontaneous invasion, entering the circulating system, 
extravasation, seeding and forming new tumour in distant sites. Additionally, 
organ specific metastasis model is also needed to study certain organ 
metastasis, such as liver metastasis or lung metastasis, as different cancers 
usually metastasis to specific organs.  
Recent studies have urged the community for a better physiological model 
for metastasis. However, this is not well-studied due to the incredible 
infrequent occurring of endogenously arising metastasis in mouse compared to 
human (McClatchey, 1999). Thus, the challenge of metastasis study in future 
is to develop better modelling system. These modelling systems would 
provide us more accurate strategies to develop rational treatment and screen 
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TIP60 levels in pathophysiological scenarios 
1.1 Downregulation of TIP60 correlates with a higher grade of 
cancer and cancer metastasis in pathophysiological scenario 
Having established that TIP60 abrogates SNAIL2 function and 
maintains cells in an epithelial state, the relevance of TIP60 in breast cancers 
was analyzed. TIP60 expression levels in 3,992 breast cancer and 22 normal 
breast tissue samples was determined, and whether TIP60 expression 
correlated with the breast cancer EMT score in these samples was investigated; 
the EMT score, ϵ [-1.0, +1.0], was used to estimate the EMT phenotype of 
each sample (Tan et al., 2014). In support of the findings, TIP60 expression 
had a negative correlation with EMT score in patient samples (Spearman 
Correlation Coefficient, Rho = -0.191, p = 2.08E-34) (Figure 44A). The levels 
of TIP60 in various grades and types of breast cancer samples was also 
checked and found TIP60 to be significantly down-regulated in high-grade 
breast cancers (Mann–Whitney U-test, p = 2.56E-11) (Figure 44B). After 
further sub-classifying these tumours into the six breast cancer subtype 
signatures (Basal, Claudin-Low, Luminal-A, Luminal-B, ERBB2+, and 
Normal-like), a significantly high TIP60 expression to be associated with the 
Luminal-A subtype was observed, which has a good prognosis (Mann–
Whitney U-test, p = 7.56E-14), and significantly lower TIP60 expression in 
the molecular subtypes with poorer prognosis, Basal, Claudin-Low, and 
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ERBB2+ was also observed (Mann–Whitney U-test, p = 3.69E-16, p = 0.0169, 





                  
 
Figure 44. TIP60 expression was negatively correlated with Epithelial-mesenchymal 
transition (EMT), and is a prognostic marker for higher grade of cancer and 
metastasis in breast cancer patients. TIP60 expression was analysed in 3,992 breast 
cancer tumours and 22 normal breast tissue samples.  
(A) TIP60 expression negatively correlated with EMT score (Spearman Correlation 
Coefficient, Rho = -0.191, p = 2.08E-34). (B) TIP60 expression decreases as breast 
cancer progresses. Samples were classified as grade 1 (G1), G2 and G3, and the p-
value was determined using the Mann–Whitney U-test (G1 vs G2, p = 9.73e-5; G1 vs 
G3, p = 2.56e-11; G2 vs G3, p = 1.28e-4). (C) TIP60 is differentially expressed in 
breast cancer subtype signatures. Relative mRNA level of TIP60 is shown for Basal, 
Claudin-Low, Luminal-A, Luminal-B, ERBB2+, and Normal-like breast cancer 
samples (Basal vs Rest, p = 3.69e-16; Claudin-Low vs Rest, p = 0.0169; Luminal-A 
vs Rest, p = 7.56e-14; Luminal-B vs Rest, p = 0.1477; ERBB2+ vs Rest, p = 1.83e-7; 









1.2 Downregulation of TIP60 correlates with low survival rate in 
pathophysiological scenarios 
In terms of a correlation between patient Overall Survival (OS)/ 
Disease Free Survival (DFS) and TIP60 expression, breast cancers with higher 
TIP60 expression to show better prognoses for OS and DFS were observed 
(log-rank test, p = 0.08 and p = 0.0017, respectively) (Figure 45A, B). 
Comparing breast cancers with the 25% highest TIP60 expression (fourth 
quartile; Q4) with those with the 25% lowest TIP60 expression (first quartile; 
Q1), even more significant differences with respect to OS and DFS were 
found (log-rank test, p = 0.0054 and p = 0.0004, respectively) (Figure 45C, 
D). These data strengthen the findings that TIP60 expression is reduced in 
more aggressive cancers, and that patients with a higher level of TIP60 have a 







Figure 45. Patients with lower levels of TIP60 have higher relapse and low survival.  
(A) Survival curve of 2,333 patients with relapse. Log-rank p = 0.0017; median 
survival (month), TIP60<median = 13.62; TIP60≥median = undefined; hazard ratio = 
1.249 (1.087 - 1.436). (B) Overall survival of 974 patients with a log-rank p = 0.0882; 
median survival (months), TIP60<median =undefined,TIP60≥median = undefined; 
hazard ratio = 1.241 (0.9682 - 1.590). (C) Survival curve of 487 patients categorized 
into quartile 4 (Q4=high TIP60), or quartile 1 (Q1=low TIP60) with a log-rank p = 
0.0054; median survival (month), TIP60_Q1 = 16.47, TIP60_Q4 = 17.1; hazard ratio 
= 1.613 (1.152 - 2.258). (D) Disease-free survival curve of 1,166 patients from Q4 
and Q1. Log-rank p = 0.0004; median survival (month), TIP60_Q1 = 10.47, 
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ORIGINAL ARTICLE
E3 ligase EDD1/UBR5 is utilized by the HPV E6 oncogene to
destabilize tumor suppressor TIP60
VK Subbaiah1,6, Y Zhang1,6, D Rajagopalan1,2, LN Abdullah1, NSL Yeo-Teh1,3, V Tomaić4, L Banks4, MP Myers4, EK Chow1,5
and S Jha1,2
Tat-interacting protein of 60 kDa (TIP60) is an essential lysine acetyltransferase implicated in transcription, DNA damage response
and apoptosis. TIP60 protein expression is reduced in cancers. In cervical cancers, human papillomavirus (HPV) E6 oncogene targets
cellular p53, Bak and some of the PDZ domain-containing proteins for proteasome-mediated degradation through E6AP ligase.
Recently, E6 oncogene from high-risk and low-risk categories was also shown to target TIP60. However, the molecular mechanisms
and whether destabilization of TIP60 contributes to HPV E6-mediated transformation remain unanswered. Our proteomic analyses
revealed EDD1 (E3 identiﬁed by differential display), an E3 ligase generally overexpressed in cancers as a novel interacting partner
of TIP60. By investigating protein turnover and ubiquitination assays, we show that EDD1 negatively regulates TIP60’s stability
through the proteasome pathway. Strikingly, HPV E6 uses this function of EDD1 to destabilize TIP60. Colony-formation assays and
soft agar assays show that gain of function of TIP60 or depletion of EDD1 in HPV-positive cervical cancer cells signiﬁcantly inhibits
cell growth in vitro. This phenotype is strongly supported by the in-vivo studies where re-activation of TIP60 in cervical cancer cells
dramatically reduces tumor formation. In summary, we have discovered a novel ligase through which E6 destabilizes TIP60.
Currently, in the absence of an effective therapeutic vaccine for malignant cervical cancers, cervical cancer still remains to be a
major disease burden. Hence, our studies implying a distinct tumor suppressor role for TIP60 in cervical cancers show that
reactivation of TIP60 could be of therapeutic value.
Oncogene (2016) 35, 2062–2074; doi:10.1038/onc.2015.268; published online 3 August 2015
INTRODUCTION
HIV-1 Tat-interacting protein of 60 kDa (TIP60) is one of the well-
characterized members of the MYST family of lysine acetyltrans-
ferases (KAT).1 Initially discovered as an HIV-1 Tat transactivator,2
several groups have later reported its role as a chromatin-
modifying enzyme in transcriptional regulation, DNA repair,
apoptosis and maintenance of stem cell features.3–7 TIP60 elicits
these functions either transcriptionally by acetylation of histones
when recruited to speciﬁc promoters8–10 or non-transcriptionally
by altering the activity of non-histone proteins.11–14 Emphasizing
its major role in gene expression regulation, the homozygous
disruption of TIP60 causes embryonic lethality, implying its
importance in mammalian development.15 In addition, mice that
are haploid for TIP60 are predisposed to tumors, making TIP60 a
haploinsufﬁcient tumor suppressor.16
Owing to TIP60’s role in diverse functions as discussed above,
the cellular levels, stability and activity of TIP60 are also tightly
regulated. In the absence of any stimuli, TIP60 is an unstable
protein with a half-life of 30–190min, maintained at low levels
by the proteasome pathway,2,17,18 and its catalytic activity is
regulated by posttranslational modiﬁcations such as phospho-
rylation.19,20
EDD1 (E3 identiﬁed by differential display) also known as UBR5
(ubiquitin protein ligase E3 component n-recognin 5) is an HECT
(homologous to E6AP C-terminus) domain-containing ligase,
which was originally isolated as a progestin-induced gene.21
Mutations in EDD1 lead to imaginal disc hyperplasia in Drosophila
and suggest a critical role for EDD1 in cellular proliferation
and differentiation.22 It is linked to DNA-damage signaling
pathway23,24 and directly regulates progestin-mediated signaling
pathway21 and mitogen-activated protein kinase pathway.25
A more direct role for EDD1 in carcinogenesis is suggested by
its overexpression in several cancers, including ovarian and breast
cancer,26,27 whereas truncating mutations have been detected in
gastric and colon cancers.28
Information regarding the functional role of TIP60 in viral-
mediated cancers has been very limited. In addition, few available
reports propose a contradictory role for TIP60 as a suppressor of
EBV and HCMV viral infection,29–31 whereas in contrast the human
T-cell lymphotropic virus type-1 p30II enhances c-Myc-transform-
ing activity by stabilizing c-Myc-TIP60-containing chromatin
remodeling complexes,32 suggesting TIP60 could promote carci-
nogenesis. In the context of human papillomavirus (HPV)-
mediated cervical cancers, TIP60 functions as a cellular repressor
of HPV E6 expression and E6 in turn destabilizes TIP60.33 This
destabilization was independent of the E6AP, an essential ligase
known to mediate E6 functions or MDM2 E3 ligases,33 and hence
information regarding the mechanisms of E6-mediated TIP60
destabilization and whether this function of E6 contributes to its
oncogenicity are currently unknown. In this study, we show that
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E3 ligase EDD1 is a novel and functionally important interacting
partner of TIP60. TIP60–EDD1 regulation is physiologically
signiﬁcant as HPV E6 destabilizes TIP60 through EDD1 in cervical
cancers. Most importantly, TIP60 strongly inhibits tumor formation
in vivo, demonstrating the biological importance of cross-talk
between HPVE6, EDD1 and TIP60.
RESULTS
Proteomic analyses identiﬁes EDD1/UBR5 as a novel interacting
partner of TIP60
To investigate the molecular mechanisms of HPV E6-mediated
TIP60 degradation, we performed a proteomic screen for TIP60-
interacting partners. HEK-293 cells were transfected with HA-TIP60
expression plasmid in the presence and the absence of HPV 16 E6.
After 24 h, the cells were treated with the proteasome inhibitor
MG132 for 4 h, to prevent the degradation of TIP60. The cellular
extracts were then immunoprecipitated with anti-hemagglutinin
(HA)-conjugated agarose beads and the complexes were sub-
jected to mass spectrometric analysis. The resulting protein
proﬁles were compared with those obtained from mock-
transfected cells to exclude nonspeciﬁc interactions. Several
known interacting proteins such as histone H4 and histone H2A
were identiﬁed in the screen, which are well-established
substrates for TIP60.34 Among the novel potential interacting
partners identiﬁed, we decided to further investigate a 300-kDa
protein called EDD1 or UBR5. EDD1 is the mammalian ortholog of
the Drosophila melanogaster hyperplastic disc protein and is a
member of the HECT domain family of E3 ubiquitin ligases.21
More interestingly, HPV E6 degrades TIP60 in a proteasomal-
dependent manner33 and EDD1 is a ubiquitin ligase closely
involved with the proteasomal pathway, which has been shown
previously to interact with E6 and E6AP.35 This raises the
possibility that EDD1 could mediate the E6 function in this
context. To conﬁrm the cellular interaction between EDD1 and
TIP60, 293T cells were transfected with HA-TIP60 expression
plasmid along with Flag-EDD1 in the presence or the absence of
HPV16 E6. After 24 h, the cells were treated with MG132 for 4 h
and then the cellular extracts were immunoprecipitated using
anti-HA-conjugated agarose beads. EDD1 bound to the agarose
beads was detected by western blotting using anti-Flag antibody.
EDD1 speciﬁcally co-immunoprecipitated with TIP60 (Figure 1a).
However, this interaction seems to be HPV E6 independent, as
TIP60 co-immunoprecipitated both in the presence or the absence
of HPV16 E6. To conﬁrm the interaction between TIP60 and EDD1
at endogenous levels, HeLa-LPCX and HeLa-TIP60 cells were
seeded in 10-cm dishes. After 24 h, the cells were collected, proteins
extracted using RIPA buffer, the lysates immunoprecipitated using
anti-Flag agarose beads and the co-immunoprecipitating EDD1
detected using anti-EDD1 antibody (Figure 1b). To further map the
binding region on TIP60, Flag-EDD1 was transfected either alone or
in combination with a series of HA-tagged deletion mutants of TIP60
(Figure 1c). The cellular extracts were immunoprecipitated using
anti-HA-conjugated agarose beads and the co-immunoprecipitating
EDD1 was detected using anti-Flag antibody. EDD1 strongly
co-immunoprecipitated with full-length wild-type (WT) TIP60
(aa 1–461) and the deletion mutant construct of TIP60 in which
the chromodomain at the N-terminus was deleted (aa 90–461)
(Figure 1d). However, this interaction was abolished on simulta-
neously deleting the chromodomain at the N-terminus and
the functional acetyl CoA domain at the C-terminus of TIP60
(aa 90–232), and this was not due to mis-localization of the
deletion mutants of TIP60 (Figure 1e). This indicates that EDD1
interacts with TIP60 speciﬁcally through the C-terminus containing
the acetyl CoA domain. To conﬁrm this, we generated a TIP60
deletion mutant construct comprising a C-terminus with the acetyl
CoA domain (aa 232–461). The results in Figure 1d conﬁrmed that
EDD1 recognizes and interacts with TIP60 through acetyl CoA
domain. Taken together, these results demonstrate that EDD1 is a
novel interacting partner of TIP60 in the presence and the absence
of HPV E6, and it recognizes TIP60 through the acetyl CoA domain
at the C-terminus.
Depletion of EDD1 increases TIP60 levels and regulates its
turnover
To address the physiological relevance of this novel interaction,
we tested whether modulating the endogenous cellular levels of
EDD1 could affect the endogenous TIP60 levels. We therefore
performed transient small interfering RNA (siRNA) knockdown
experiments in HPV-positive CaSki and HeLa cells. Cells were
transfected with siRNA against control, EDD1 or TIP60 for 72 h and
cellular lysates were immunoblotted for endogenous TIP60
protein using anti-TIP60 antibody. The results show that ablation
of endogenous EDD1 increases TIP60 protein levels and the
speciﬁcity of the TIP60 band was conﬁrmed, as siRNA against
TIP60 decreased the levels of the respective band (Figures 2a and
b). We next tested whether EDD1 regulates TIP60 stability in
cervical cancer cell line lacking HPV E6 expression; for this, C33A
cells were transfected with siRNA against control, EDD1 or TIP60
for 72 h, and cellular lysates were immunoblotted for endogenous
TIP60 protein. The results show that ablation of endogenous EDD1
by siRNA does not result in increased TIP60 protein level
(Figure 2c). In order to investigate the mechanism of EDD1-
mediated decrease in TIP60 levels, we generated HeLa cells with
stable knockdown of endogenous EDD1 and conﬁrmed the
increase in TIP60 protein levels in these cells (Figure 2d).
As EDD1 negatively regulates TIP60 protein levels, we next sought
to resolve whether this is due to EDD1 regulating TIP60
transcriptionally. For this, total RNA was isolated from HeLa cells
stably expressing short hairpin RNA against control or EDD1
sequences and was subjected to real-time PCR analysis (Figure 2e).
The TIP60 mRNA levels in the shEDD1-stable cells did not change
signiﬁcantly compared with the control cells. Hence, we hypo-
thesized that EDD1 might directly increase TIP60 protein turnover.
To investigate this, HeLa-shcontrol or HeLa-shEDD1 cells were
treated with cycloheximide for various time points, to block
protein synthesis. The residual levels of endogenous TIP60 were
then determined using anti-TIP60 antibody. Under normal
circumstances, TIP60 has a half-life of o1 h, which is extended
on depleting endogenous EDD1 (Figures 2f and g). Based on these
results, we decided to ascertain the effects of HPV E6 on TIP60
protein levels in the absence of endogenous EDD1. For this,
we generated 293T cells stably expressing short hairpin RNA
against EDD1. Cells stably expressing shEDD1 were selected with
puromycin antibiotic and depletion of EDD1 was ascertained by
western blotting (Figure 2h). As shown earlier, HPV18 E6
destabilizes TIP60;33 however, this function of E6 was impaired
in EDD1-depleted cells (Figures 2i and j). To test whether this is
due to decreased half-life of TIP60, Flag-TIP60 was transfected in
the cells with decreased EDD1 levels (shEDD1) either alone or in
combination with HPV18 E6 for 24 h, then treated with
cycloheximide for indicated times and the total cellular lysates
were analyzed by western blotting. The results and quantiﬁcations
in Figures 2k and l demonstrate that ectopically expressed TIP60
has a half-life o2 h, which is further decreased in the presence of
HPV 18E6. More interestingly, this effect of E6 is abolished in
shEDD1 cells, suggesting that E6 regulates TIP60 half-life through
EDD1. In addition, the expression level of TIP60 is not signiﬁcantly
altered in shEDD1 cells compared with shcontrol. In summary,
these results demonstrate the direct role for EDD1 in regulating
TIP60 protein levels in HPV-positive cells.
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EDD1 ubiquitinates and degrades TIP60 through proteasomal
pathway
EDD1 is an E3 ubiquitin ligase and is involved in ubiquitination or
ubiquitin binding.36 We aimed to explore the mechanism of
EDD1-mediated destabilization of TIP60. To do so, 293T cells were
transfected with Flag-TIP60 expression plasmid, either alone or in
combination with Flag-EDD1 expression plasmid. After 24 h, the
cells were treated with dimethyl sulfoxide vehicle control or
treated with 10 μg/ml of MG132 for 4 h. The total cellular lysates
were subjected to western blotting and the remaining TIP60 levels
were detected using anti-Flag antibody. The results in Figure 3a
show that EDD1 induces a signiﬁcant decrease in TIP60 protein
levels and this is due to the enhanced proteasomal degradation of
TIP60, as treatment with MG132 for 4 h abolished the effect of
EDD1. TIP60 alone on treatment with MG132 is restored to similar
levels. Plasmid expressing β-galactosidase was used to demon-
strate the transfection efﬁciency and also served as a negative
control. The key feature of the HECT class of E3 ligases is their
ability to covalently bind ubiquitin through a conserved cysteine
residue located in their HECT domain.37 Furthermore, substitution
of this conserved cysteine at position 2768 to alanine abolishes
the ability to bind to the ubiquitin and degrade its substrates.21,23
We were interested in comparing the effects of the ligase-dead
mutant of EDD1 (referred to as EDD1-Mut (C2768A)) and the wild
type EDD1-WT on TIP60 levels. To do so, 293T cells were
transfected with Flag-TIP60 expression plasmid, either alone or
in combination with increasing amounts of EDD1-WT or EDD1-Mut
(C2768A). After 24 h, cellular extracts were prepared and
both TIP60 and EDD1 were detected using anti-Flag antibody.
Although both the proteins are Flag tagged, they could be
distinguished on a western blot because of the marked
differences in their molecular weights. The results in Figure 3b
show that EDD1-WT decreases TIP60 protein levels in a dose-
dependent manner and this effect is not observed in the presence
of EDD1-Mut (C2768A), suggesting that destabilization of TIP60
by EDD1 requires the ligase activity of EDD1. We then extended
our study to address the question whether EDD1 could also
polyubiquitinate TIP60 in vivo. For this, 293T cells were transfected
with Myc-TIP60 expression plasmid, either alone or co-transfected
with the Flag-EDD1-WT or EDD1-Mut (C2768A) and HA-Ubiquitin
expression plasmids in various combinations as shown in
Figure 3c. After 24 h, the cellular extracts were immuno-
precipitated using anti-HA-conjugated agarose beads and
the HA-Ubiquitin-bound TIP60 was then detected by western
blotting using anti-Myc antibody. The results from Figure 3c and
quantiﬁcation from four independent experiments in Figure 3d
show that TIP60 co-immunoprecipitated with ubiquitin and this is
clearly enhanced in the presence of EDD1-WT. Interestingly, TIP60
co-immunoprecipitated less efﬁciently when the EDD1-Mut
(C2768A) was expressed, suggesting that destabilization of TIP60
by EDD1 is through ubiquitin-mediated proteasome degradation.
In order to investigate whether EDD1 targets the functionally
active form of TIP60, Flag-TIP60-WT or the HAT (histone
acetyltransferase) mutant of TIP60 (TIP60-KD) was transfected
alone or in combination with the EDD1-WT and analyzed by
western blotting. TIP60-WT protein levels were efﬁciently
downregulated by EDD1, conﬁrming the earlier results, whereas
in sharp contrast the HAT mutant of TIP60 is resistant to
degradation by EDD1 (Figure 3e). We next investigated whether
EDD1 interacts with TIP60-KD. For this, EGFP-EDD1 was
transfected alone or in combination with Flag-TIP60-WT or
Flag-TIP60-KD and co-immunoprecipitation assay was per-
formed. Intriguingly, EDD1 interacted with TIP60-KD mutant
similar to TIP60-WT (Figure 3f), although EDD1 failed to degrade
the TIP60-KD mutant.
Overexpression of TIP60 inhibits cellular growth
TIP60 is a tumor suppressor and is a transcriptional repressor of E6
expression. Therefore, we reasoned that gain of function of TIP60
might also antagonize E6-mediated cellular growth, thereby
inhibiting tumor cell growth in cervical cancer cells. To address
this, we used retroviral system to generate HeLa cells (Figure 4a)
and CaSki cells (Figure 4b) stably expressing Flag-TIP60. TIP60
regulation by EDD1 was conﬁrmed by transfecting HeLa-TIP60
cells individually with siRNA against control, EDD1, 18E6/E7 or
TIP60 for 72 h and cellular lysates were immunoblotted for TIP60
protein using anti-Flag antibody. The results in Figure 4c show
that transient depletion of EDD1 in HeLa-TIP60 stable cells did not
signiﬁcantly change TIP60 mRNA levels compared with the control
cells, despite efﬁcient depletion of EDD1. In addition, depletion of
endogenous EDD1 stabilizes TIP60 protein levels conﬁrming our
earlier results. Similarly, ablation of HPV 18E6/E7 also stabilized
TIP60 levels as previously published33 (Figure 4d). Ablation of HPV
18E6/E7 was conﬁrmed by rescue in p53 levels. In addition,
the speciﬁcity of the TIP60 band was also conﬁrmed, as siRNA
against TIP60 showed a signiﬁcant decrease in TIP60 levels
detected using the anti-Flag antibody. Similar results were
obtained in CaSki cells and off-target effect was ruled out by
using three independent siRNA targeting EDD1 (Figure 4e and
Supplementary Figure S1). Finally, transient depletion of EDD1
combined with cycloheximide treatment shows that under
normal circumstances ectopically expressed TIP60 has a half-life
of o1 h, which is extended on depleting endogenous EDD1
(Figures 4f and g). These results further conﬁrm our previous
results at the endogenous level.
We then characterized the growth ability of HeLa-TIP60 and
CaSki-TIP60 stable cells in vitro by colony-forming assay. HeLa-
LPCX vector control or HeLa-TIP60-expressing cells were seeded at
very low density (1 × 103/9.5 cm2) for colony-formation assays
(CFAs) and maintained in antibiotic selection. After 3 weeks the
colonies were ﬁxed, stained and quantiﬁed. Representative images
in Figures 5a (i)and (ii) and the quantiﬁcations in Figure 5b show
that expression of TIP60 compared with control inhibited the
ability of HeLa cells to form colonies by 90%. Interestingly, the
morphology of HeLa-TIP60 cells were dramatically different and
suggested that the cells undergo senescence under the reduced
serum conditions in comparison with the control cells. Similar
results were observed in CaSki cells (Figures 5c and d).
Figure 1. EDD1 interacts with TIP60. (a) TIP60 interacts with EDD1. 293T cells were transfected with plasmids as shown and treated with
MG132 for 4 h before using the lysates for co-immunoprecipitation. TIP60 and EDD1 were detected using anti-HA and anti-Flag antibodies,
respectively. (b) HeLa-LPCX or HeLa-TIP60 cells (1 × 106) were seeded in 10-cm dishes. After 24 h, total cellular lysates were subjected to Flag
immunoprecipitation and western blotted for endogenous EDD1. (c) Schematic of the different TIP60 mutant constructs used in the
experiment depicting the length of the fragments. The amino acid numbers corresponds to TIP60 isoform 3 (NP_874368). (d) EDD1 interacts
with TIP60 WT through TIP60’s C-terminal acetyl CoA domain. Co-immunoprecipitation assay performed on 293T lysates transfected with
various plasmids as shown. EDD1 was detected using anti-Flag antibody. (e) TIP60 full length and deletion proteins are localized in the
nucleus. 293T cells were transfected with plasmids expressing various TIP60 fragments. Nuclear and cytoplasmic fractionation was performed,
and TIP60 fragments were probed by immunoblotting with anti-HA antibody. Histone H3 and β-tubulin serve as a marker for nuclear and
cytoplasmic fraction, respectively.
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Furthermore, TIP60 was also able to efﬁciently inhibit the ability of
HeLa cells to form colonies in in vitro anchorage-independent CFA
when compared with the control (Figures 5e and f). The cellular
phenotype observed in Figure 5a (ii) suggests that stable
expression of TIP60 in HeLa cells induces cell cycle arrest and
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cellular extracts from HeLa-TIP60 cells showed a marked down-
regulation of endogenous HPV 18 E6 levels compared with the
control cells (Figure 5g) and this is consistent with mRNA data
from previous studies.33 We next asked the question whether the
growth defects seen in HeLa-TIP60 cells could be rescued by
overexpression of HPV 18 E6. For this, HeLa-LPCX and HeLa-TIP60
cells were transiently transfected with pcDNA vector alone or
pcDNA 18 E6 expression plasmids. After 24 h, 2 × 103 number of
cells were seeded for CFAs and were maintained in antibiotic
selection. After 14 days, the colonies were ﬁxed, stained and
quantiﬁed. Representative images in Figure 5i and the quanti-
ﬁcations in Figure 5j show that expression of HPV 18 E6 in HeLa-
TIP60 cells could signiﬁcantly rescue the growth compared with
control and there was no change in growth of HeLa-LPCX cells
expressing HPV 18 E6 compared with HeLa-LPCX. The expression
of transfected HPV 18 E6 was veriﬁed by western blot analysis
(Figure 5h).
Based on promising in vitro results, we wanted to conﬁrm this
strong phenotype of TIP60 on cellular growth in vivo. Six-week-
old NOD/SCID mice were subcutaneously injected with 1 × 106
HeLa-LPCX or HeLa-TIP60 cells. The tumor size was measured at
every 7-day interval for 7 weeks. The representative images and
quantiﬁcations from Figures 6a (i–iii) and Supplementary
Figures S2A and B show that the tumors induced by HeLa-
LPCX cells were signiﬁcantly reduced with TIP60 expression. We
were then highly interested in verifying the TIP60 expression in
these tumors. The total protein from the tumor tissue was
extracted and western blotted for anti-Flag to detect TIP60. As
shown in Figure 6a (iv), anti-Flag band corresponding to TIP60
was detected only from tumors induced by HeLa-TIP60 cells and
not in the control.
Depletion of EDD1 affects cell growth
As EDD1 destabilizes TIP60, we wanted to investigate whether
stable depletion of endogenous EDD1 could result in a similar
phenotype as observed with HeLa-TIP60 stable cells. To do this,
we tested the ability of HeLa-shcontrol and shEDD1 cells to form
colonies in vitro in CFAs. The representative images and
quantiﬁcations in Figures 6b and c show that loss of EDD1
(HeLa-shEDD1) signiﬁcantly inhibits the colony-forming efﬁciency
of HeLa cells similar to HeLa-TIP60 cells and this was TIP60
speciﬁc, as depletion of TIP60 rescued the growth inhibition
(Figures 6b and c and Supplementary Figures S3A and B). We
wanted to conﬁrm the growth inhibition with reduced levels of
EDD1 in vivo. To do so, 1 × 105 cells of either HeLa-shcontrol or
HeLa-shEDD1 cells were injected subcutaneously into the mice.
The tumor size was measured at 7-day intervals over a period of 5
weeks. The representative images and quantiﬁcations from
Figures 6d (i–iii) and Supplementary Figures S4A and B show that
the tumors induced by HeLa-shcontrol cells were signiﬁcantly
reduced on stable ablation of endogenous EDD1 expression,
suggesting the biological importance of TIP60’s regulation by
EDD1. The knockdown of EDD1 expression and stabilization
of TIP60 in the tumors were veriﬁed by western blot analysis
(Figure 6d (iv)).
DISCUSSION
The deregulation in the expression of upstream transcriptional
regulators, either at mRNA or protein levels, leading to an
abnormal activation or repression of essential cellular targets is a
prominent feature reported in various diseases and cancers. TIP60
is a transcriptional co-factor involved in several essential cellular
physiological processes and its aberrant expression has been
reported in several cancers.2,33,38,39 TIP60’s major role in main-
taining genomic stability enables the suppression of potential
transforming activities leading to cancer. These observations
hence suggest the requirement for tight regulation of TIP60
expression and function. In HPV-driven cervical cancers, HPV E6
destabilizes TIP60; however, information about molecular mechan-
isms regulating E6-mediated TIP60 destabilization and its implica-
tions in HPV-driven cervical cancers is still lacking. Our ﬁndings
demonstrate that the E3 ubiquitin ligase EDD1 is a potential
cellular-interacting partner of TIP60 in both HPV-negative
293T cells and HPV-positive cells (HeLa) (Figures 1a and b), a
negative regulator of TIP60 stability in HPV-positive cells (HeLa
and CaSki) (Figures 2a and b). On the same lines, overexpression
shows that TIP60 associates with EDD1 independent of HPV E6
(Figure 1a), suggesting that the EDD1 and TIP60 interaction is a
general phenomenon not restricted to cells derived from cervical
cancers, and factors that could increase TIP60–EDD1 interaction
would regulate EDD1-mediated destabilization of TIP60. This
ﬁnding is signiﬁcant considering the inverse correlation in TIP60
and EDD1 expression reported in a variety of cancers (breast,
gastric and colon) and also the common function shared by EDD1
and TIP60 in the maintenance of genomic stability during DNA
damage. The HAT activity of TIP60 can have pleiotropic effects in
regulating cellular physiology. Our protein expression analysis
demonstrating that EDD1 cannot destabilize the HAT mutant
TIP60 (Figure 3e) demonstrates this versatility of HAT function.
However, EDD1 is able to interact with HAT mutant TIP60, as the
TIP60-KD mutant construct was made by point mutation and
hence still retains the C-terminus with acetyl CoA region, essential
for its interaction. Whether EDD1 is also affecting the HAT activity
of TIP60 needs further analysis. E6AP is critical in mediating HPV
E6 function in degradation of its substrates such as the major
Figure 2. EDD1 regulates the expression and stability of endogenous TIP60 in HPV-positive cells. (a–c) TIP60 expression is stabilized in EDD1-
depleted HPV-positive cells (CaSki and HeLa) but not in HPV-negative cells (C33A). Cells were transiently transfected with indicated siRNA and
the whole-cell lysates prepared from cells 72 h after transfection were probed for indicated proteins. Endogenous EDD1 was detected using
EDD1 antibody and endogenous TIP60 was detected using anti-TIP60 antibody. (d) Whole-cell lysates prepared from HeLa-shcontrol and
shEDD1 stable cells were probed for indicated proteins. (e) Real-time PCR analysis showing no signiﬁcant change in TIP60 mRNA levels in HeLa
shEDD1 cells compared with the control. The level of a given mRNA was measured by quantitative reverse transcriptase–PCR relative to that of
actin mRNA. (f) HeLa-shcontrol and HeLa-shEDD1 cells were treated with 100 μg/ml of cycloheximide in phosphate-buffered saline (PBS) for
indicated times, to inhibit protein synthesis. The cellular lysates were probed with indicated antibodies. (g) Graph represents collated results
from three independent half-life experiments performed in HeLa-shcontrol and HeLa-shEDD1 cells. The band intensities were quantiﬁed
using Image J software. TIP60 levels were normalized to 100% at time zero and s.d. estimated. (h) Generation of 293T stable shEDD1 cell line.
Western blot analysis showing the stable knockdown of endogenous EDD1 in 293T shEDD1 cells compared with the shcontrol cells.
(j–l) HPV18 E6 destabilizes TIP60 through EDD1. 293T cells stably expressing short hairpin RNA (shRNA) against control or EDD1 were
transfected with Flag-TIP60 along with indicated plasmids. After 24 h, the cell lysates were analyzed by western blotting and probed for
indicated proteins. (k and l) 293T shcontrol and 293T shEDD1 cells were transfected with 2.5 μg of Flag-TIP60 along with 5 μg of either pcDNA
vector or pcDNA HPV 18 E6 expression plasmids. After 24 h, cells treated with 100 μg/ml of cycloheximide in PBS for indicates times and the
cellular lysates were probed with indicated antibodies. (k and l) Graph representing collated results from three independent half-life
experiments performed in 293T shcontrol and 293T shEDD1 stable cells. The band intensities were quantiﬁed using Image J software. TIP60
levels were normalized to 100% at time zero and s.d. estimated. Signiﬁcance is represented as *Po0.05 and **Po0.01.
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tumor suppressor p53 and apoptosis-inducing Bak protein.40,41
However, the mutant form of HPV16 E6 was unable to bind to
E6AP, showing that E6AP is dispensable for E6-mediated TIP60
destabilization.33 Likewise MDM2, a ligase known to regulate
TIP60 turnover, was also dispensable. We provide three lines of
evidence to show that EDD1 mediates E6 function in this context:
(i) depletion of endogenous EDD1 in HeLa and CaSki cells
upregulates TIP60 protein levels (both endogenous and exogen-
ous (Figures 2 and 4)) but not the RNA (Figures 2e and 4c). (ii)
Ablation of EDD1 in HeLa cells extends the half-life of TIP60 (both
endogenous and exogenous (Figures 2 and 4)) from o1 to > 2 h,
demonstrating that EDD1 directly regulates TIP60 protein stability.
(iii) Finally, we show that 18 E6 regulates TIP60 protein stability
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Figure 3. EDD1 destabilizes TIP60 through ubiquitin/proteasome pathway. (a) EDD1 destabilizes TIP60 through proteasome pathway.
293T cells were transfected with the plasmids shown and treated with 10 μg/ml MG132 for 4 h before harvesting. The total cellular lysates
were probed with indicated antibodies. (b) EDD1 requires its ligase function to destabilize TIP60. 293T cells were transfected with different
concentrations of WT EDD1 or ligase-dead mutant (C2768A). Cellular lysates were probed with anti-Flag to detect both TIP60 and EDD1.
(c) EDD1 polyubiquitinates TIP60 in vivo. 293T cells were transfected with the various plasmids as shown. After 24 h, the lysates were
immunoprecipitated with anti-HA-conjugated agarose beads and analyzed by western blot with indicated antibodies. (d) Quantitation of
polyubiquitinated TIP60 from four independent experiments. (e) EDD1 regulates catalytically active form of TIP60. 293T cells were transfected
with MSCV-TIP60 WT or MSCV-TIP60 HAT mutant along with EDD1. After 24 h, total cell lysates were probed with indicated antibodies.
(f) EDD1 interacts with catalytically inactive form of TIP60. 293T cells were transfected with MSCV-TIP60 WT or MSCV-TIP60 HAT mutant along
with EGFP-EDD1. After 24 h, total cell lysates were co-immunoprecipitated using anti-Flag beads and western blotted for EDD1 using anti-GFP
antibody.
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(Figures 2i–l). This mechanism is intriguing, as E6 interacts with
EDD1, which negatively regulates E6 expression and its function in
conjunction with E6AP.35 The current study highlights another
function of the E6–EDD1 interaction, independent of E6AP, which
is favorable to E6 in the context of TIP60. These observations also
suggest that EDD1 has a dual role in HPV-driven cervical cancers,
where it could function as a tumor suppressor by negatively
regulating E6 function, but in contrast also functions as a tumor
promoter by mediating TIP60 destabilization. This is reminiscent of
EDD1’s role in colon cancer where it functions as a tumor
suppressor by stabilization of adenomatous polyposis coli and
hence upregulates its function to inhibit β-catenin;42 in contrast,
EDD1 also ubiquitinates and upregulates Wnt-signaling-mediated
β-catenin, thus promoting cancer development.43 In addition to
high-risk HPV16 and 18 E6, E6 from low-risk HPV11 and 8 also
destabilizes TIP60,33 but whether EDD1 mediates E6 function of
these viruses also will be an interesting avenue to explore. HPV11












































































Figure 4. EDD1 regulates TIP60 turnover in HeLa-TIP60 stable cells. Western blot analysis conﬁrming retroviral-induced TIP60 expression in
HeLa-TIP60 (a) and in CaSki-TIP60 stable cell line (b). TIP60 was detected using anti-Flag antibody. (c) Endogenous EDD1 mRNA levels are
decreased after transfecting HeLa-TIP60 stable cells with siRNA against EDD1, when compared with the control. Under the same conditions,
there is no signiﬁcant change in TIP60 mRNA levels. The level of a given mRNA was measured by quantitative reverse transcriptase–PCR
relative to that of actin mRNA. (d) TIP60 expression is stabilized in EDD1-depleted HeLa-TIP60 cells. HeLa-TIP60 cells were transiently
transfected with indicated siRNA and lysates prepared from cells 72 h after transfection were probed for indicated proteins. Endogenous
EDD1 was detected using EDD1 antibody and TIP60 was detected using anti-Flag antibody. (e) TIP60 expression is stabilized in EDD1-depleted
CaSki-TIP60 cells. Rest as in d. (f) HeLa-TIP60 cells were transfected with siRNA against control or EDD1. After 72 h, cells were treated with
50 μg/ml cycloheximide in phosphate-buffered saline (PBS) at indicated times, to inhibit protein synthesis. The cellular lysates were probed
with indicated antibodies. (g) Graph represents the collated results obtained from three independent half-life experiments performed in HeLa-
TIP60 cells to measure residual TIP60. The band intensities were quantiﬁed using Image J software. TIP60 levels were normalized to 100% at
time zero and s.d. estimated. Signiﬁcance is represented as **Po0.01.
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HPV 18.35 Based on this, we speculate that EDD1 could mediate
HPV 11 E6-mediated destabilization of TIP60.
Ubiquitylation mostly targets proteins to the 26 S proteasome
for degradation, but it can also result in lysosomal targeting,
alteration in subcellular localization, regulation of transcription
and DNA repair.44 By elucidating further the molecular mechanism
through which EDD1 destabilizes TIP60, we provide evidence to
show that EDD1 uses its ligase function to polyubiquitinate TIP60
and further subjects it to proteasome-mediated degradation
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In the case of cervical cancer, HPV E6 destabilizes TIP60 and TIP60
suppresses the early major promoter of E6. We now show that gain
of function of TIP60 in cervical cancers inhibits the ability of HPV-
positive cells to form colonies in vitro (Figures 5a–f) and this
strongly corresponds to inhibition of tumor growth in vivo
(Figure 6a). The molecular mechanisms governing this strong
phenotype of TIP60 needs further study. However, the CFA
(Figures 5i and j) suggests that suppression of E6 expression—
one of the major oncogenes regulating the transforming ability of
papilloma viruses and possibly its downstream effector pathways—
could mediate TIP60 function. This implies that in cervical cancers,
one of the essential mechanisms through which HPV E6 oncogene
promotes tumorigenesisis is by downregulating TIP60 protein level.
We further provide evidence showing that regulation of TIP60 by
EDD1 also contributes to TIP60-mediated phenotype both in vitro
and in vivo. This is supported by similar in-vitro phenotype observed
in HeLa-shEDD1 (Figures 6b and c) cells and HeLa-TIP60 stable cells
(Figure 5a), and in-vivo phenotype (Figures 6a and d). Based on our
studies, we propose a model (Figure 7) where in HPV-driven cervical
cancers, HPV E6 destabilizes TIP60 through EDD1 to promote
tumorgenesis and this activity is counteracted by TIP60, which
suppresses E6 expression leading to tumor suppression. In
summary, we propose that re-activation of TIP60 possibly through
the inhibition of EDD1 could be of therapeutic value in treating
HPV-driven malignant cervical cancers.
MATERIALS AND METHODS
Cells and transfection
All the cell lines used were cultured in Dulbecco’s modiﬁed Eagle’s
medium with 10% fetal bovine serum. CaSki (American Type Culture
Collection catalog number CRL-1550) was grown in RPMI medium with
10% fetal bovine serum. HeLa (American Type Culture Collection catalog
number CLL-2) and HEK 293T (American Type Culture Collection catalog
number CRL-3216) cells were transfected using calcium phosphate
precipitation method. For siRNA transfection in HeLa, CaSki and C33A
(American Type Culture Collection catalog number HTB-31) cells, transfec-
tion was carried out using 35 nM of annealed siRNA duplex (AIT) with
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) reagent following
the manufacturer’s instruction.
Plasmids and siRNAs
All the TIP60 constructs are described elsewhere.33 pRcCMV-His-EDD1,
pCDNA-β-Gal, short hairpin RNA constructs against control and EDD1 were
kindly provided by Professor Lawrence Banks (ICGEB, Trieste, Italy). pCMV-
Tag2B EDD1 (37188), pCMV-Tag2B EDD1 C2768A (37189) and EGFP-EDD1
(37190) were purchased from Addgene (Cambridge, MA, USA) and we
thank the principal investigator Henderson MJ who deposited this plasmid
in Addgene. MSCV-Flag-TIP60WT was generated by subcloning full-length
TIP60 from pEF1α-TIP60-WT construct as described elsewhere8 and MSCV-
Flag-TIP60HAT mutant was generated by introducing point mutations4 in
TIP60-WT. siRNA sequences for sicontrol, siTIP60 and si18E6/E7
are as described elsewhere.33 siEDD1A: forward: 5′-CAACUUAGAUCUCCU
GAAAdTdT-3′, reverse: 5′-UUUCAGGAGAUCUAAGUUGdTdT-3′; siEDD1B:
forward: 5′-GAACAGCCCUUACAUGCAAdTdT-3′, reverse: 5′-UUGCAUGUAAGG
GCUGUUCdTdT-3′; and siEDD1C was purchased from Life Technologies
(Carlsbad, CA, USA; siRNA ID: s60863).
Western blotting and antibodies
Western blotting was performed as described elsewhere.45 TIP60
antibody was generated in the lab as described previously.46 Commercial
available antibodies used are follows: Anti-HA (11583816001) Roche Life
Science, Germany, anti-β-Gal (Z37880) (Promega, Madison, WI, USA), anti-
penta-His (34660) (Roche, Germany), Anti-HA (E6779) beads, and anti-
FlagM2 (A2220) beads (SIGMA, St Louis, MO, USA) all the other antibodies
were purchased from SantaCruz (Santa Cruz, CA, USA), anti-Flag (sc-807),
anti-Myc (sc-40), anti-EDD1 (H-300) (sc-367559), anti-p53 (sc-126), anti-GFP
(GFP-B2) (sc9996) and anti-actinin (B-12) (sc-166524).
Mass spectrometry analysis and co-immunoprecipitation assays
Mass spectrometry analysis and co-immunoprecipitation assays was
performed as described elsewhere.45
In vivo ubiquitination and half-life experiments
In vivo ubiquitination and half-life experiments was performed as
described elsewhere.45
Real-time PCR analysis
Real-time PCR analysis was performed as described elsewhere.33 Primers
for real-time PCR were as follows: TIP60 forward primer: 5′-AATG
TGGCCTGCATCCTAAC-3′ and reverse primer: 5′-TGTTTTCCCTTCCACTTTGG-3′;
EDD1 forward primer: 5′-GAAGAGGTTGAGGTGGTGGA-3′ and reverse primer:
5′-CAGCTCCATATCACTCCCGT-3′; and Actin forward primer: 5′-CCAGAT
CATGTTTGAGACCTTCAAC-3′ and reverse primer: 5′-CCAGAGGCGTACA
GGGATAGC-3′.
Stable cell line generation
Stable cell line generation was performed as described elsewhere.38
CFA and soft agar assays
Cells (1 × 103) either in 5% serum or 2 × Dulbecco’s modiﬁed Eagle’s
medium supplemented with 20% fetal calf serum and 0.4% agar were used
for CFA and soft agar assay, respectively. After 3 weeks, the colonies
were stained with Giemsa stain and quantiﬁed using Image J software
(http://imagej.nih.gov/ij/).
Cell fractionation assays
HEK293 cells in 10-cm dishes were transfected with 5 μg of plasmids
expressing HA-tagged deletion mutants of TIP60. Twenty-four hours post
transfection, the cells were collected and subjected to cytoplasmic and
Figure 5. TIP60 inhibits the growth of HPV-positive cells in vitro. (a) (i) Representative images from the CFA performed in HeLa stable cells (top
panel) and the magniﬁed images (ii) from the same assay (lower panel). The assay was performed as mentioned in ‘Materials and Methods’.
The cells were ﬁxed and stained with crystal violet after 21 days. (b) Bar graph represents the collated results obtained from quantiﬁcations of
two independent experiments (as shown in a) each in triplicates. Quantiﬁcations were performed using Image J software; s.d. is also shown.
(c) Representative images from the CFA performed in CaSki stable cells. (d) Bar graph represents the collated results obtained from
quantiﬁcations of two independent experiments (as shown in c), each in triplicates. Quantiﬁcations were performed using Image J software;
s.d. is also shown. (e) Representative images from the soft agar assay performed in HeLa stable cells. The assay was performed as mentioned in
the ‘Materials and Methods’. The colonies were ﬁxed and stained with crystal violet after 21 days. (f) Bar graph representing the collated results
obtained from quantiﬁcations of two independent experiments, each in triplicates; s.d. is also shown. Quantiﬁcations were done using Image J
software assigning a threshold value to deﬁne a colony. (g) TIP60 inhibits the ability of HeLa cells to form colonies by downregulating HPV 18
E6 protein levels. Total cellular extracts from HeLa-LPCX and HeLa-TIP60 were probed with indicated antibodies. (h–j) HPV 18 E6 rescues the
growth defect in HeLa-TIP60 cells. HeLa-LPCX or HeLa-TIP60 cells were transiently transfected with indicated plasmids and western blotted for
indicated antibodies. (i) Representative images from the CFA performed in HeLa stable cells indicated in h. The assay was performed as
mentioned in ‘Materials and Methods’. The cells were ﬁxed and stained with crystal violet after 14 days. (j) Bar graph represents the collated
results obtained from quantiﬁcations of four independent experiments. Quantiﬁcations were performed using Image J software; s.d. is also
shown. Signiﬁcance is represented as **Po0.01 and ***Po0.001.
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nuclear fractionation using NE-PER Cytoplasmic and Nuclear Extraction
reagents (Life Technologies, catalog number 78833) following the manu-
facturer’s instructions. The different fractions were run on SDS–polyacryla-
mide gel electrophoresis and the localization of the TIP60 deletion mutants
was observed. β-Tubulin for cytoplasmic fraction and Histone H3 for
nuclear fraction were used to validate the extraction procedure.
In-vivo mice experiment
Six-week-old NOD/SCID mice obtained from Invivos (Singapore) were
randomly distributed and HeLa stable cell lines (HeLa-LPCX, HeLa-TIP60,
HeLa-shcontrol or HeLa-shEDD1) resuspended in 100 μl of serum-free
Dulbecco’s modiﬁed Eagle’s medium at a concentration of 1 × 107 cells/ml
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or HeLa-shEDD1) supplemented with BD Matrigel matrix (BD Biosciences,
Bedford, MA, USA; 354234) and were injected subcutaneously into the
right or the left ﬂank of the mice. Tumors were examined at indicated
times and total tumor volume recorded. Tumor volume (mm3) was
calculated using the formula: Volume (V) =Width (W)(2) × Length (L)/2. The
National University of Singapore Institutional Animal Care and Use
Committee has approved the work done in this study, under protocol
102/12 in accordance with the National Advisory Committee for Laboratory
Animal Research Guidelines (Guidelines on the Care and Use of Animals for
Scientiﬁc Purposes) in facilities licensed by the Agri-Food and Veterinary
Authority of Singapore, the regulatory body of the Singapore Animals and
Birds Act.
Statistical analysis
For indicated experiments, an unpaired two-tailed Student’s t-test was
performed. Error bars indicate the s.d. of data collected from mentioned
experimental repeats. Signiﬁcance is represented as *Po0.05, **Po0.01
and ***Po0.001.
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ABSTRACT
MicroRNAs (miRNAs) are 22- to 24-nucleotide, small, non-coding RNAs that 
bind to the 3′UTR of target genes to control gene expression. Consequently, their 
dysregulation contributes to many diseases, including diabetes and cancer. miR-22 
is up-regulated in numerous metastatic cancers and recent studies have suggested 
a role for miR-22 in promoting stemness and metastasis. TIP60 is a lysine acetyl-
transferase reported to be down-regulated in cancer but the molecular mechanism of 
this reduction is still unclear. In this study, we identify TIP60 as a target of miR-22. 
We show a negative correlation in the expression of TIP60 and miR-22 in breast 
cancer patients, and show that low levels of TIP60 and high levels of miR-22 are 
associated with poor overall survival. Furthermore, pathway analysis using high 
miR-22/low TIP60 and low miR-22/high TIP60 breast cancer patient datasets 
suggests association of TIP60/miR-22 with epithelial-mesenchymal transition (EMT), 
a key alteration in progression of cancer cells. We show that blocking endogenous 
miR-22 can restore TIP60 levels, which in turn decreases the migration and invasion 
capacity of metastatic breast cancer cell line. These results provide mechanistic 
insight into TIP60 regulation and evidence for the utility of the combination of TIP60 
and miR-22 as prognostic indicator of breast cancer progression.
INTRODUCTION
Breast cancer is one of the most common and 
significant malignant diseases in women worldwide [1]. 
Although improvements in detection and treatment have 
decreased breast cancer mortality in recent years, the stage 
of detection and ability of cancer cells to metastasize to 
distant organs have been the major challenges in the 
successful prevention of and therapy, for this deadly 
disease. Cancer metastasis is a complex, multi-step 
process and is driven, promoted, and modulated by 
aberrantly deregulated cellular signals.
MicroRNAs (miRNAs) are a family of small non-
protein-coding RNA molecules of approximately 22–24 
nucleotides (nt) that function as key regulators of gene 
expression at the post-transcriptional level [2]. Since their 
initial discovery in Caenorhabditis elegans [3], thousands 
of microRNAs have been annotated and currently 2588, 
765 and 1915 mature miRNA sequences in human, 
rat and mouse, respectively, have been catalogued in 
the microRNA registry (http://www.mirbase.org, V 
21 June, 2014). miRNA dysregulation has been shown to 
contribute to the etiology of multiple diseases, including 
cancer, where miRNAs can act as either oncogenes or 
tumor suppressors [4–8]. Indeed, emerging evidence 
demonstrates that aberrant miRNA expression is linked to 
breast cancer progression [9, 10].
TIP60 (lysine acetyl-transferase) is part of a 
conserved multisubunit complex, NuA4, which is 
recruited by many transcription factors to their target 
promoters, where it acetylates histones and is involved 
in transcriptional regulation. TIP60 has been shown 
to play an important role in many processes such as 
cellular signaling, DNA damage repair and apoptosis 
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[11, 12], as well as cell cycle and checkpoint control [13]. 
Involvement of TIP60 in these various processes implies 
that its expression, stability and localization are regulated 
in the cell by various mechanisms.
In the current study, we show the first evidence of 
a non-coding RNA as regulator of TIP60 expression. We 
find the expression of miR-22 and TIP60 to be negatively 
correlated in invasive breast cancer tissues and breast 
cancer cell lines. Furthermore, we identified TIP60 as a 
miR-22 target and show that, by targeting TIP60, miR-22 
stimulates the expression of epithelial-mesenchymal 
transition (EMT) genes. Using various cell culture models, 
we find miR-22 expression results in increased cell 
migration and invasion. Our data suggest that TIP60 and 
miR-22 could act as prognostic markers in breast cancer 
disease progression and that targeting the TIP60–miR-22 
axis could lead to an effective therapeutic strategy for 
metastatic breast cancer.
RESULTS
TIP60 is a direct target of miR-22
TIP60 is known to be down-regulated in multiple 
cancers [14, 15]. Whereas we and others have identified 
TIP60 to be destabilized by viral oncogenes [16–19], other 
potential mechanisms of its downregulation are unknown. 
In order to investigate whether TIP60 expression could be 
regulated by miRNAs, we performed an in silico analysis 
using the Targetscan database (http://www.targetscan.org/) 
to identify putative miRNA seed-matching sequences 
in TIP60. We found one putative target binding site for 
miR-22 at the position 249–255 nt in the 3′UTR of TIP60 
(Figure 1A). This identified seed sequence was also 
conserved among different species of TIP60, indicating the 
likely functional importance of this motif (Figure 1B). To 
further validate TIP60 as a target of miR-22, we cloned the 
3′UTR of TIP60 into the pmirGLO dual-luciferase vector, 
and transiently co-transfected pmirGLO-TIP60 WT 3′UTR 
into MCF7 cells along with a miRNA mimic negative 
control (that does not target any known mRNA within 
the human transcriptome) or a miR-22 mimic either alone 
or in combination with miR inhibitor negative control. 
A miR-22 hairpin inhibitor was also transfected and used 
to show specificity of miR-22 for TIP60. After 48 h of 
transfection, cells were lysed and the protein was analyzed 
for luciferase activity. We measured a 40% reduction in 
the luciferase activity of pmirGLO-TIP60 WT 3′UTR 
with miR-22 mimic overexpression (Figure 1C), and this 
reduction could be rescued upon the co-transfection with 
the miR-22 hairpin inhibitor, suggesting specificity of this 
regulation (Figure 1C). In addition, we did not observe 
any difference in luciferase activity when pmirGLO-
TIP60 WT 3′UTR was transfected with either miR mimic 
negative control or with miR inhibitor negative control 
alone, suggesting target specificity. To further demonstrate 
that the decrease in luciferase activity is due to miR-22 
binding to the seed sequence in the 3′ UTR of TIP60, 
we generated two 3′UTR mutant constructs: the first 
comprised point mutations in the miR-22 binding sites 
of TIP60 (pmirGLO-TIP60 Mut 3′UTR); in the second, 
we deleted the miR-22 seed sequence at the TIP60 3′UTR 
using site-directed mutagenesis (pmirGLO-TIP60 Del 
3′UTR). Clones were confirmed by sequencing (Figure 
1D). These mutants were then co-transfected along with 
the miR mimic negative control or miR-22 mimic. We 
observed no repression in luciferase activity after mutating 
or deleting the binding site (Figure 1E), suggesting that 
miR-22 directly interacts with the TIP60 3′UTR and 
targets TIP60.
miR-22 and TIP60 expression is negatively  
co-related
Having identified a miR-22 binding site in the 3′UTR 
of TIP60, we next sought to understand the physiological 
relevance of this regulation. We decided to focus on breast 
cancer, as a recent study by Song et al. [20] implicated the 
role of miR-22 in breast cancer. To this end, we analyzed 
the expression of TIP60 and miR-22 in a breast cancer 
dataset from The Cancer Genome Atlas (TCGA) database 
and found a small but significant negative correlation 
between TIP60 and miR-22 expression (Figure 2A). To 
investigate the potential biological significance of this 
negative correlation, we sought to identify a cell culture 
model that also showed a negative correlation between 
TIP60 and miR-22. For this, we analyzed the expression 
of miR-22 and TIP60 (mRNA and protein) in 12 breast 
cancer cell lines on the basis of their EMT score as 
described by Tan et.al. [21]. Interestingly, mesenchymal 
cell lines such as MDA-MB-231, Hs578T and MDA-
MB-468 and epithelial cell line such as MCF-7 and T47D 
showed a negative correlation between miR-22 and TIP60 
mRNA expression (Figure 2B and 2C), with high miR-
22 and low TIP60 expression in the highly metastatic 
MDA-MB-231 cell line and Hs578T cell line, but high 
TIP60 and low miR-22 expression in the MCF7, T47D 
mild metastatic cells and MDA-MB-468 basal, triple-
negative cells. A similar expression profile of TIP60 was 
also observed at the protein level (Figure 2D).
To further investigate whether miR-22 affects 
endogenous TIP60 expression, we focused on 2 of the 
12 breast cancer cell lines: MCF7, an epithelial cell 
line that is mildly metastatic and has low miR-22 and 
high TIP60 expression and MDA-MB-231 which is a 
mesenchymal cell line, highly metastatic and has high 
miR-22 and low TIP60 expression. We then transfected 
the miR‐22 mimic or miR mimic negative control and 
compared the level of TIP60 protein in MCF7 cells under 
these two conditions. Similarly, the MDA-MB-231 cell line 
was transfected with the miR-22 inhibitor or with a miR 
inhibitor negative control to examine endogenous changes 
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Figure 1: miR-22 binding site at the TIP60 3′UTR. A. Putative target binding site for miR-22 at the 3′UTR of the TIP60 gene, as 
predicted by Targetscan (http://www.targetscan.org/). B. The target site is highly conserved across the various indicated species. Highlighted 
nucleotides (in bold) indicate the putative miR-22 binding site. C. The miR-22 binding site on TIP60 3′UTR was confirmed by luciferase 
activity in MCF7 cells after co-transfection of pmirGLO-TIP60 3′-UTR plasmid with the indicated miRs (50 nM). D. Mutation of the 
miR-22 binding site in the 3′UTR of TIP60. E. MCF7 cells were co-transfected with a wild-type pmirGLO-TIP60 3′-UTR luciferase 
construct, or a construct containing a mutation in the predicted miR-22 binding site or construct having binding site deleted with either 
the miR-22 mimic or the negative control mimic. Luciferase expression was normalized to Renilla luciferase and the data is depicted as the 
mean ± SEM. The figure summarizes data from three independent experiments performed in triplicate. Analysis was performed using an 
unpaired two-tailed student’s t-test. Significance is represented as ***P < 0.001; **P < 0.01.
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Figure 2: Negative correlation of TIP60 and miR-22 mRNA and protein levels in breast cancer patients and cell lines.  
A. Negative correlation between miR-22 and TIP60 mRNA levels for each individual sample from the TCGA dataset. B, C. The expression 
of TIP60 mRNA and miR-22 mRNA was detected by QRT-PCR in a panel of 12 breast cancer cell lines. Mild metastatic and metastatic 
cell lines are shown in yellow and blue colors, respectively. D. Western blot showing the expression of TIP60 in a panel of 12 breast 
cancer cell lines E. mRNA levels of miR-22 were decreased on miR-22 inhibition in MDA-MB-231 cells when transfected with miR-22 
inhibitor for 48 h (50 nM). F–G. mRNA and protein levels of TIP60 were increased following inhibition of miR-22 in MDA-MB-231 cells 
when transfected with miR-22 inhibitor for 48 h (50 nM). H. Relative miR-22 levels were determined by QRT-PCR on miR-22 mimic 
overexpression (miR-22OE, 50 nM) in MCF7 cells. I–J. mRNA and protein levels of TIP60 were decreased following miR-22 mimic 
overexpression (50 nM) in MCF7 cells. The figure illustrates data from three independent experiments performed in triplicate. Significance 
is represented as *P < 0.05; **P < 0.01; ***P < 0.001.
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in TIP60. We found that TIP60 expression was increased 
in MDA-MB-231 cells (Figure 2F–2G) and reduced in 
MCF7 cells (Figure 2I–2J) after inhibition (Figure 2E) or 
overexpression of miR-22 mimic (Figure 2H), respectively 
both at mRNA and protein level. These data indicate that 
miR-22 down-regulates endogenous TIP60 expression.
miR-22 regulates EMT genes by repressing 
TIP60
To determine the downstream effects of TIP60 
regulation by miR-22, we performed Gene-Set Enrichment 
Analysis (GSEA) using msigdb.v4 (http://www.broad.
mit.edu/gsea/) and compared 28 TCGA samples with 
high TIP60/low miR-22 expression with 28 samples with 
low TIP60/high miR-22 expression. Our GSEA analysis 
revealed enrichment of the epithelial-mesenchymal 
transition (EMT) pathway (Figure 3A). Since EMT is 
related to cellular migration and invasion, we sought to 
determine the effect of miR-22 on various EMT markers. 
We ablated miR-22 activity by transfecting MDA-
MB-231 cells with the miR-22 inhibitor or overexpressed 
the miR-22 mimic in MCF7 cells. Aside from increased 
TIP60 levels (Figure 3B), we found that miR-22 inhibition 
in MDA-MB-231 cells resulted in increased E-cadherin 
levels, an epithelial marker that is lost upon execution 
of the EMT program (Figure 3C). Similar increase in 
E-cadherin was also found in MDA-MB-231-LPCX-
TIP60 stable cell line. In comparison, MCF7 cells showed 
decreased TIP60 (Figure 3D) and E-cadherin levels 
(Figure 3E) and increased N-cadherin (mesenchymal 
marker) levels in the presence of miR-22 mimic 
(Figure 3E) and this effect was rescued on overexpressing 
TIP60 in MCF7 cell line. Further, we did not observe any 
changes in other EMT markers. These data suggest that 
miR-22 induces EMT like phenotype and this is associated 
with a change in the expression of TIP60. The phenotypic 
alterations induced by miR-22 mimic overexpression 
in MCF7 cells is observed by immuno-fluorescence 
staining of the E-cadherin. MCF7 cells treated with miR 
mimic negative control showed expression of E-cadherin 
(Figure 4A, mimic negative control) and this was reduced 
in miR-22 mimic overexpressed MCF7 cells (Figure 4A, 
miR-22 OE). We further examined the status of F-actin in 
the cells by phalloidin staining, since actin reorganization 
occurs during the EMT process [22]. In contrast to miR 
mimic negative control treated cells (Figure 4B, mimic 
negative control), overexpression of miR-22 mimic 
significantly induced actin fiber formation, typical of EMT 
(Figure 4B, miR-22 OE). These results indicated that the 
epithelial property of the cells might be lost when miR-
22 mimic is overexpressed. We next examined whether 
miR-22 inhibition in MDA-MB-231 cell line shows the 
opposite effect. Indeed, inhibition of miR-22 activity 
in MDA-MB-231 cells showed increased E-cadherin 
expression (Figure 4C, miR-22 inhibitor) and decreased 
Vimentin expression (Figure 4D, miR-22 inhibitor), 
which suggested the reversal of the EMT process and this 
effect was also observed in TIP60-overexpression MDA-
MB-231 cell line (Figure 4C, 4D).
miR-22 inhibition suppresses cell migration and 
invasion by regulating TIP60 levels
Two key features of EMT are the ability of cells 
to migrate and invade. In order to investigate the role of 
miR-22 in these processes, we performed wound-healing 
and cell invasion assays. For this, MDA-MB-231 cells 
were transfected with miR-22 hairpin inhibitor or control 
hairpin inhibitor for 48 h and cells were serum starved for 
the next 12 h. We found that inhibiting miR-22 caused a 
significant decrease in the rate of wound closure in the 
MDA-MB-231 cell cultures at 12 h and 24 h as compared 
to that of control cells (Figure 5A). To further demonstrate 
that miR-22 increased cell migration through TIP60, we 
performed the wound-healing assay in MDA-MB-231 
cell line stably overexpressing TIP60 without miR-22 
target sequence. Interestingly, overexpression of TIP60 
decreased cell migration and we did not observe any 
effect on migration in the presence of miR-22 inhibitor 
(Figure 5B). On the other hand, when miR-22 mimic was 
overexpressed in MCF7 cells, we observed a significant 
increase in cell migration as compared to the control cells 
(transfected with miR mimic negative control; Figure 5C). 
These findings suggest that repression of TIP60 by miR-22 
increases cell migration and this can be reverted by 
ablating activity of miR-22 or through the overexpression 
of a TIP60 that lacks miR-22 binding site. Thus, miR-22 
stimulates cell migration by targeting TIP60.
To assess invasion, we transfected MDA-MB-231 
cells with or without the miR-22 inhibitor for 48 h. Cells 
were suspended in serum-free medium and loaded onto 
matrigel invasion chamber inserts. We observed that 
miR-22 inhibition reduces the invasive capacity of these 
cells (Figure 6A). To further confirm that this effect is 
mediated through TIP60, we transfected the stable TIP60-
overexpressing MDA-MB-231 cells (lacking miR-22 
binding site) with the miR-22 inhibitor, using vector-
expressing cells as a control. To confirm the expression of 
the miR-22 and TIP60 after inhibition or overexpression 
of the miRNA, we quantitated the expression of 
miR-22 and TIP60 in the MDA-MB-231 cells transfected 
with or without miR-22 inhibitor and miR-22 mimic 
by Q-PCR (Supplementary Figure S1). We found a 
decrease in cell invasion in TIP60-overexpressing cells, 
which further confirms that the effect on cell invasion 
is mediated through TIP60 (Figure 6B). We also noted 
that, upon transfection with the miR-22 inhibitor, TIP60-
overexpressing cells showed a further reduction in 
invasion. This may be due to an increase in endogenous 
TIP60 levels in these cell lines or miR-22 may target 
an additional factor involved in regulating invasion. 
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Figure 3: Expression levels of TIP60 and miR-22 suggest an epithelial-mesenchymal transition (EMT). A. Gene-Set 
Enrichment Analysis (GSEA) shows enrichment of factors linked to EMT in the samples with high miR-22 and low TIP60. B. The 
expression of TIP60 mRNA was detected by QRT-PCR in cells transfected with either miR inhibitor negative control or miR-22 inhibitor 
and also MDA-MB-231-LPCX-TIP60 stable cell line. C. QRT-PCR showing mRNA expression of EMT markers in cells transfected with 
either miR inhibitor negative control or miR-22 inhibitor and also MDA-MB-231-LPCX-TIP60 stable cell line. D. The expression of TIP60 
mRNA was detected by QRT-PCR in cells transfected with either miR mimic negative control or miR-22 mimic overexpression and also 
MCF7-MSCV-TIP60 stable cell line. E. QRT-PCR showing mRNA expression of EMT markers in cells transfected with either miR mimic 
negative control or miR-22 mimic overexpression and also MCF7-MSCV-TIP60 stable cell line. The figure represents data from three 
independent experiments performed in triplicate. Significance is represented as *P < 0.05; **P < 0.01.
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Figure 4: Immuno-fluorescence showing phenotypic alterations. A–B. Representative immuno-fluorescence images of 
E-cadherin and F-actin (red) are shown for MCF7 cells transfected with either miR mimic negative control or miR-22 mimic. Nuclei 
are stained with DAPI (blue). C–D. Representative immuno-fluorescence images of E-cadherin and Vimentin (red) are shown for MDA-
MB-231 cells transfected with either miR-22 inhibitor negative control or miR-22 inhibitor or MDA-MB-231-LPCX-TIP60 stable cell line. 
Nuclei are stained with DAPI (blue). Immuno-fluorescence images were taken at 60X magnification with a nikon confocal microscope.
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Figure 5: miR-22 increases cell migration by targeting expression of TIP60. MDA-MB-231 cells A. and MDA-MB-231-
LPCX and MDA-MB-231-LPCX-TIP60 cells B. were treated with or without the miR-22 inhibitor for 24 h and analyzed by wound-healing 
assays 48 h after transfection using live-cell imaging (Nikon). The solid white line highlights the wound edge at 0 h and 24 h. C. MCF7 
cells were transfected with miR-22 mimic and wound closure was analyzed as for (A) and (B) Data compiled from three independent 
experiments in triplicate, and images from one representative experiment are shown. Decreases in the gap area between the migrating cells 
from the opposite wound edge were quantified by measuring the distance (by scale) at three random points in the image. This quantification 
is represented in the figure. Data are the mean ± SEM with significance measured using unpaired two-tailed student’s t-test. Significance is 
represented as *P < 0.05; ** P < 0.01; ***P < 0.001.
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Figure 6: miR-22 inhibition results in decreased cell invasion. A. MDA-MB-231 cells were treated with or without miR-22 
inhibitor and analyzed for their ability to invade into Matrigel transwell 48 h after transfection. B. MDA-MB-231-LPCX and MDA-MB-
231-LPCX-TIP60 cells were treated with or without miR-22 inhibitor and analyzed using an invasion assay 48 h after transfection. miR-22 
decreased MDA-MB-231-LPCX and MDA-MB-231-LPCX-TIP60 cell invasion, with a similar effect also seen in the TIP60 stable cell 
lines, as compared with vector alone. C. MCF7 cells were transfected with miR-22 mimic and wound closure was analyzed 48 h after 
transfection. miR-22 mimic overexpression increases cell invasion. Data compiled from three independent experiments in triplicate, and 
images from one representative experiment are shown. Data are the mean ± SEM and significance was determined using an unpaired two-
tailed student’s t-test. Significance is represented as *P < 0.05; **P < 0.01; ***P < 0.001.
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Since miR-22 inhibition decreased cell invasion capacity, 
we next overexpressed miR-22 mimic in MCF7 cells for 
48 h (Supplementary Figure S1). Cells were suspended 
in serum-free medium and loaded onto matrigel 
invasion chamber inserts. We found that miR-22 mimic 
overexpression increased the invasiveness of the cells 
(Figure 6C). These results suggest that miR-22 targets 
TIP60 leading to an increase in cell migration and invasion 
of breast cancer cells thereby promoting metastasis.
Levels of TIP60 and miR-22 as a predictor of 
disease progression in breast cancer
Having identified this interesting regulatory link 
between miR-22 and TIP60 in cell culture models and 
patient datasets, we sought to investigate its significance in 
a pathophysiological scenario. For this, we used available 
gene expression and survival data from the TCGA dataset 
and the GSE19783 from gene expression omnibus (GEO) 
database to compare overall survival between patient 
cohorts that exhibited high versus low TIP60 expression 
levels. We found that patients with high TIP60 and low 
miR-22 expression were associated with good survival 
prognoses (P = 0.015; Figure 7A, 7C) whereas patients 
with low TIP60 and high miR-22 levels showed poorer 
prognoses for survival (P = 0.029; Figure 7B, 7D). 
Breast cancer is classified into molecular subtypes; we 
investigated the expression of miR-22 and TIP60 in 
TCGA dataset for breast cancer and found no significant 
differences between different subtypes (Supplementary 
Figure S2). To rule out the possibility of other factors 
such as age, stage, ER status, PR status, and Her2 status 
determining the relationship between miR-22 and TIP60, 
multivariate analysis was performed. As summarized in 
Table 3, multivariate analysis linear regression elucidates 
variables significantly affecting expression level of TIP60 
in breast cancer survival. Among factors such as age, stage, 
ER, PR and Her2 status, the strongest component that 
determines expression level of TIP60 in patient samples 
was miR-22 as illustrated by high eigenvalue (data not 
shown). Similarly, TIP60 was found to be the strongest 
factor in determining miR-22 expression level in breast 
cancer patient samples. Therefore, the model remained 
essentially unchanged when other components (age, stage, 
ER, PR and Her2 status) were dropped. Besides, patients 
with high expression of miR-22 are likely to have low 
expression of TIP60 and vice versa due to the negative 
regression coefficient of miR-22 and TIP60.
DISCUSSION
Metastasis—a cessation of neoplastic progression—
is one of the main causes of death in patients with breast 
cancer. Epithelial–mesenchymal transition (EMT) is 
thought to be one of the key processes that causes benign 
tumor cells to transition into invasive and metastatic cells 
[23]. In this study, we showed that miR-22 expression 
potently activates the migration and invasive capacity of 
basal breast cancer cells. In addition, we show evidence 
to suggest that miR-22 has an oncogenic function in these 
cells. These findings are in line with the upregulation of 
miR-22 in more advanced stages of breast cancer and with 
previous reports which have also implicated miR-22 as 
an oncogene in breast cancer [24, 25]. Recently, Song et 
al. [20] showed that miR-22 antagonizes another miRNA, 
miR-200, through directly targeting of the methyl cytosine 
dioxygenase TET (ten-11 translocation) family members 
and, hence, chromatin remodeling toward miR-200 
transcriptional silencing. Further, Lee et al. demonstrate 
a central role of miR-22 in the physiological regulation of 
MDC1-dependent DDR, a molecular mechanism of Akt1 
activation and senescence leading to increased genomic 
instability, which fosters an environment that promotes 
tumorigenesis [26]. Although these studies implicate miR-
22 as an oncogene, other studies have suggested a tumor 
suppressor function of miR-22. miR-22 was identified as a 
tumor suppressor gene in human colon cancers, influencing 
p53-dependent cellular fate through the formation of the 
p53–miR-22–p21 axis [27]. Another study showed miR-
22 acts as tumor suppressor by targeting the Sp1 gene and 
inhibiting gastric cancer cell migration and invasion [28]. 
Additionally, miR-22 was also implicated in activating the 
cellular senescence program in cancer cells and acts as a 
tumor suppressor [29]. A recent study also shows miR-
22 acts as a tumor suppressor by targeting GLUT1 and 
is directly correlated with the TNM stage, local relapse, 
distant metastasis, and survival of breast cancer patients 
[30]. Further investigations along these lines will be 
needed to ascertain whether miR-22 is an oncogene or a 
tumor suppressor.
The acetyl-transferase TIP60 is a bona fide 
tumor suppressor in cancer and its expression is down-
regulated in colon carcinomas [15] and lung cancers [31]. 
Interestingly, in colon carcinoma, the ratio between TIP60 
and p400 mRNAs is important for cancer progression 
[32]. However, the molecular determinant and underlying 
mechanism is yet to be discovered. Interestingly, 
downregulation of TIP60 in colorectal cancer is correlated 
with larger tumor size, distant metastasis, and a higher 
stage of tumor node metastasis classification; yet, the 
molecular mechanism of TIP60’s downregulation is not 
known. Our study identifies a non-coding RNA that can 
regulate the expression of TIP60 in breast cancer. It would 
be interesting to investigate whether this regulation exists 
in colon cancer as well.
Pathways governed by TIP60 via its tumor suppressor 
function have yet to be identified. Gorrini et al. [33] 
showed that TIP60 is a haplo-insufficient tumor suppressor 
in Eμ-myc transgenic mice, and suggested that it is re-
quired for an oncogene-induced DNA damage response. 
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Collectively, these findings indicated that decreased TIP60 
expression correlates with tumor development; but the 
molecular mechanism of TIP60’s downregulation was 
still not clarified. We show, for the first time, that TIP60 
is a direct target of miR-22 and its downregulation by 
miR-22 subsequently results in the activation of an EMT 
program. EMT is characterized by a loss of cell adhesion 
and the suppression of epithelial genes, such as E-cadherin 
concomitant with an acquisition of mesenchymal markers 
(including N-cadherin, Vimentin, and Fibronectin) and 
increased cell motility and invasiveness. Numerous 
miRNAs have been linked to EMT pathways. For example, 
miR-9 can directly regulate E-cadherin by targeting 
its 3′UTR in human mammary epithelial cells, thereby 
promoting mesenchymal-like characteristics of the cells 
with increased motility and invasiveness [34]. miR-661 is 
shown to regulate Nectin-1 and StarD10 in the disassembly 
of epithelial cell junctions in SNAI1-expressing breast 
cancer cells [35]. Recently, the expression of miR-197 was 
found to induce EMT along with the downregulation of 
Figure 7: TIP60 and miR-22 expression in breast cancer tumors correlated with high and low survival, respectively.  
A–B. Kaplan-Meier plot, based on breast cancer data from The Cancer Genome Atlas (TCGA), illustrates the survival probability for patients 
with low or high TIP60 and miR-22 expression levels in breast cancers. High expression of TIP60 leads to higher survival probability, 
whereas high expression of miR-22 leads to lower survival probability. P < 0.015 and P < 0.029, respectively. C–D. Kaplan-Meier plot, 
based on Gene express omnibus expression dataset (GSE19783), illustrates the survival probability for patients with low or high TIP60 and 
miR-22 expression levels in breast cancers. P < 0.03 and P < 0.11, respectively.
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p120-catenin in pancreatic cancer cells [36]. In contrast, 
in hepatic cancer cells, miR-194 overexpression results 
in reduced cell invasion, migration and metastasis by 
targeting N-cadherin [37]. Thus, we also investigated the 
regulatory effect of miR-22 on E-cadherin and N-cadherin 
in vitro. MCF7 is an estrogen alpha positive (ER+) 
and also an epithelial cell line. It is known that miR-22 
regulates ER and miR-22 levels are reduced in ER+ cell 
lines [38, 39]. We showed that MCF7 cell line has reduced 
miR-22 levels and high TIP60 (tumor suppressor gene) 
levels. Overexpression of miR-22 in these cells reduced 
TIP60 levels and promotes invasion and migration. MDA-
MB-231 being triple negative cell line (ER-, PR-, and 
Her2-) and a mesenchymal cell line has elevated level of 
miR-22 and reduce level of TIP60. We have shown that 
miR-22 is required to maintain the metastasis levels of the 
MDA-MB-231 cell line by targeting TIP60. Inhibition of 
miR-22 by the miR-22 inhibitor in highly metastatic MDA-
MB-231 cells leads to a reduction of metastatic phenotypes, 
as well as an elevation of the expression of TIP60. Our data 
also showed that overexpression of miR-22 in MCF7 cells 
caused a decrease in E-cadherin levels and an increase in 
N-cadherin levels, thus promoting EMT. Alternatively, 
inhibition of miR-22 expression in MDA-MB-231 cells 
resulted in increased E-cadherin levels and suppressed 
EMT. Thus, miR-22 may promote EMT by inhibiting 
TIP60. During the initial stages of metastasis, epithelial 
cells undergo EMT, causing a loss of cell-cell contacts, 
increased motility and cell invasion. Further, in our gain- 
and loss-of-function experiments, we have demonstrated 
that miR-22 inhibition in the MDA-MB-231 metastatic cell 
line causes a decrease in cell migration as well as invasion, 
whereas its overexpression in MCF7 cells resulted in 
increased cell migration and invasion.
In conclusion, we have identified a novel link 
between miR-22 and TIP60 in breast cancer metastasis. 
miR-22 is upregulated in metastatic breast cancer cell 
lines as well as in patients with breast cancer, and causes 
the downregulation of TIP60 and modulation of the EMT 
pathway. Our study suggests that miR-22 and TIP60 levels 
could be used as a prognostic marker for breast cancer.
MATERIALS AND METHODS
Cell culture and reagents
Human breast epithelial and cancer cell lines, 
MCF10A (CRL-10317™), MCF-7, MDA-MB-231, were 
obtained from ATCC (Manassas, VA, USA). SkBR3, 
BT474, BT549, T47D, HS578T cells were generously 
provided by Prof. H. Phillip Koeffler (Cancer Science 
Institute, Singapore). MCF10A cells were cultured in 
DMEM/F12 medium supplemented with 5% horse serum 
and the medium was further supplemented with 20 ng/ml 
epithelial growth factor (EGF), 0.5 mg/ml hydrocortisone, 
100 ng/ml cholera toxin, 10 μg/ml insulin. MCF-7 and 
MDA-MB-231 were maintained in DMEM; SkBR3 in 
DMEM supplemented with L-glutamine; HS578T in 
DMEM supplemented with insulin; and T47D and BT474 
in RPMI-40 medium. All media were supplemented with 
10% FBS and 100 U of penicillin and streptomycin and 
grown at 37°C with 5% CO
2
. All tissue culture reagents 
were purchased from Invitrogen (Carlsbad, CA, USA) and 
Sigma-Aldrich (St. Louis, MO, USA).
Oligonucleotides, plasmids, and transfection
Lipofectamine RNAiMAX (Invitrogen) was used 
to transfect MCF7 and MDA-MB-231 cells. miR-22 
mimic, miR mimic negative control, miR-22 inhibitor, and 
miR-22 negative control miRNA inhibitor were purchased 
from Dharmacon Research Inc. (Lafayette, CO, USA). 
The pmirGLO Dual-Luciferase vector was obtained from 
Promega (E1330; Fitchburg, WI, USA). To overexpress 
TIP60, the open reading frame was cloned into LPCX 
vector.
Quantitative reverse transcription PCR
Total RNA from cell lines was extracted using 
TRIzol Reagent (Invitrogen) as per manufacturer’s 
instructions. RNA (2 μg) was reverse transcribed in a 
20-μl reaction using iScript Supermix master mix (Bio-
Rad, Hercules, CA, USA). For miRNA, cDNA was 
synthesized using a stem-loop specific primer for miR-22, 
and then subjected to real time PCR using 2 μl of a 1:5 
dilution of the reverse-transcribed cDNA and SYBR green 
in an ABI Fast Q-PCR machine (Applied Biosystems, 
Foster City, CA, USA). The cycling conditions were as 
follows: 50°C for 2 min, 95°C for 5 min, and 40 cycles 
of 95°C for 15 sec followed by 60°C for 1 min (annealing 
and extension). Primer sequences are listed in Table 1. 
Each reaction was performed in triplicate. The data were 
normalized to GAPDH and U6 expression for mRNA and 
miRNA, respectively. The relative expression of each gene 
was quantified by the ΔΔCT method.
Luciferase assays
A dual-luciferase reporter vector was used to 
generate the luciferase constructs. The TIP60 3′UTR, 
containing the predicted binding site for miR-22, was 
amplified from genomic DNA by PCR. The PCR product 
was digested by PmeI and NotI enzymes and the digested 
fragment was cloned into pmirGLO luciferase plasmid 
to obtain a wild-type luciferase construct pmirGLO-
TIP60 3′-UTR. To generate point mutant and deletion 
constructs, the putative miR-22 binding site in TIP60 
3′-UTR was mutated or deleted using Quick-change 
Site-Direct Mutagenesis Kit (200522–5; Stratagene, 
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La Jolla, CA, USA) as per manufacturer’s instructions. 
Cloning was confirmed by sequencing. Primers used for 
PCR and sequencing are listed in Table 2. For luciferase 
assays, MCF7 cells were plated in 12-well plates and 
24 h later co-transfected with 50 nM miR-22 or miR 
mimic negative control and 50 nM miR-22 inhibitor, 
100 ng pmirGLO or pmirGLO containing wild-type 
TIP60 3′-UTR or the corresponding mutant or deleted 
constructs. Forty-eight hours later, luciferase activity 
was measured using Dual-Luciferase Reporter Assay Kit 
(E1960; Promega) on a GLOmax microplate luminometer 
(Promega). Firefly luciferase signals were normalized 
using Renilla luciferase signals. All experiments were 
performed in triplicate.
Western blotting
Cells were lysed using RIPA lysis buffer [50 mM 
Tris (pH 7.5), 150 mM NaCl, 1% NP40, 0.25% sodium 
deoxycholate, 1 mM EDTA, 1 mM DTT and protease 
inhibitor cocktail]. Protein concentration was determined 
using the Bradford Protein Assay kit (500–0001; Bio-
Rad). Equal amounts of protein were separated on SDS 
polyacrylamide gels and transferred to nitrocellulose 
membranes (162–0115; Bio-Rad) using the Bio-Rad 
semi-dry transfer apparatus. Membranes were blocked for 
1 h with 5% skim milk in Tris-buffered saline containing 
0.1% Tween-20, and then incubated overnight with 
primary antibody. Blots were then washed and incubated 
with secondary antibody, washed again, and visualized 
by chemiluminescence. β-actin (sc-81178) and α-actinin 
(sc-166524) were used as loading controls. The TIP60 
serum antibody was generated in the lab. E-cadherin 
(BD-Bioscience), Vimentin (Cell Signaling), Alexa 594 
secondary antibody and Alexa 594 phalloidin staining 
was bought from Life Technologies and mounting 
medium containing DAPI was purchased from Santa Cruz 
Biotechnology Inc.
Immuno-fluorescence
MDA-MB-231 cells were transfected with either 
miR mimic negative control or miR-22 mimic. Cells 
were cultured on cover slips for 48 h and then immuno-
fluorescence assay was performed by fixing the cells for 
15 min at room temp in 3.7% paraformaldehyde. Cells 
were washed 3 times with PBS and permeabilized by 
0.5% Triton-X-100 for 5 min. Cells were then washed 
2 times with PBS and 1 time with 0.1 M glycine in PBS. 
Cells were incubated in E-cadherin (1:400) and Vimentin 
(1:100) antibodies overnight in 0.5% Triton-X-100 in PBS. 
Next day cells were washed 3 times with PBS and then 
Table 1: List of Q-PCR Primers
Serial 
No.
Name of the 
Gene
Forward primer Sequences Reverse primer Sequences
1 TIP60 AATGTGGCCTGCATCCTAAC TGTTTTCCCTTCCACTTTGG
2 miR-22 ACACTCCAGCTGGGAAGCTGCCAGTTGAAG GGTGTCGTGGAGTCGGCAA
3 U6 CTCGCTTCGGCAGCACATATACT ACGCTTCACGAATTTGCGTGTC
4 18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
5 E-cadherin TTACTGCCCCCAGAGGATGA TGCAACGTCGTTACGAGTCA
6 Epcam GCTGGCCGTAAACTGCTTTG ACATTTGGCAGCCAGCTTTG
7 N-cadherin CCGGTTTCATTTGAGGGCAC TCCCTCAGGAACTGTCCCAT
8 Fibronectin AACCCTTCCACACCCCAATC ACTGGGTTGCTGACCAGAAG
9 Snail1 TCTTTCCTCGTCAGGAAGCC GATCTCCGGAGGTGGGATGG
10 Snail2 CTCCTCATCTTTGGGGCGAG CTTCAATGGCATGGGGGTCT







Table 2: List of Cloning 3′UTR Primers
Serial No. Name of the primers (Q-PCR) Sequences
1 TIP60–3′UTR- Forward primer ATATGCGGCCGCGTGACCAGACACTGCCCACT
2 TIP60–3′UTR- Reverse primer GCGCATCGATTGCATGGCTCTGGCATATAG
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incubated at 37°C for 30 min with secondary antibodies 
or with the F-actin dye. Cells were then washed 3 times 
with ultrapure water to remove the salts and were mounted 
on the slides using antifade reagent, and examined with 
confocal microscope (Nikon) at 60 X magnification. 
Similarly, MCF7 cells were transfected with either miR 
mimic negative control or miR-22 mimic for 48 h and 




MB-231-LPCX-TIP60 and MCF7 cells were seeded in 
12-well plates and grown to 90% confluence. Cells were 
transfected with or without miR-22 inhibitor or miR-22 
mimic. After 36 h of transfection, cells were serum starved 
overnight and a linear wound was created using a pipette 
tip. Wound closure was monitored using live cell imaging 
microscopy (Nikon, Tokyo, Japan) at an interval of 30 min 
for 24–48 h. Wound size was then measured randomly at 
three sites perpendicular to the wound.
Invasion assay
For the invasion assay, Corning BioCoat Matrigel 
Invasion Chambers with 8.0-μm PET Membrane were 
used (354480; Corning, Corning, NY, USA). As per the 
protocol, inserts were rehydrated for 2 h at 37°C and then 
MDA-MB-231, MDA-MB-231-LPCX, MDA-MB-231-
LPCX-TIP60 cells transfected with or without miR-22 
inhibitor and MCF7 cells transfected with or without 
miR-22 mimic were suspended in serum-free medium 
and loaded onto the chamber inserts. The inserts were 
placed into the wells of a 24-well plate that contained 
media supplemented with 10% FBS. Cells were incubated 
at 37°C and allowed to migrate and invade through the 
Matrigel and membrane pores. The upper Matrigel layer 
and cells were removed after 24 h (for MDA-MB-231 
cells) or 72 h (for MCF7 cells) by scrubbing. The cells 
on the surface of the lower side of the membrane were 
fixed with 100% methanol and stained with Hoechst stain 
(33342; Life Technologies). Cells that migrated onto the 
lower surface were counted from representative areas 
using ImageJ software (NIH, Bethesda, MD).
Stable cell lines
Virus was generated by transfecting 5 × 106 293T 
cells with the plasmids [MSCV construct: i.e., MSCV 
vector alone (MSCV) and TIP60 overexpressing vector 
(MSCV TIP60) and LPCX construct: i.e., LPCX vector 
alone (LPCX) and TIP60 overexpressing vector (LPCX 
TIP60)], using Lipofectamine 2000, as per manufacturer’s 
protocol. Viruses were harvested after 72 h of transfection 
and were used to infect 1 × 106 MCF7 or 2 × 106 MDA-
MB-231-luc-D3H2LN cells together with polybrene 
(107689, Sigma-Aldrich) reagent (0.4 mg/ml). After 6 h, 
media containing the virus was replaced by growth media. 
After 24 h, puromycin was added into the growth media 
for selection. Media with antibiotics was changed every 
48 h until the mock-transfected cells died. The cells were 
continuously selected for 2 weeks for the generation of 
stable cell lines.
Bioinformatics analysis
For survival data analysis, raw gene expression 
data were downloaded from The Cancer Genome Atlas 
(TCGA) breast cancer database (https://tcga-data.nci.
nih.gov/tcga/) and from GEO databases, respectively. 
The downloaded TCGA breast cancer data were the 
RNA-seq dataset of level 3 and normalization of the 
data was performed based on the total mapable reads. 
Table 3: Multivariant analysis
Variable Sample number R with miR-22 P value
ER-alpha_status positive 320 0.037 0.45
negative 101
PR_status positive 289 0.094 0.054
negative 132
Her2_status positive 83 0.036 0.46
negative 338
Age < = 50 141 0.006 0.90
> 50 280
Stage I–II 321 0.030 0.54
III–X 100
TIP60 421 0.193 < 0.0001
Oncotarget41304www.impactjournals.com/oncotarget
For microarray data (GSE19783), the Cross-Correlation 
method was used for data normalization [40]. In 
the survival analysis, the median intensity cross all 
samples was first used to classify the samples into the 
respective expression high and low groups. In order to 
minimize the false positives in classification of high 
and low expression groups, the samples with middle 
expression within the 15% range from the median 
expression value were removed. The analysis of the 
survival data was based on the Kaplan-Meier method. 
Gene-Set Enrichment Analysis (GSEA) was performed 
using msigdb.v4 (http://www.broad.mit.edu/gsea/), 
comparing 28 TCGA samples with high TIP60/low 
miR-22 expression versus 28 samples with low TIP60/
high miR-22 expression.
A correlation of TIP60 with miR-22 was obtained 
based on the normalized data cross all samples in the 
cohort. In order to ensure that this correlation is not 
independent of subtypes, the multivariate analysis was 
performed. Using 400+ TCGA breast cancer samples 
available with all these factors, we performed principal 
component analysis (PCA) to identify the contributing 
fraction of each principal component (PC), and found that 
the first PC is dominant and contributes 98.2% among 
all PCs. Multiple linear regression with miR-22 as the 
dependent variable was performed, and the exploratory 
variables for the multiple regression included not only 
TIP60 expression but also the age, stage, ER status, PR 
status, and Her2 status.
ACKNOWLEDGMENTS AND FUNDING
We thank the members of the Jha laboratory 
for helpful discussions and comments. We thank 
Dr. Rebecca Jackson (Department of Biochemistry, 
National University of Singapore) for the comments 
on the manuscript. SJ was supported by grants from 
the National Research Foundation Singapore and the 
Singapore Ministry of Education under its Research 
Centres of Excellence initiative to the Cancer Science 
Institute of Singapore, National Medical Research 
Council (NMRC CBRG-NIG BNIG11nov001) and 
Ministry of Education Academic Research Fund (MOE 
AcRF Tier 1 T1-2012 Oct-04).
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
Author contributions
AKP and SJ designed the experiments and wrote 
the manuscript. AKP performed all the experiments. 
YZ generated the MDA-MB-231-LPCX and MDA-MB-
231-LPCX-TIP60 cell lines. HY and YL performed the 
bioinformatics analysis. SZ and GT-K were involved in 
multivariate analysis. SJ proposed and supervised the 
project.
REFERENCES
1. Wang Q, Zhao ZB, Wang G, Hui Z, Wang MH, Pan JF, 
Zheng H. High expression of KIF26B in breast cancer asso-
ciates with poor prognosis. PloS one. 2013; 8:e61640.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, 
and function. Cell. 2004; 116:281–297.
3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heter-
ochronic gene lin-4 encodes small RNAs with antisense 
complementarity to lin-14. Cell. 1993; 75:843–854.
4. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, 
Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, 
Dell’Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, 
Negrini M, et al. MicroRNA profiling reveals distinct signa-
tures in B cell chronic lymphocytic leukemias. Proceedings 
of the National Academy of Sciences of the United States 
of America. 2004; 101:11755–11760.
5. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, 
Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, 
Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, 
Nenci I, et al. MicroRNA gene expression deregulation in 
human breast cancer. Cancer research. 2005; 65:7065–7070.
6. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, 
Peck D, Sweet-Cordero A, Ebert BL, Mak RH, 
Ferrando AA, Downing JR, Jacks T, Horvitz HR, 
Golub TR. MicroRNA expression profiles classify human 
cancers. Nature. 2005; 435:834–838.
7. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, 
James RJ. Reduced accumulation of specific microRNAs 
in colorectal neoplasia. Molecular cancer research: MCR. 
2003; 1:882–891.
8. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, 
Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, 
Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, 
Negrini M, et al. A microRNA expression signature 
of human solid tumors defines cancer gene targets. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2006; 103:2257–2261.
9. Cui J, Bi M, Overstreet AM, Yang Y, Li H, Leng Y, Qian K, 
Huang Q, Zhang C, Lu Z, Chen J, Sun T, Wu R, Sun Y, 
Song H, Wei X, et al. MiR-873 regulates ERalpha transcrip-
tional activity and tamoxifen resistance via targeting CDK3 
in breast cancer cells. Oncogene. 2015; 34:3895–3907.
10. Ujihira T, Ikeda K, Suzuki T, Yamaga R, Sato W, Horie-
Inoue K, Shigekawa T, Osaki A, Saeki T, Okamoto K, 
Takeda S, Inoue S. MicroRNA-574–3p, identified by 
microRNA library-based functional screening, modulates 
tamoxifen response in breast cancer. Scientific reports. 
2015; 5:7641.
Oncotarget41305www.impactjournals.com/oncotarget
11. Ikura T, Ogryzko VV, Grigoriev M, Groisman R, Wang J, 
Horikoshi M, Scully R, Qin J, Nakatani Y. Involvement of 
the TIP60 histone acetylase complex in DNA repair and 
apoptosis. Cell. 2000; 102:463–473.
12. Kamine J, Elangovan B, Subramanian T, Coleman D, 
Chinnadurai G. Identification of a cellular protein that spe-
cifically interacts with the essential cysteine region of the 
HIV-1 Tat transactivator. Virology. 1996; 216:357–366.
13. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, 
Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, 
Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, 
Linsley PS, Beijersbergen RL, Bernards R. A large-scale 
RNAi screen in human cells identifies new components of 
the p53 pathway. Nature. 2004; 428:431–437.
14. Chen G, Cheng Y, Tang Y, Martinka M, Li G. Role of 
Tip60 in human melanoma cell migration, metastasis, and 
patient survival. J Invest Dermatol. 2012; 132:2632–2641.
15. Sakuraba K, Yasuda T, Sakata M, Kitamura YH, 
Shirahata A, Goto T, Mizukami H, Saito M, Ishibashi K, 
Kigawa G, Nemoto H, Sanada Y, Hibi K. Down-regulation 
of Tip60 gene as a potential marker for the malignancy of 
colorectal cancer. Anticancer research. 2009; 29:3953–3955.
16. Gupta A, Jha S, Engel DA, Ornelles DA, Dutta A. Tip60 
degradation by adenovirus relieves transcriptional repres-
sion of viral transcriptional activator EIA. Oncogene. 2013; 
32:5017–5025.
17. Jha S, Vande Pol S, Banerjee NS, Dutta AB, Chow LT, 
Dutta A. Destabilization of TIP60 by human papillomavirus 
E6 results in attenuation of TIP60-dependent transcriptional 
regulation and apoptotic pathway. Molecular cell. 2010; 
38:700–711.
18. Reitsma JM, Savaryn JP, Faust K, Sato H, Halligan BD, 
Terhune SS. Antiviral inhibition targeting the HCMV 
kinase pUL97 requires pUL27-dependent degradation of 
Tip60 acetyltransferase and cell-cycle arrest. Cell host & 
microbe. 2011; 9:103–114.
19. Subbaiah VK, Zhang Y, Rajagopalan D, Abdullah LN, 
Yeo-Teh NS, Tomaic V, Banks L, Myers MP, Chow EK, 
Jha S. E3 ligase EDD1/UBR5 is utilized by the HPV E6 
oncogene to destabilize tumor suppressor TIP60. Oncogene. 
2015. doi: 10.1038/onc.2015.268. [Epub ahead of print].
20. Song SJ, Poliseno L, Song MS, Ala U, Webster K, 
Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, 
Richardson AL, Pandolfi PP. MicroRNA-antagonism 
regulates breast cancer stemness and metastasis via TET-
family-dependent chromatin remodeling. Cell. 2013; 
154:311–324.
21. Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, 
Thiery JP. Epithelial-mesenchymal transition spectrum 
quantification and its efficacy in deciphering survival and 
drug responses of cancer patients. EMBO molecular medi-
cine. 2014; 6:1279–1293.
22. Kalluri R, Weinberg RA. The basics of epithelial- 
mesenchymal transition. J Clin Invest. 2009; 119:1420–1428.
23. Wang L, Wang J. MicroRNA-mediated breast cancer 
metastasis: from primary site to distant organs. Oncogene. 
2012; 31:2499–2511.
24. Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM, Jongen-
Lavrencic M, Manova-Todorova K, Teruya-Feldstein J, 
Avigan DE, Delwel R, Pandolfi PP. The oncogenic 
microRNA miR-22 targets the TET2 tumor suppressor to 
promote hematopoietic stem cell self-renewal and transfor-
mation. Cell stem cell. 2013; 13:87–101.
25. Wang X, Wang HK, Li Y, Hafner M, Banerjee NS, 
Tang S, Briskin D, Meyers C, Chow LT, Xie X, Tuschl T, 
Zheng ZM. microRNAs are biomarkers of oncogenic 
human papillomavirus infections. Proceedings of the 
National Academy of Sciences of the United States of 
America. 2014; 111:4262–4267.
26. Lee JH, Park SJ, Jeong SY, Kim MJ, Jun S, Lee HS, 
Chang IY, Lim SC, Yoon SP, Yong J, You HJ. 
MicroRNA-22 Suppresses DNA Repair and Promotes 
Genomic Instability through Targeting of MDC1. Cancer 
research. 2015; 75:1298–1310.
27. Tsuchiya N, Izumiya M, Ogata-Kawata H, Okamoto K, 
Fujiwara Y, Nakai M, Okabe A, Schetter AJ, Bowman ED, 
Midorikawa Y, Sugiyama Y, Aburatani H, Harris CC, 
Nakagama H. Tumor suppressor miR-22 determines 
p53-dependent cellular fate through post-transcriptional 
regulation of p21. Cancer research. 2011; 71:4628–4639.
28. Guo MM, Hu LH, Wang YQ, Chen P, Huang JG, Lu N, 
He JH, Liao CG. miR-22 is down-regulated in gastric can-
cer, and its overexpression inhibits cell migration and inva-
sion via targeting transcription factor Sp1. Medical oncol-
ogy. 2013; 30:542.
29. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, 
Tamaki A, Matsunaga J, Takahashi RU, Takata T, 
Shimamoto A, Ochiya T, Tahara H. miR-22 represses can-
cer progression by inducing cellular senescence. J Cell Biol. 
2011; 193:409–424.
30. Chen B, Tang H, Liu X, Liu P, Yang L, Xie X, Ye F, 
Song C, Xie X, Wei W. miR-22 as a prognostic factor tar-
gets glucose transporter protein type 1 in breast cancer. 
Cancer Lett. 2015; 356:410–417.
31. Lleonart M, Vidal F, Gallardo D, Diaz-Fuertes M, Rojo F, 
Cuatrecasas M, Lopez-Vicente L, Kondoh H, Blanco C, 
Carnero A, Ramon y Cajal S. New p53 related genes in 
human tumors: significant downregulation in colon and 
lung carcinomas. Oncology reports. 2006; 16:603–608.
32. Mattera L, Escaffit F, Pillaire MJ, Selves J, Tyteca S, 
Hoffmann JS, Gourraud PA, Chevillard-Briet M, Cazaux C, 
Trouche D. The p400/Tip60 ratio is critical for colorectal 
cancer cell proliferation through DNA damage response 
pathways. Oncogene. 2009; 28:1506–1517.
Oncotarget41306www.impactjournals.com/oncotarget
33. Gorrini C, Squatrito M, Luise C, Syed N, Perna D, 
Wark L, Martinato F, Sardella D, Verrecchia A, Bennett S, 
Confalonieri S, Cesaroni M, Marchesi F, Gasco M, 
Scanziani E, Capra M, et al. Tip60 is a haplo-insufficient 
tumour suppressor required for an oncogene-induced DNA 
damage response. Nature. 2007; 448:1063–1067.
34. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, 
Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, 
Valastyan S, Westermann F, Speleman F, Vandesompele J, 
Weinberg RA. miR-9, a MYC/MYCN-activated 
microRNA, regulates E-cadherin and cancer metastasis. 
Nature cell biology. 2010; 12:247–256.
35. Vetter G, Saumet A, Moes M, Vallar L, Le Bechec A, 
Laurini C, Sabbah M, Arar K, Theillet C, Lecellier CH, 
Friederich E. miR-661 expression in SNAI1-induced 
 epithelial to mesenchymal transition contributes to breast 
cancer cell invasion by targeting Nectin-1 and StarD10 
messengers. Oncogene. 2010; 29:4436–4448.
36. Hamada S, Satoh K, Miura S, Hirota M, Kanno A, 
Masamune A, Kikuta K, Kume K, Unno J, Egawa S, 
Motoi F, Unno M, Shimosegawa T. miR-197 induces epi-
thelial-mesenchymal transition in pancreatic cancer cells 
by targeting p120 catenin. Journal of cellular physiology. 
2013; 228:1255–1263.
37. Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, Xu R, 
Huang W. miR-194 is a marker of hepatic epithelial cells 
and suppresses metastasis of liver cancer cells in mice. 
Hepatology. 2010; 52:2148–2157.
38. Xiong J, Yu D, Wei N, Fu H, Cai T, Huang Y, Wu C, 
Zheng X, Du Q, Lin D, Liang Z. An estrogen receptor alpha 
suppressor, microRNA-22, is downregulated in estrogen 
receptor alpha-positive human breast cancer cell lines and 
clinical samples. FEBS J. 2010; 277:1684–1694.
39. Pandey DP, Picard D. miR-22 inhibits estrogen signaling 
by directly targeting the estrogen receptor alpha mRNA. 
Molecular and cellular biology. 2009; 29:3783–3790.
40. Chua SW, Vijayakumar P, Nissom PM, Yam CY, 
Wong VV, Yang H. A novel normalization method for 
effective removal of systematic variation in microarray 
data. Nucleic acids research. 2006; 34:e38.
384 j Journal of Molecular Cell Biology (2016), 8(5), 384–399 doi:10.1093/jmcb/mjw038
Published online September 20, 2016
Article
TIP60 inhibits metastasis by ablating
DNMT1−SNAIL2-driven epithelial-mesenchymal
transition program
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HIV-Tat-interacting protein of 60 kDa (TIP60) is a lysine acetyltransferase and known to be downregulated in multiple cancers.
Among various signalling pathways, TIP60 is implicated in regulating epithelial-mesenchymal transition (EMT). Here, we show
that TIP60 expression abrogates cell migration and metastatic potential of breast cancer cells using in vitro and in vivo models.
Mechanistically, we show that this is through its ability to destabilize DNMT1 and inhibit SNAIL2 function (SNAIL2-mediated
EMT/cell migration). Depletion of TIP60 stabilizes DNMT1 and increases SNAIL2 levels, resulting in EMT. Recruitment of DNMT1
to the SNAIL2 targets in the absence of TIP60 increases DNA methylation on their promoter region and further represses the
expression of epithelial markers. In pathophysiological scenario, we find TIP60 to be significantly downregulated in breast cancer
patients with poor overall survival and disease-free survival prognoses. These data suggest that levels of TIP60 can be a prog-
nostic marker of breast cancer progression and stabilization of TIP60 could be a promising strategy to treat cancers.
Keywords: TIP60, SNAIL2, DNMT1, EpCAM, epithelial-mesenchymal transition, DNA methylation
Introduction
Epigenetic regulators play an important role in maintaining
chromatin state. One group of the key regulators of chromatin
organization are enzymes that are involved in modification of
histones. Among them, HIV-Tat-interacting protein 60 kDa
(TIP60) is a lysine acetyltransferase implicated in multiple cellu-
lar pathways, including transcription, DNA damage-induced
checkpoint activation, and apoptosis (Sun et al., 2005, 2007;
Sapountzi et al., 2006; Squatrito et al., 2006; Sykes et al.,
2006; Tang et al., 2006; Jha et al., 2008). This is achieved
through its ability to acetylate both histones and non-histone
proteins (Sun et al., 2005, 2007; Sykes et al., 2006; Tang et al.,
2006). TIP60 also functions as a haploinsufficient tumour sup-
pressor (Gorrini et al., 2007) and is downregulated in multiple
types of cancer, including those induced by viruses (Jha et al.,
2010; Gupta et al., 2013; Subbaiah et al., 2016).
Epithelial-mesenchymal transition (EMT) is considered as an
important step in cancer metastasis and describes the process
whereby polarized, immotile epithelial cells transform to motile,
invasive mesenchymal-like cells capable of dissemination to
multiple organs (Yang and Weinberg, 2008; Polyak and
Weinberg, 2009; Thiery et al., 2009; Huang et al., 2012; De
Craene and Berx, 2013; Tam and Weinberg, 2013). The tran-
scription factors SNAIL1, SNAIL2, TWIST, ZEB1, and ZEB2 are
among the most potent inducers of EMT in various physiological
and pathological contexts.
Aberrant DNA methylation is one of the key epigenetic
mechanisms that contributes to the process of carcinogenesis
(Robertson, 2001). There are three classes of DNA methyltrans-
ferase (DNMTs): DNMT1, DNMT2, and DNMT3 (DNMT3A and
DNMT3B) (Bestor, 2000). De novo DNA methylation is catalysed
by DNMT3A and DNMT3B, whereas maintenance of DNA
Received March 31, 2016. Revised July 17, 2016. Accepted July 20, 2016.
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methylation during cell proliferation is by DNMT1 (Jones and
Baylin, 2007). Among all the DNMTs, DNMT1 is most abundantly
expressed (Espada et al., 2011). DNA methylation catalysed by
DNMTs primarily occurs on the CpG island of the promoter
regions and results in gene repression (McCabe et al., 2009).
DNMT1 is reported to methylate the promoter of epithelial genes
such as the epithelial cell adhesion molecule (EpCAM) and CDH1,
resulting in the repression of cell adhesion molecules and pro-
motion of EMT process (Alberti et al., 1994; Melki et al., 1999;
Spizzo et al., 2007; Tai et al., 2007; Fukagawa et al., 2015).
Recent studies have shown that TIP60 downregulation corre-
lates with node positivity, metastasis, and poor survival rates
(Kim et al., 2005; Sakuraba et al., 2009; Chen et al., 2012). In
addition, TIP60 acetylation on DNMT1 promotes its degradation
through an acetylation-driven ubiquitination mechanism (Du
et al., 2010b). In this study, we show that TIP60 is an inhibitor
of EMT. By using in vitro and in vivo models, we identify that
TIP60 regulates SNAIL2 expression and function to promote
expression of epithelial genes. Interestingly, this is through
TIP60-mediated destabilization of DNMT1 and the ability of
SNAIL2 to recruit DNMT1 to the promoter. In summary, we have
identified the molecular mechanism of TIP60 inhibiting DNMT1
−SNAIL2-driven EMT program and suggest that targeting this
axis might be of therapeutic importance.
Results
TIP60 inhibits cell migration and invasion both in vitro and
in vivo
To identify the role of TIP60 as an inhibitor of EMT, we over-
expressed TIP60 in a highly metastatic triple negative breast
cancer cell line (MDA-MB-231), and depleted TIP60 in normal
breast epithelial cells (MCF10A). Wound-healing and Boyden
chamber assays were used to score for migration and invasion
potential in each of these two scenarios. For all the experiments
related to the metastatic breast cancer cell line, we used a
derivative of MDA-MB-231 cells that stably express the lucifer-
ase gene (MDA-MB-231-Luc-D3H2LN); this enabled us not
only to monitor cell migration, early tumour growth, and metas-
tasis in vivo, but also to quantify tumour burden in an animal
model. To test the ability of TIP60 to inhibit metastasis, we
modified this cell line to stably overexpress either wild-type
TIP60 (MM-Luc-FT60WT) or its catalytically inactive form (MM-
Luc-FT60KD) (Supplementary Table S1). Cells stably expressing
the vector (MM-Luc-MSCV) were used as the negative control.
Overexpression of wild-type TIP60 inhibited cell migration and
cell invasion in vitro by 50% (Figure 1A, B and Supplementary
Figure S1A–E). Interestingly, this inhibition was dependent on
the catalytic activity of TIP60, as overexpression of its catalytic-
ally inactive form failed to inhibit cell migration (Figure 1A and
B). To confirm if the same phenotype could be observed in other
metastatic breast cancer cell lines, wild-type TIP60 and catalytic
inactive form of TIP60 were overexpressed in two other cell
lines: HCC1937 (HCC1937-MSCV, HCC1937-TIP60WT, HCC1937-
TIP60KD) and MDA-MB-468 (MM468-MSCV, MM468-TIP60WT,
MM468-TIP60KD) (Supplementary Table S1). Similar to the
observation in MDA-MB-231 cells, overexpression of wild-type
TIP60 inhibited the migration of both HCC1937 and MDA-MB-
468 cells, while catalytic inactive form of TIP60 was unable to
do so (Supplementary Figure S1G–L). Conversely, to test
whether depletion of TIP60 could increase cell migration, we
reduced TIP60 levels in MCF10A cells using siRNA and per-
formed wound-healing assays. TIP60 depletion enhanced cell
motility by >40%, resulting in a much faster closure of the
wound as compared to siControl-treated cells (Figure 1C, D and
Supplementary Figure S2A and B).
To extend these studies into an animal model system, we
studied the metastasis of MDA-MB-231 cells in 6-week-old
NOD/SCID mice, comparing the metastatic potential of TIP60
wild-type and control cells. In this in vivo study, MDA-MB-231
cells expressing the luciferase reporter gene (i.e. MM-Luc-MSCV,
MM-Luc-FT60WT, and MM-Luc-FT60KD) were injected into mice
through the tail vein, and fluorescence-based non-invasive
imaging was used to monitor the metastasis of cells (Figure 1E).
The results show that TIP60 overexpression led to a dramatic
reduction in the extravasation potential of these cells scored by
reduced lung metastasis as compared with the control cells,
which is dependent on the catalytic activity of TIP60 (Figure 1E–
G). These data suggest that TIP60 levels regulate the late pro-
cess of metastasis in vivo and cell migration in vitro.
Depletion of TIP60 decreases the expression of epithelial genes
and increases the expression of mesenchymal genes
TIP60-mediated EMT phenotype was verified by screening the
expression of EMT markers in TIP60-depleted cells.
Interestingly, we found that the transcript levels of two major
mesenchymal markers SNAI2 (SNAIL2) and FN1 (FIBRONECTIN)
were elevated by ~2 and ~10 folds, respectively. We also
observed a 50% reduction in the expression of epithelial
marker EpCAM (Figure 2A, Supplementary Figure S2C and
Table S2). These findings were re-capitulated at the protein
level (Figure 2B and Supplementary Figure S2D) and in another
epithelial cell line MCF7 (Supplementary Figure S2E). SNAIL2 is
one of the master regulators of EMT, as its expression in epithe-
lial cells triggers the first and necessary phase of the EMT pro-
cess, i.e. desmosomal disruption and cell spreading (Taube
et al., 2010; Villarejo et al., 2014). This essentially occurs
because SNAIL2 functions as a transcriptional repressor of epi-
thelial genes, such as EpCAM, and as an activator of the mesen-
chymal gene FN1. EpCAM is involved in cell−cell recognition and
adhesion, whereas FIBRONECTIN is a key component of the
extracellular matrix promoting cell migration (Stanisavljevic
et al., 2011; Park and Schwarzbauer, 2014; Sun et al., 2014).
We also found that the cells depleted of TIP60 lose cell−cell
adhesion, become more elongated and mesenchymal-like
(Figure 2C and Supplementary Figure S1F) along with plasma
membrane-to-cytoplasmic re-localization of E-CADHERIN and β-
CATENIN (Figure 2D and E) compared to the control cells.
To rule out any off-target effects of the siRNA, we generated
three cell lines using MCF10A cells as the parental cell line:
MSCV vector control (M10MSCV), wild-type TIP60 (M10FT60WT),
TIP60 inhibits metastasis j 385
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and a siRNA-resistant wild-type TIP60 (M10FT60*WT)
(Supplementary Table S1). The siRNA-resistant constructs were
generated by synonymous mutations, i.e. the siRNA-targeting
site was mutated such that the protein sequence would not
change. To test whether these cell lines behaved similar to the
parental cell line, we depleted both the endogenous and
exogenous TIP60 and performed wound-healing assays, mRNA
quantitation, and protein expression assays. Figure 3A–D con-
firms that the knockdown of both exogenous and endogenous
TIP60 produced phenotypes similar to that of the parental
MCF10A cell line. Overexpression of TIP60 resulted in a 50%
reduction in FN1 expression and a 2-fold increase in EpCAM
Figure 1 TIP60 inhibits EMT. (A and B) Overexpression of TIP60 inhibits cell migration. Wound-healing assays were performed using MDA-
MB-231-Luc-D3H2LN cells expressing vector (MM-Luc-MSCV), wild-type TIP60 (MM-Luc-FT60WT), or the catalytically inactive form of TIP60
(MM-Luc-FT60KD) (see Materials and methods). Cell migration images are shown in A and the quantitation in B; ***P < 0.001. (C and D)
Depletion of TIP60 increases cell migration. MCF10A cells were treated with indicated siRNAs. Representative images are shown in C and
quantitation in D; ***P < 0.001. (E–G) TIP60 inhibits metastasis in an animal model. MDA-MB-231-Luc-D3H2LN cells (5 × 105) expressing
different proteins as indicated were injected through the tail vein and tumour growth and metastasis were monitored through biolumines-
cence imaging (see Materials and methods). Representative images are shown in E, quantitation in F, and expression of TIP60 in G.
386 j Zhang et al.
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expression (Figure 3C and D). Importantly, the expression of
siTIP60-resistant TIP60 rescued the levels of FN1 and EpCAM at
both RNA and protein levels, indicating that this phenotype was
TIP60 specific (Figure 3A–D and F). However, SNAI2 expression
could only be rescued partially in such a scenario (Figure 3E).
Because FIBRONECTIN has been previously shown to upregulate
SNAIL2 to promote metastasis, it is plausible that the reduction
in TIP60 provides the initial trigger to upregulate SNAIL2, then
Figure 2 Reduced expression of TIP60 promotes EMT. (A) Expression analysis of the genes involved in EMT after depletion of TIP60. Results
were analysed as fold change against siControl-treated cells. (B) Western blot analysis of the proteins showing changes in expression after
depletion of TIP60. Total cell lysates were resolved on SDS-PAGE and probed with the indicated antibodies. ACTIN serves as a loading con-
trol for western blotting. (C) Morphology of MCF10A cells treated with siControl and siTIP60. (D and E) Depletion of TIP60 results in cell
membrane-to-cytoplasmic re-localization of E-CADHERIN (D) and β-CATENIN (E).
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FIBRONECTIN maintains SNAIL2 levels during metastasis
(Knowles et al., 2013).
To gain a deeper insight into the molecular mechanism of
TIP60 function, we next sought to determine whether the lysine
acetyltransferase activity of TIP60 is required for SNAIL2-
mediated regulation of EMT. We thus generated a cell line
expressing TIP60 that was catalytically inactive and siRNA-
resistant (M10FT60*KD). Intriguingly, this form of TIP60 failed to
rescue the expression level of FN1 and EpCAM (Figure 3A–F),
indicating that the catalytic activity of TIP60 is required to regu-
late the expression of these genes, at both mRNA and protein
levels.
To further strengthen that this observation is TIP60 specific
and catalytic activity dependent, cell lysates from MDA-MB-231
cells with overexpression of either wild-type TIP60 or catalytic
inactive form of TIP60 (MM-Luc-MSCV, MM-Luc-FT60WT, MM-
Figure 3 TIP60-mediated inhibition of EMT is specific to TIP60 and depends on its catalytic activity. (A–E) Expression analysis of genes iden-
tified to change when TIP60 is depleted using siTIP60 in parental (MCF10A), vector control (M10MSCV), or stable cells expressing wild-type
TIP60 (M10FT60WT), siRNA-resistant wild-type TIP60 (M10FT60*WT), and catalytically inactive and siRNA-resistant TIP60 (M10FT60*KD).
Results are represented as fold change against siControl-treated MCF10A cells. (F) Western blots for the proteins with differential expression
upon TIP60 depletion. Lysates were prepared from the indicated cell lines, and proteins were resolved on SDS-PAGE and blotted for the indi-
cated antibodies. ACTIN served as a loading control.
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Luc-FT60KD) were examined by western blotting. EpCAM level
increased by overexpressing wild-type TIP60 compared to con-
trol but not catalytic inactive form of TIP60 (Supplementary
Figure S2F). This was in contrast to MCF10A, where the expres-
sion of EpCAM was inversely modulated upon depleting TIP60
(Figure 2B). FN1 and SNAI2 expression was not altered in MDA-
MB-231 cells by overexpressing wild-type TIP60 or catalytic
inactive form of TIP60 (data not shown). This could be due to
the feedback regulation between FN1 and SNAI2 in highly
metastatic cells, as discussed earlier. High levels of FN1 and
SNAI2 could upregulate each other and ensure the maintai-
nance of both genes at high level in more metastatic cells.
However, restoration of EpCAM level is sufficient to inhibit cell
migration and invasion (Tai et al., 2007), which explains the
inhibitory function of TIP60 in MDA-MB-231 cell metastasis.
This suggests that the regulation of EpCAM plays a predomin-
ant role in TIP60-mediated inhibiton of breast cancer
metastasis.
Alteration of expression of EMT-related genes in the absence of
TIP60 is SNAIL2 dependent
SNAIL2 belongs to the family of zinc finger transcription fac-
tors, which regulates the expression of EMT-related genes by
interacting with the E-boxes in their promoter regions (Yang and
Weinberg, 2008; Thiery et al., 2009; Huang et al., 2012;
Villarejo et al., 2014). To test the role of SNAIL2 in TIP60-
mediated alteration of the expression of EMT markers, we
depleted both TIP60 and SNAIL2 and found that compared with
the depletion of TIP60 alone, the co-depletion could rescue both
FN1 and EpCAM at both mRNA and protein levels (Figure 4A and
B), suggesting that TIP60 regulation of the expression of FN1
and EpCAM is SNAIL2 dependent. To further investigate the bio-
logical implication, wound-healing assay using MCF10A cells
depleting either TIP60 alone or TIP60 and SNAIL2 together was
performed. A 40% increase in cell migration by depleting TIP60
was observed and this was further reduced by nearly 30% upon
Figure 4 TIP60 regulates EMT through regulating SNAIL2. (A) The change in gene expression under TIP60-depleted condition is SNAIL2
dependent. mRNA levels of genes identified to be differentially expressed when TIP60 is depleted either alone or in combination with
SNAIL2 in MCF10A cells. Results were analysed and are represented as fold change against siControl-treated cells. (B) Western blot analysis
of the differentially expressed genes. Lysates were prepared from MCF10A cells treated with indicated siRNAs and resolved on SDS-PAGE.
The levels of proteins were checked by probing with indicated antibodies. ACTIN served as a loading control. (C and D) The increased cell
migration after depletion of TIP60 was restored by co-depleting TIP60 and SNAIL2. Wound-healing assay was performed as described in
Materials and methods. The representative pictures are shown in C and quantification in D. **P < 0.01; ***P < 0.001.
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co-depleting TIP60 and SNAIL2 (Figure 4C and D), suggesting
that regulation of cell migration by TIP60 is SNAIL2 dependent.
TIP60 affects SNAIL2 localizing on its target promoters
SNAIL2 has previously been implicated in the promoter-
dependent transcriptional regulation of EMT genes. Thus, we
next sought to ascertain whether the TIP60-mediated transcrip-
tional regulation of EpCAM and FN1 also occurred through the
promoter regions of these genes. To this end, chromatin immu-
noprecipitation quantitative polymerase chain reaction (ChIP-
qPCR) was performed using an anti-SNAIL2 antibody in the pres-
ence or absence of TIP60. Primers were designed to amplify
different regions of the promoters of FN1 and EpCAM
(Supplementary Figure S3A and C). Among the primers tested,
two were chosen for each promoter, one from the distal site,
which lacked SNAIL2 binding, and the other from the proximal
site, which showed enrichment for SNAIL2 occupancy
(Supplementary Figure S3B, D, and E). When the occupancy of
SNAIL2 on these promoters was tested in wild-type (MCF10A)
cells, we found a significant increase in SNAIL2 binding on the
FN1 and EpCAM promoters in the absence of TIP60 (Figure 5A).
In order to test whether these changes were TIP60 specific and
whether the catalytic activity of TIP60 was required to inhibit
the binding of SNAIL2 to the promoters, we checked SNAIL2
occupancy in the three stable cell lines M10FT60WT,
M10FT60*WT, and M10FT60*KD (Figure 5B–D). Remarkably, we
found that the enrichment of SNAIL2 on FN1 and EpCAM promo-
ters (Figure 5B) can be restored back to control level by
Figure 5 TIP60 affects SNAIL2 occupancy on target promoters. (A) ChIP-qPCR assays were performed to check the occupancy of SNAIL2 in
the presence or absence of TIP60. MCF10A cells were transfected with siControl or siTIP60. Binding of SNAIL2 to the FN1 and EpCAM promo-
ters were investigated using anti-SNAIL2 antibody by qPCR analysis. Results were analysed and are represented as percent input. Aliquots
of the cells from the same experiment were used to isolate RNA to check the expression levels by RT-qPCR. The TIP60 knockdown efficiency
and levels of indicated genes are shown in Supplementary Figure S4. (B–D) SNAIL2 binding to its target promoter is regulated by TIP60 and
depends on its catalytic activity. ChIP-qPCR analysis for SNAIL2 binding was performed in the presence (siControl) or absence of TIP60
(siTIP60) in MCF10A cells stably expressing wild-type TIP60 (M10FT60WT), siRNA-resistant wild-type TIP60 (M10FT60*WT), or the catalytic-
ally inactive siRNA-resistant form of TIP60 (M10FT60*KD). The FN1 and EpCAM promoters were immunoprecipitated and analysed as in A.
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overexpressing wild-type TIP60 (Figure 5C), but this was not
observed when catalytically dead form of TIP60 was overex-
pressed (Figure 5D), suggesting that the SNAIL2 promoter occu-
pancy was regulated by TIP60 and was dependent on the
catalytic activity of TIP60. The TIP60 knockdown and the effect
on EpCAM and FN1 expression were confirmed by qPCR
(Supplementary Figure S4).
The regulation of SNAIL2 by TIP60 is DNMT1 dependent
DNMT1 is a known EMT inducer by repressing expression of
cell adhesion molecules (Fukagawa et al., 2015). Since DNMT1
is destabilized by TIP60 (Du et al., 2010b), we tested whether
SNAIL2-mediated repression of epithelial genes is DNMT1
dependent. We depleted DNMT1 using siRNA either alone or in
combination with TIP60. Depletion of TIP60 stabilized DNMT1 at
protein level (Figure 6A–C), suggesting that TIP60 regulates the
protein stability of DNMT1. When compared to TIP60 depletion
alone, the co-depletion of TIP60 and DNMT1 rescued FN1 and
EpCAM at both mRNA and protein levels (Figure 6D and E).
Interestingly, SNAI2 was also rescued at both mRNA and protein
levels when TIP60 and DNMT1 were co-depleted (Figure 6D and
E). These data suggest that TIP60 regulates the expression of
SNAI2 as well as FN1 and EpCAM through its ability to destabil-
ize DNMT1. To test the biological significance of DNMT1-
mediated activation of EMT program, we tested the effect of
DNMT1 on cell migration under TIP60-depleted condition. We
observed a 50% increase of cell migration when TIP60 was
depleted alone and this was rescued to 20% when TIP60 and
DNMT1 were co-depleted (Figure 6F, G and Supplementary
Figure S5A). These data suggest that decreased levels of TIP60
stabilize DNMT1, which results in increased cell migration.
SNAIL2 recruits DNMT1 to repress EpCAM expression in the
context of TIP60
In order to identify the molecular determinant of DNMT1
−SNAIL2-driven EMT program, we sought to estimate DNA
methylation on SNAIL2-regulated promoters. For this, MCF10A
cells were treated with different siRNA combinations (siControl,
siTIP60, siDNMT1, siTIP60+siDNMT1). Genomic DNA was iso-
lated and the methylation-specific sequencing was performed.
We observed a significant increase in DNA methylation on
EpCAM promoter (−51 to −32) in TIP60-depleted cells.
Interestingly, this was rescued when TIP60 was co-depleted
with DNMT1 (Figure 7A, Supplementary Figures S6A and S5B),
suggesting that the increased methylation observed was
dependent on DNMT1. However, depleting DNMT1 alone did not
change DNA methylation in this region. This may be because
the basel level of DNA methylation in this region is due to other
DNA methyltransferases (Supplementary Figure S6C–F). The
DNA methylation in this region (−51 to −32) was fully depend-
ent on DNMT1 only in the absence of TIP60, as co-depleting
TIP60 and DNMT1 reduced the increased DNA methylation level
to nearly zero (Figure 7A and Supplementary Figure S6A). We
also noted that depleting TIP60 did not change DNA methylation
on EpCAM 1st intron region (+542 to +601) (Figure 7B and
Supplementary Figure S5B), suggesting that this region is not
responsive to decreased levels of TIP60. However, depletion of
DNMT1 alone showed decrease in DNA methylation on 1st
intron region (+542 to +601) (Figure 7B). In summary, these
results suggest that DNMT1 methylates both regions on EpCAM
promoter, but TIP60 only affects DNMT1-mediated DNA methyla-
tion on promoter region (−51 to −32), which has SNAIL2-
binding sites and overlaps with the SNAIL2 enrichment region
on EpCAM promoter tested earlier (Figure 5).
Next, we sought to investigate the molecular mechanism of
DNMT1-mediated repression of EpCAM expression. For this, we
checked methylation status of EpCAM promoter upon depleting
SNAIL2 and TIP60. We observed that DNA methylation on
EpCAM promoter region (−51 to −32) was significantly
increased by depleting TIP60 but further decreased by depleting
both TIP60 and SNAIL2 (Figure 7C, Supplementary Figures S6B
and S5C), suggesting that TIP60 regulates DNMT1-dependent
DNA methylation on EpCAM promoter through SNAIL2. However,
this was not observed on EpCAM 1st intron region (+542 to
+601) (Figure 7D and Supplementary Figure S5C). To further
investigate the mechanism of SNAIL2-regulated DNA methyla-
tion on EpCAM promoter, we depleted SNAIL2 but did not
observe any change in DNMT1 level (both protein and mRNA)
(Figure 7E and data not shown). Following this, ChIP-qPCR
experiment using antibody against DNMT1 was performed.
Interestingly, we observed an increase in the enrichment of
DNMT1 on EpCAM promoter region (−51 to −32) upon depleting
TIP60, but the DNMT1 enrichment was similar to control level
upon co-depleting SNAIL2 and TIP60 (Figure 7F). However, the
enrichment of DNMT1 on EpCAM 1st intron region (+542 to
+601) did not change upon depleting SNAIL2. These data sug-
gests that SNAIL2 regulates the recruitment of DNMT1 to
EpCAM promoter region (−51 to −32), which contains SNAIL2-
binding site in the absence of TIP60. To further investigate the
association between DNMT1 and SNAIL2, FLAG-DNMT1 and
SNAIL2-MYC were co-expressed in 293T cells. FLAG-DNMT1 was
immunoprecipitated and association with SNAIL2-MYC was
observed by western blotting (Figure 7G). Taken together, these
results suggest that DNMT1 catalyses DNA methylation on both
EpCAM promoter region (−51 to −32) and 1st intron region
(+542 to +601) and TIP60 inhibits SNAIL2−DNMT1-dependent
methylation on EpCAM promoter region (−51 to −32)
(Figure 7H).
Lower levels of TIP60 is a poor prognosis for overall survival
and disease-free survival of breast cancer patients
Having established that TIP60 abrogates SNAIL2 function and
maintains cells in an epithelial state, we then analysed the rele-
vance of TIP60 in breast cancers. We determined TIP60 expres-
sion levels in 3992 breast cancer and 22 normal breast tissue
samples, and sought to investigate whether TIP60 expression
correlated with the breast cancer EMT score in these samples.
The EMT score, ε [−1.0, +1.0], was used to estimate the EMT
phenotype of each sample (Tan et al., 2014). In support of our
findings, TIP60 expression had a negative correlation with the
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EMT score in patient samples (Spearman Correlation Coefficient,
Rho = −0.191, P = 2.08E−34) (Figure 8A). We also checked the
levels of TIP60 in various grades and types of breast cancer
samples and found that TIP60 was significantly downregulated
in high-grade breast cancers (Mann–Whitney U-test, P = 2.56E
−11) (Figure 8B). After further sub-classifying these tumours
into the six breast cancer subtype signatures (Basal, Claudin-
Low, Luminal-A, Luminal-B, ERBB2+, and Normal-like), we
observed a significantly high TIP60 expression associated with
the Luminal-A subtype, which has a good prognosis (Mann–
Whitney U-test, P = 7.56E−14), and significantly lower TIP60
expression in the poorer-prognosed molecular subtypes,
Figure 6 EMT in the absence of TIP60 is DNMT1 dependent. (A–C) TIP60 regulates DNMT1 protein stability. MCF10A cells transfected with
siControl or siTIP60 were treated with 100 µg/ml cycloheximide for up to 12 h. Cell lysates from indicating time points were examined by
western blotting (B) and quantified (C). **P < 0.01; ***P < 0.001. The TIP60 knockdown efficiency is shown in A. (D) Protein levels of genes
identified to be differentially expressed when TIP60 is depleted either alone or in combination with DNMT1 in MCF10A cells. Cells were har-
vested after 72 h and lysates were resolved on SDS-PAGE and membrane was probed with indicated antibodies. ACTIN served as a loading
control. (E) mRNA expression analysis of the differentially expressed genes. Results were analysed and are represented as fold change
against siControl-treated cells. (F and G) The increased cell migration after depletion of TIP60 was restored by co-depleting TIP60 and
DNMT1. Wound-healing assay was performed as described in Materials and methods. The representative pictures are shown in F and quanti-
fication in G. ***P < 0.001.
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Figure 7 SNAIL2-dependent recruitment of DNMT1 to EpCAM promoter results in its hypermethylation in the context of depleting TIP60. (A
and B) TIP60 only regulates DNMT1-mediated DNA methylation on EpCAM promoter region (−51 to −32) (A) but not on region (+542 to
+601) (B). TIP60 and DNMT1 were depleted in MCF10A cells either alone or together. DNA from cells was isolated and bisulphite pyrose-
quencing was performed as mentioned in Materials and methods. (C and D) SNAIL2 recruits DNMT1 to EpCAM promoter region (−51 to −32)
(C) but not to region (+542 to +601) (D), which is required for TIP60-mediated regulation of EpCAM promoter hypermethylation. (E)
Depletion of SNAIL2 does not change the level of DNMT1. (F) DNMT1 was recruited to EpCAM promoter region (−51 to −32) by SNAIL2 in
the absence of TIP60. ChIP-qPCR using the antibody against DNMT1 was performed. Two pairs of primers were designed to amplify the
EpCAM promoter region (−51 to −32) and EpCAM 1st intron region (+542 to +601), respectively. The EpCAM promoter region amplified
here overlaps with the region amplified by the EpCAM proximal primers used in Figure 5, but more specific to CpG sites tested in this region.
(G) DNMT1 associates with SNAIL2. FLAG-DNMT1 and SNAIL2-MYC were co-expressed in 293T. Co-immunoprecipitation was performed as
indicated in Materials and methods. FLAG-DNMT1 was immunoprecipitated and associated SNAIL2-MYC was probed by western blotting. (H)
A model of the mechanism of the regulation of EpCAM promoter hypermethylation, which involves TIP60, DNMT1, and SNAIL2.
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Figure 8 TIP60 expression was negatively correlated with EMT, and is a prognostic marker for OS and DFS in breast cancer patients. TIP60
expression was analysed in 3992 breast cancer tumours and 22 normal breast tissue samples (see Materials and methods). (A) TIP60
expression negatively correlated with EMT score (Spearman Correlation Coefficient, Rho = −0.191, P = 2.08E−34). (B) TIP60 expression
decreases as breast cancer progresses. Samples were classified as grade 1 (G1), G2, and G3, and the P-value was determined using the
Mann–Whitney U-test (G1 vs. G2, P = 9.73e−5; G1 vs. G3, P = 2.56e−11; G2 vs. G3, P = 1.28e−4). (C) TIP60 is differentially expressed in
breast cancer subtype signatures. Relative mRNA level of TIP60 is shown for Basal, Claudin-Low, Luminal-A, Luminal-B, ERBB2+, and
Normal-like breast cancer samples (Basal vs. Rest, P = 3.69e−16; Claudin-Low vs. Rest, P = 0.0169; Luminal-A vs. Rest, P = 7.56e−14;
Luminal-B vs. Rest, P = 0.1477; ERBB2+ vs. Rest, P = 1.83e−7; Normal-like vs. Rest, P = 1.77e−5; Mann–Whitney U-test). (D and E) Higher
TIP60 expression associated with better prognosis in OS and DFS. (D) Survival curve of 487 patients categorized into quartile 4 (Q4 = high
TIP60) or quartile 1 (Q1 = low TIP60) with a log-rank P = 0.0054; median survival (month), TIP60_Q1 = 16.47, TIP60_Q4 = 17.1; hazard
ratio = 1.613 (1.152–2.258). (E) DFS curve of 1166 patients from Q4 and Q1. Log-rank P = 0.0004; median survival (month),
TIP60_Q1 = 10.47, TIP60_Q4 = undefined; hazard ratio = 1.429 (1.175–1.738). (F) A model for TIP60-mediated inhibition of EMT. TIP60
destabilizes DNMT1 and inhibits SNAIL2-driven EMT program. Decreased level of TIP60 increases SNAIL2 level and DNA methylation level on
EpCAM promoter.
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including Basal, Claudin-Low, and ERBB2+ (Mann–Whitney U-
test, P = 3.69E−16, P = 0.0169, and P = 1.83E−7, respectively)
(Figure 8C). In terms of a correlation between patient overall
survival (OS)/disease-free survival (DFS) and TIP60 expression,
we found breast cancers with higher TIP60 expression to show
better prognoses for OS and DFS (log-rank test, P = 0.08 and
P = 0.0017, respectively) (Supplementary Figure S7). Comparing
breast cancers with the 25% highest TIP60 expression (fourth
quartile; Q4) with those with the 25% lowest TIP60 expression
(first quartile; Q1), we found even more significant differences
in terms of OS and DFS (log-rank test, P = 0.0054 and
P = 0.0004, respectively) (Figure 8D and E). These data
strengthen our findings that TIP60 expression is reduced in
more aggressive cancers and patients with a higher level of
TIP60 have a better prognosis in terms of OS and DFS.
Discussion
Changes in chromatin landscape play an important role in the
process of carcinogenesis. DNA methylation and post-
translation modification on histone tails are among the most
investigated epigenetic alterations and have been implicated in
tumorigenesis. TIP60 is a chromatin remodeler involved in mul-
tiple cellular physiological process and its decreased expression
has been reported in several cancers (Gorrini et al., 2007;
Sakuraba et al., 2009; Jha et al., 2010; Chen et al., 2012; Gupta
et al., 2013). Viral oncoproteins were also reported to destabil-
ize TIP60 in virus-induced cancers (Jha et al., 2010; Gupta et al.,
2013), and restoring its level inhibits tumour growth (Subbaiah
et al., 2016), suggesting a tumour suppressor function.
In this study, we propose TIP60 as a potential inhibitor of
breast cancer metastasis (Figure 8F). Our data suggest that
TIP60 inhibits metastasis by inhibiting DNMT1 and SNAIL2—key
regulators of EMT program. We provide four lines of evidence to
support this mechanism: (i) TIP60 inhibits cell migration in both
in vitro models and in vivo cancer metastasis model (Figure 1).
(ii) TIP60 alters the expression of several EMT markers (SNAI2,
EpCAM, and FN1), which depends on its catalytic activity
(Figures 2 and 3). (iii) The alteration of expression of EpCAM
and FN1 by TIP60 is SNAIL2 dependent (Figures 4 and 5). (iv)
TIP60 inhibits EMT process through both destabilizing DNMT1
(Figure 6) and inhibiting SNAIL2-dependent recruitment of
DNMT1 to EpCAM promoter, resulting in promoter hypomethyla-
tion (Figure 7).
TIP60 is known to form a complex with DNMT1 through
UHRF1, resulting in TIP60-mediated acetylation on DNMT1 and
promoting DNMT1 ubiquitination-dependent degradation (Du
et al., 2010b). This regulation of DNMT1 maintains the DNMT1
level at different stages of cell cycle, which would promote
DNMT1 degradation at the end of S phase or the beginning of
G2 phase (Du et al., 2010b). Previous studies also reported that
TIP60-mediated DNMT1 degradation can be facilitated by regu-
lator of G-protein signalling 6 (RGS6) to suppress Ras-induced
cellular transformation (Huang et al., 2014), suggesting a
tumour suppressor function of TIP60 by targeting DNMT1 for
degradation. In this study, we have reported a novel function of
TIP60 to regulate DNMT1 degradation and inhibit EMT process.
Whether TIP60−DNMT1 axis is also involved in other cellular
processes needs further investigation.
SNAIL2 is one of the members of SNAIL family proteins.
Among all the members, SNAIL1 is studied extensively, while
less is known about SNAIL2. In most of the cases, SNAIL1/2
were considered to be involved in similar pathways; however,
in some cases they were demonstrated to be diverse (Ye et al.,
2015). As far as SNAIL1 is concerned, it is regulated at differ-
ent levels. For instance, at transcriptional level, SNAI1 is regu-
lated by signalling pathways such as TGF-β (Peinado et al.,
2003), NOTCH (Timmerman et al., 2004; Sahlgren et al., 2008),
WNT (Zhou et al., 2004; Bachelder et al., 2005; Zhou and
Hung, 2005), and HIF1-α (Imai et al., 2003). At post-
transcriptional level, SNAIL1 is known to be regulated by sev-
eral microRNAs such as miR-9 (Liu et al., 2012a), miR-34 (Kim
et al., 2011), Let-7d (Chang et al., 2011), and miR-30a
(Kumarswamy et al., 2012). At the protein level, SNAIL1 stabil-
ity is known to be regulated by E3 ubiquitin ligases such as
FBXL14 (Lander et al., 2011) and β-TRCP (Zhou et al., 2004)
and kinases such as GSK3β (Yook et al., 2006), LATS2 (Zhang
et al., 2012), PKD1 (Du et al., 2010a), and PAK1 (Yang et al.,
2005). SNAI2 has been previously reported to be transcription-
ally regulated by several transcription factors, such as ELF5
(Chakrabarti et al., 2012), FOXA1, KLF4 (Liu et al., 2012b),
SOX3 (Acloque et al., 2011), and SIM2s (Laffin et al., 2008). At
post-transcriptional level, SNAIL2 is regulated by several
microRNAs such as miR-1/200 (Liu et al., 2013) and miR-203
(Zhang et al., 2011), and is known to be phosphorylated by
kinases such as GSK3β (Wu et al., 2012) and FBXL14 (Vernon
and LaBonne, 2006). Interestingly, these phosphorylations sta-
bilize SNAIL2, which is similar to SNAIL1. In this study, we
have identified that the expression of SNAI2 is regulated by
DNMT1 (Figure 6D and E). However, we did not observe any
change in DNA methylation on SNAI2 promoter (data not
shown), suggesting an indirect role of DNMT1 in regulating
SNAI2 transcription. Further studies investigating the molecu-
lar mechanism of DNMT1-dependent SNAI2 regulation will be
an exciting avenue to explore.
SNAIL family proteins are known to repress expression of cell
adhesion molecule and promote expression of mesenchymal
related molecules. Previous studies have indicated that SNAIL1
recruits epigenetic repressor complex such as HDAC1/2, PRC2,
LSD1, and G9a (Lin et al., 2014) to CDH1 promoter for maintain-
ing the repression. On the other hand, recruitment of p65 sub-
unit of NK-kB and PARP1 by SNAIL1 to FN1 promoter activate its
expression (Stanisavljevic et al., 2011). However, not much is
known about the mechanism of SNAIL2-mediated regulation.
Previous studies investigating both SNAIL1 and SNAIL2 together
assumed that SNAIL2 behaves similar to SNAIL1, thus SNAIL2
was not studied in detail. A non-equivalent role of SNAIL1 and
SNAIL2 in repression of CDH1 expression has been recently
reported (Villarejo et al., 2014; Ye et al., 2015) and it would be
interesting to identify the molecular determinants involved in
regulating the mechanism of SNAIL2-mediated regulation. Here,
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we show that both EpCAM and FN1 are direct targets of SNAIL2
and SNAIL2 enrichment on target promoters was regulated by
TIP60 (Figure 5). Additionally, we show that SNAIL2 recruits
DNMT1 to EpCAM promoter region (−51 to −32), which overlaps
with SNAIL2 enrichment site, and maintains repression of
EpCAM expression through promoter hypermethylation in the
absence of TIP60 (Figure 7A–D).
EpCAM is one of the epithelial genes involved in inhibiting
EMT process. It is known that EpCAM level would decrease dra-
matically during malignant transformation and progression (Joo
et al., 2005). Mechanistically, it was shown that hypermethyla-
tion of EpCAM promoter was the key determinant for repression
of EpCAM expression (Tai et al., 2007). Interestingly, DNA
methyltransferase inhibitor (5-aza-2′-deoxycytidine) and HDACi
(Trichostatin A) treatment reactivated the EpCAM expression
and inhibited cancer cell invasiveness (Alberti et al., 1994;
Spizzo et al., 2007). Our findings indicated an upstream mech-
anism of regulation of DNA hypermethylation on EpCAM pro-
moter, which involved TIP60, DNMT1, and SNAIL2.
In summary, we show that TIP60 acts as an inhibitor of EMT
in breast cancer cells. Mechanistically, depletion of TIP60 pro-
motes EMT by stabilizing DNMT1, which results in increased
expression of SNAIL2. The excess SNAIL2 would then recruit
DNMT1 to EpCAM promoter region (−51 to −32), resulting in
hypermethylation of EpCAM promoter and repression of EpCAM
expression. This study has identified the mechanism of TIP60-
mediated inhibition of EMT program and has discovered an
important link between two epigenetic modulators—TIP60 and
DNMT1. The data presented in this study also imply that the
reactivation of TIP60 or the restoration of TIP60-dependent
acetylation on DNMT1 might be a potential therapeutic strategy
to treat SNAIL2-driven metastatic breast cancers.
Materials and methods
In vitro invasion assay
In vitro invasion assay was performed as described previously
(Korah et al., 2000) using the BD Matrigel™ Invasion chamber
and 24-well plate 8.0 Micron insert (BD Biocoat™, Cat. No.
354480). Briefly, 50000 MM-Luc-MSCV, MM-Luc-FT60WT, or
MM-Luc-FT60KD cells were seeded onto the top layer of the
chamber and mixed with serum-free media. The bottom layer
was filled with 750 µl growth media comprising 2% foetal
bovine serum. After 8 h, cells that had invaded into the bottom
layer were stained and quantitated using ImageJsoftware
(http://imagej.nih.gov/ij/).
Wound-healing assay
Wound-healing assays were performed as described previ-
ously (Oxmann et al., 2008; Chen et al., 2012). Briefly, siRNA-
transfected (siControl, siTIP60, siDNMT1, siTIP60/siDNMT1,
siSNAI2, siTIP60/siSNAI2, and siDNMT3B) MCF10A cells or the
stable metastatic breast cancer cells were seeded into the wells
of 24-well plates at 100% confluence. Cells were maintained in
complete media for 12 h for adhesion. Cells were then subjected
to serum-starved conditions for next 24 h. A wound was created
using a fine pipette tip and the detached cells were removed by
gently washing the wells with phosphate-buffered saline. The
closure of wound was monitored every 24 h. For MCF10A,
HCC1937, and MDA-MB-468 cells, the area of the wound was
measured at 0 h and the percentage of movement was calcu-
lated by using the following formula: (area of wound at 0 h −
area of wound at n h)/area of wound at 0 h × 100, where n is a
specific time. For MDA-MB-231-luc-D3H2LN, the number of cells
migrated during gap healing were counted. Each experimental
group was repeated three times.
Chromatin immunoprecipitation quantitative PCR (ChIP-qPCR)
ChIP was performed as described earlier (Karnani et al., 2007;
Jha et al., 2010). Briefly, 5 × 106 cells were transfected with
siControl or siTIP60 in a 15-cm plate. After 72 h of siRNA treat-
ment, cells were cross-linked with 1% formaldehyde (SantaCruz
Biotechnology, Cat. No. sc-203049A) for 10 min at room tem-
perature, and then washed twice with ice-cold phosphate-buf-
fered saline. For DNMT1 ChIP, cells were treated with 0.005 µM
5-aza-2′-deoxycytidine for 10 h before harvesting, in order to
enrich chromatin bound DNMT1 (Lu et al., 2006; Patel et al.,
2010). Cells were harvested by scraping and centrifuged at
1750 g for 15 min to collect the cell pellet. Cells were then
resuspended in SDS lysis buffer (1% SDS, 0.01 M EDTA, and
0.05 M Tris-HCl, pH 8.0) and sonicated (ON: 15 sec and OFF:
45 sec at 30% amplitude for 15 cycles) to obtain DNA fragments
ranging from 100 to 500 bp. Chromatin was isolated by centrifu-
ging at 15300 g for 15 min at 4°C and the supernatant was col-
lected for immunoprecipitation.
Immunoprecipitation was performed with anti-SNAIL2 anti-
body (Cell Signaling Technology, Cat. No. 9585) or anti-DNMT1
antibody (Abcam, Cat. No. ab87656) overnight at 4°C, followed
by incubation with protein A/G PLUS agarose beads (SantaCruz
Biotechnology, Cat. No. sc-2003) for 3 h. Beads were then
washed with (i) low-salt immune complex buffer (0.1% SDS, 1%
Triton X-100, 0.002 M EDTA, 0.02 M Tris-HCl, pH 8.0, and
0.15 M NaCl), (ii) high-salt immune complex buffer (0.1% SDS,
1% Triton X-100, 0.002 M EDTA, 0.02 M Tris-HCl, pH 8.0, and
0.5 M NaCl), (iii) LiCl buffer (0.25 M lithium chloride, 1% NP40,
0.001 M EDTA, 0.01 M Tris-HCl, pH 8.0, and 1% deoxycholate),
and (iv) TE buffer (0.001 M EDTA and 0.01 M Tris-HCl, pH 8.0).
Beads were eluted in 100 µl elution buffer (1% SDS and
0.0084% NaHCO3) three times with agitation for 15 min each.
Chromatin was reversedly cross-linked by adding 0.2 M NaCl
and was heated at 65ºC for 4 h. The proteins bound to DNA
were digested by adding 20 µg proteinase K (AppliChem, Cat.
No. 39450-01-6) and incubated at 45°C for 1 h. DNA was puri-
fied using a PCR purification kit (QIAGEN, Cat. No. 28106) and
used as template for qPCR. The results were analysed and are
represented as percent input. Supplementary Table S3 shows
the sequence information for the primers used for qPCR.
DNA methylation analysis using bisulphite pyrosequencing
DNA methylation analyses were performed as described previ-
ously (Mikeska et al., 2011). Briefly, DNA was bisulphite
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converted using EpiTect Fast DNA bisulfite kit (Qiagen) accord-
ing to the manufacturer’s protocol. Prior to pyrosequencing,
PCR reactions were carried out using PyroMark PCR kit (Qiagen)
in a 50 µl reaction volume (PCR primers used: promoter region:
forward: GAAGGTTTTTTGTTTGTGTTTGTAT; reverse: [Btn]
ACCCTCTCCACAAATATAAACC. 1st intron region: forward:
GGGTATAATAGGGAGGGGATTAAG; reverse: [Btn]
CCAAAACCATTTCCCTACCAA. Btn, biotin). An initial polymerase
activation step of 15 min at 95°C was followed by 40 cycles of
30 sec at 94°C, 30 sec at 56°C, and 30 sec at 72°C, and a final
step of 5 min at 72°C. The biotinylated PCR products were
extracted with streptavidin sepharose beads (GE Healthcare)
according to the manufacturer’s instructions and released into a
PSQ 96 Low Plate (Biotage) containing 40 µl pyrosequencing
primer (promoter region: GAGACGAAGTATTTGGGG; 1st intron
region: GGGAGGGGATTAAGA), which has been diluted with
annealing buffer to a final concentration of 0.4 µM. The plate
was incubated at 80°C for 2 min, cooled to room temperature,
and run on a PyroMark ID machine (Biotage) using PyroMark
Gold reagents (Qiagen) as specified by the manufacture. Results
were analysed with PyroMark software for DNA methylation
quantification.
Bioluminescence assay in mice
Tail-vein injection was performed as described previously
(Liang et al., 2005; Yang et al., 2012). Briefly, 6-week-old NOD/
SCID mice (Invivos) were divided into three groups with four
mice per group. Each mouse received a tail-vein injection of
5×105 MM-Luc-MSCV, MM-Luc-FT60WT, or MM-Luc-FT60KD
cells, and images were taken every 7 days after injection using
IVIS 200 Pre-clinical in vivo Imaging System. All protocols for
animal studies were reviewed and approved by the Institutional
Animal Care and Use Committee at the National University of
Singapore. Analyses of the images were performed as described
previously (Wu et al., 2001; Craft et al., 2005) using Living
Image software (IVIS imaging system).
Data preprocessing of Affymetrix microarray gene expression
Data processing of microarray gene expression of breast can-
cer samples is described elsewhere (Kumar et al., 2014). Briefly,
26 breast cancer cohorts on Affymetrix U133A or U133Plus2
were downloaded from Gene Expression Omnibus (GEO) and
Array Express. Robust Multichip Average (RMA) normalisation
was performed on each cohort, and the normalised data were
standardised using ComBat (Johnson et al., 2007) to remove
batch effects. The standardised data yielded a dataset of 3992
breast cancer tumours and 22 normal breast tissue samples.
Identification of breast cancer subtypes
Breast cancer subtype signature was obtained from the study
by Prat et al. (2010). Subsequently, single sample Gene Set
Enrichment Analysis (ssGSEA) (Verhaak et al., 2010) was per-
formed to estimate enrichment scores for the six breast cancer
subtype signatures (Basal, Claudin-Low, Luminal-A, Luminal-B,
ERBB2+, and Normal-like) expressed in each sample. Each
sample was then assigned a subtype depending on the ssGSEA
enrichment score.
Statistical analysis
Statistical significance evaluations were computed by Mann–
Whitney test, Spearman Correlation Coefficient, log-rank test of
Graphpad Prism® version 5.04 and two sample two tailed stu-
dent t-test. Error bars represent the standard deviation from at
least three times of experiments.
Details for antibodies, siRNA sequences, generation of stable
cell lines, siRNA transfection, immunofluorescences, co-
immunoprecipitation, and primers for mutagenesis are in
Supplementary Materials and methods.
Supplementary material
Supplementary material is available at Journal of Molecular
Cell Biology online.
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